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RESUMO 
 
O periodonto é composto por populações heterogêneas de células, compreendendo células 
relacionadas a tecidos não mineralizados, ligamento periodontal e gengiva, e outros dois tecidos 
mineralizados, cemento e osso alveolar. Quando o periodonto é destruído na periodontite, a 
regeneração dos tecidos perdidos é bastante difícil de ser alcançada. Recentemente, abordagens 
regenerativas baseadas no conhecimento biológico da formação tecidual têm sido investigadas. 
Contudo, o entendimento do comprometimento das células do ligamento periodontal para 
formar os diferentes tecidos ainda não foi completamente elucidado. Para melhor compreender 
os mecanismos envolvidos na diferenciação das células periodontais, neste estudo, nós isolamos 
clones derivados de uma única célula e avaliamos o potencial de diferenciação em fenótipo 
osteoblástico/cementoblástico (O/C) (clones C-O) ou fenótipo fibroblástico (clones C-F) e 
analizamos o perfil transcricional dos clones celulares cultivados em meio padrão (DMEM - 
sem  meio de indução O/C - e sob indução O/C (OM), usando tecnologia de sequenciamento 
de nova geração (RNA-seq). O objetivo deste estudo foi esclarecer o transcriptoma diferencial 
das células do periodonto com maior propensão da diferenciar em fenótipo O/C. Os clones C-
O apresentaram maior número de genes diferencialmente expressos (DEG) com aumento da 
regulação do que os clones C-F, tanto quando cultivados em DMEM ou em OM. Além disso, 
os clones C-O mostraram maior enriquecimento dos processos biológicos que os clones C-F 
em ambas as condições de cultivo. A análise das vias  revelou que as vias de sinalização da 
Caderina e Wnt estavam aumentadas nos clones C-O cultivados em DMEM, enquanto que as 
vias angiogênese e CCKR estavam aumentadas nos clones C-O quando cultivadas em OM. Nós 
experamos que o melhor entendimento da regulação molecular das células do periodonto possar 
ser potencialmente utilizada para promover melhores protocolos de terapias periodontais 
regenerativas no futuro. 
 
Palavras-chave: calcificação; expressão gênica; ligamento periodontal;  transcriptoma.  
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ABSTRACT 
 
The periodontium is composed by heterogeneous cell populations, comprising cells related to 
non-mineralized tissues, the periodontal ligament and gingiva, and other two mineralized 
tissues, cementum and alveolar bone. When the periodontium is destructed in periodontitis, the 
regeneration of lost tissues is very difficult to be achieved. Recently, regenerative approaches 
based on biological knowledge of tissue formation have been investigated. However, the 
understanding of commitment of periodontal ligament cells to form different tissues still not 
been fully elucidated. In order to better comprehend the characteristics of periodontal-derived 
cells committed to distinct differentiation capacities, in this study, we isolated single-cell-
derived clones and evaluated their potential to differentiation into osteo/cementoblastic (O/C) 
phenotype (C-O clones) or fibroblastic phenotype (C-F clones) in vitro, and analyzed the 
transcriptomic profile of the groups of clones in standard medium cultivation (DMEM - without 
O/C induction medium) and under O/C induction (OM), using next-generation sequencing 
technology (RNA-seq). The aim of this study was to clarify the differential transcriptome 
profile of periodontal cells more prone to differentiate into O/C phenotype. The C-O clones 
showed higher number of up-regulated differentially expressed genes (DEG) than C-F clones, 
when cultivated in DMEM or in OM. Also, C-O clones showed higher enrichment of biological 
processes than C-F clones in both cultivation conditions. Pathway analysis revealed that 
Cadherin and Wnt signaling pathways were up-regulated in C-O clones cultivated in DMEM, 
whereas angiogenesis, and CCKR signaling pathways were up-regulated in C-O clones 
cultivated in OM. We expect that better understating of molecular regulation of periodontium 
cells can be potentially used to promote better protocols for periodontal regenerative therapies 
in the future. 
  
Keywords:  calcification; gene expression profiling; periodontal ligament; transcriptome.
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1 INTRODUÇÃO 
O periodonto corresponde ao aparato de proteção e inserção que circunda o dente e 
é composto por gengiva, cemento, ligamento periodontal e osso alveolar (Elangovan et al., 
2009). A função do periodonto é ancorar o dente ao osso alveolar, de forma a permitir a função 
mastigatória concomitantemente à manutenção da integridade dos tecidos ao redor do dente. A 
periodontite é uma doença inflamatória iniciada pelo biofilme bacteriano, a qual resulta em 
destruição da inserção conjuntiva e de osso alveolar, podendo levar à perda dentária (Elangovan 
et al., 2009). O principal objetivo da terapia periodontal é controlar a inflamação induzida pelas 
bactérias periodontopatogênicas a fim de restabelecer a saúde periodontal, permitindo a 
preservação do dente e do sistema mastigatório como um todo. Uma vez que o aspecto 
infeccioso-inflamatório da doença esteja controlado, a correção de defeitos anatômicos e a 
regeneração dos tecidos periodontais perdidos também devem ser objetivos da terapia 
periodontal (Elangovan et al., 2009; Ivanovski, 2009).  
Desde o início dos anos de 1980, várias técnicas têm sido propostas com o objetivo 
de regenerar o periodonto, tais como regeneração tecidual guiada (RTG), utilização de enxertos 
e substitutos ósseos, condicionamento da superfície radicular, uso de proteínas derivadas do 
esmalte e fatores de crescimento (Bosshardt, 2008; Sculean et al., 2008; Ivanovski, 2009). 
Contudo, como o periodonto é uma estrutura bastante complexa, não sendo composto apenas 
por um tipo tecidual, mas por tecidos mineralizados (osso alveolar e cemento) e não 
mineralizados (gengiva e ligamento periodontal), os quais estão intimamente relacionados, a 
regeneração do periodonto tem mostrado-se extremamente difícil de ser atingida. Estudos 
utilizando tais técnicas regenerativas têm demonstrado ampla variabilidade dos resultados e 
baixa previsibilidade de regeneração (Aichelmann-Reidy & Reynolds, 2008; Ivanovski, 2009). 
Além disso, as mesmas apresentam indicação clínica limitada, restringindo-se a defeitos 
periodontais infra-ósseos e lesões de furca Grau II de Hamp (Ivanovski, 2009; Avila-Ortiz et 
al., 2015; Kao et al., 2015).  
Novas abordagens regenerativas tem sido propostas com embasamento em 
fundamentações do entendimento biológico da regeneração dos tecidos, com o objetivo de 
alcançar resultados clínicos melhores e mais previsíveis (Ivanovski et al., 2014; Lin et al., 
2015). Contudo, o entendimento dos mecanismos regulatórios que coordenam a diferenciação 
das células que compõe o periodonto ainda não é completamente compreendido.  Neste 
contexto, o presente estudo teve como objetivo isolar clones do ligamento periodontal e 
caracterizar o perfil transcricional dos clones com alto potencial para diferenciação 
osteoblástica/cementoblástica (O/C) em meio sem e com estímulo à diferenciação.  
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2 ARTIGOS  
2.1. Artigo 1: Differential transcriptome profile of periodontal ligament cell clones 
 
Miki T Saito1, Luciana S Mofatto2, Mayra L Albiero1 Márcio Z Casati1, Enilson A Sallum1, 
Francisco H Nociti Jr1, Gonçalo Amarante Guimarães Pereira2, Karina G Silvério1* 
 
1 Department of Prosthodontics and Periodontics, Division of Periodontics, Piracicaba Dental 
School, University of Campinas - UNICAMP, Piracicaba, São Paulo, Brazil. 
2 Department of Genetics, Evolution and Bioagents, Genomics and expression laboratory, 
Biology Institution, University of Campinas - UNICAMP, Campinas, São Paulo, Brazil. 
* Corresponding author: Department of Prosthodontics and Periodontics, Division of 
Periodontics, Piracicaba Dental School, University of Campinas – UNICAMP.  Av. Limeira, 
901. Piracicaba, São Paulo, Brazil. 13414-903. Phone/Fax: +55-19-2106-5301. E-mail: 
kgsilverio@fop.unicamp.br 
 
Keywords (MeSH terms): cell differentiation; clone cells; gene expression profiling; high 
throughput RNA sequencing; molecular biology; tooth calcification.  
 
Abstract word count: 255 (max 300) 
Total word count: 3167 (max 3200) 
Number of figures and tables: 5 (4 figures and 1 table) (max 5) 
Number of references cited: 39 (max 40)  
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Abstract 
 
Periodontal ligament (PDL) is constituted by heterogeneous cell populations and the 
mechanisms that regulate cell commitment to osteo/cementoblastic (O/C) or fibroblastic 
phenotypes in PDL are not fully understood. The better understanding of subpopulations of 
PDL cells that form different tissues is important to propose regenerative approaches based on 
a sound biological rationale. In order to better comprehend the characteristics of periodontal-
derived cells committed to distinct differentiation capacities, we isolated single-cell-derived 
clones and evaluated their potential to differentiation into osteo/cementoblastic (O/C) 
phenotype (C-O clones) or fibroblastic phenotype (C-F clones) in vitro, and evaluated the 
transcriptomic profile of the groups of clones in standard medium cultivation (without O/C 
induction medium), using next-generation sequencing technology (RNA-seq). The aim of this 
study was to clarify the differential transcriptome profile of PDL cells more prone to 
differentiate into O/C phenotype. Our result revealed a total of 235 differentially expressed 
genes (DEG), where C-O clones showed higher number of up-regulated genes (193), and 42 
down-regulated genes. Up-regulated genes were related to the Cadherin and Wnt signaling 
pathways and many biological processes, including “anatomical structure development” and 
“cell adhesion”. Both transcriptome and qRT-PCR showed up-regulation of WNT2, WNT16 and 
WIF1 in C-O clones. This was the first study to make a comprehensive assessment of the 
transcriptome of human PDL progenitor cell clones with high O/C differentiation commitment, 
and revealed that expression of transcripts related biological process “anatomical structure 
development”, Cadherin and Wnt signaling pathways, WNT2, WNT16 and WIF1, are important 
to distinguish PDL cells with higher potential to commitment to O/C phenotype.  
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Introduction  
Regenerative approaches based on biological rationale of periodontal tissues 
formation have been proposed to achieve more predictable clinical outcomes (Ivanovski et al. 
2014). However, a profound comprehension of molecular mechanisms involved in periodontal-
derived cell homeostasis, that is crucial for these emerging approaches, still not well elucidated 
(Fujii et al. 2008; Han et al. 2015; Yamada et al. 2016). Although we know that PDL is 
constituted by heterogeneous cell populations (Fujii et al. 2008; Saito et al. 2014), the molecular 
profile of cells committed to osteo/cementoblastic (O/C) or fibroblastic phenotypes in PDL are 
not fully understood (Fujii et al. 2008; Han et al. 2015).  
Recently, emerging methods using high throughput deep sequencing technology, 
such as RNA-seq, has broadened our view of extent and complexity of transcriptome 
(Kebschull et al. 2017).  The RNA-seq analysis allows to detect and quantify a large range of 
transcripts and their splice-forms without the need for a priori target specification, leading to 
an unbiased and systematic approach to get insights into biological pathways and molecular 
mechanisms important for cell regulation in a hypothesis-neutral environment (Ayturk et al. 
2013; Kebschull et al. 2017; Twine et al. 2014). In this study, we purified PDL cell clones with 
potential to commitment to O/C phenotype (C-O clones) or potential to committment to 
fibroblastic phenotype (C-F clones), and employed RNA-seq to describe the differential 
transcriptional profile between them. The understanding of molecular regulation of different 
cells of periodontium can help to promote a microenvironment more favorable to formation of 
mineralizing and non-mineralizing tissues of periodontium and therefore lead to a more 
predictable outcome for future regenerative approaches. 
 
Material and Methods 
Cell culture, sorting, flow cytometric analysis, and cell cloning 
The design and procedures of this study was approved by Institutional Review 
Board of Piracicaba Dental School – University of Campinas (#053/2013). Human completely 
erupted third molars were collected from healthy subjects (18-25 years old) after they had 
signed a written informed consent. PDL tissue isolation, culture of PDL-derived cells and flow 
cytometric analysis were performed as previously described  (Silverio et al. 2010), using mouse 
anti-human monoclonal antibodies against CD105-allophycocianin (eBioscience, USA), 
CD146-allophycocianin (BioLegend, USA), CD166-phycoerythrin (BD, USA), CD34-
fluorescein isothicyanate (BD, USA), CD45-peridinin chlorophyll (BD, USA), Stro-1 Alexa 
Fluor 647 (BioLegend, USA), or isotype-matched control IgGs /IgM for 40 min at 4°C. The 
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CD105+ enriched cell subset was used for cell cloning by plating 500 cells in 100-mm culture 
dishes and obtaining single cell-derived colonies (clones) using colony rings as previously 
described (Saito et al. 2014). 
 
In vitro biomineralization assay 
To evaluate the ability to form mineralized matrix in vitro, unsorted PDL cell 
population and CD105+ enriched population, and each cell clone were seeded (2x105cells/well) 
in 24-well plates with standard medium (Control), that was composed by Dulbecco’s modified 
Eagle medium high glucose (DMEM) supplemented with 10% FBS, penicillin (100 U/ml) and 
streptomycin (100 mg/mL) (Gibco, USA) and incubated for 24 hours. After this period, cells 
were cultivated in fresh standard medium, or osteogenic medium (OM), composed by standard 
medium supplemented with 50 mg/mL ascorbic acid (Sigma-Aldrich, China) 10 mM b-
glycerophosphate (Sigma-Aldrich, USA), and 10-8M dexamethasone (Sigma-Aldrich, USA). 
At the end of the 28-day induction period, the Alizarin Red staining (AR-S) assay was 
performed as previously described (Zhao et al. 2015). The cell clones that were able to form 
mineralized matrix in vitro were classified as clones of oste/cementoblastic (O/C) phenotype 
(C-O), whereas the cell clones that were not able to form mineralized matrix in vitro were 
named as clones of fibroblastic phenotype (C-F). 
 
Cell Metabolic Activity Assay 
For the metabolic analysis, cell clones were seeded (5 x 103 cells/well) in a 96-well 
plate (Corning Costar, USA) using standard medium, and incubated in a humidified incubator 
at 37°C and 5% CO2 for 24 h to allow cell adhesion to the discs. After this period, the medium 
was changed for DMEM supplemented with 2% FBS, penicillin (100 U/ml) and streptomycin 
(100 mg/mL) and this time point was considered the time 0h for the metabolic assay. The 
medium was changed on days 3 and 7, and the metabolic activity of the cell on the experimental 
groups were evaluated at days 1, 3, 7 and 10, as previously described (Marques et al. 2016).  
 
RNA isolation, RNA-seq, and quantitative reverse transcription-polymerase chain reaction 
(qRT-PCR) 
Each cell clone was seeded and RNA extraction was performed as previously 
described (Saito et al. 2014). RNA isolated from two C-O clones and two C-F clones cultivated 
in standard medium during 14 days were submitted to RNA-seq, and each clone was considered 
a biological replicate for C-O and C-F group. RNA-seq was performed using Illumina TruSeq 
17 
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RNA Sample Preparation kit v2 (Illumina, USA), according to the manufacturer’s instruction. 
For qRT-PCR, single-stranded complementary DNA (cDNA) was synthesized from 1 µg total 
DNA-free RNA using Transcriptor First Strand cDNA synthesis kit (Roche Applied Science, 
USA), following the manufacturer’s recommendations. qRT-PCR was performed using the 
samples of cDNA and  LightCycler 480 SYBR Green I master kit (Roche Applied Science, 
USA) on the LightCycler 480 II real-time PCR system (Roche Applied Science, USA) for 
primers sequences WNT2, WNT2B, WNT16, WIF1, PCDHGA10, BMP4 and GAPDH 
(Appendix Table 1). Water (no template control) was used as negative control for all 
experiments. Relative quantification of reactions products was accomplished to GAPDH and 
calculated by the ΔCT-method. 
 
Analysis of data 
For RNA-seq data, quality of raw data was evaluated by FastQC 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Data was filtered by quality 
using Perl scripts, with quality cut over 20. The adapters were removed with Cutadapt (Martin 
2011) and trim galore (http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/). 
Filtered reads of RNA library were mapped against the human genome (GRCh38) using the 
pipeline Tophat2-Cufflinks (Trapnell et al. 2012). Number of reads aligned per genes and 
fragments per kilobase of transcript per million mapped reads (FPKM) were calculated by 
RSEM program (Li and Dewey 2011). Differentially expressed genes (DEG) between C-O and 
C-F clones were obtained by DESeq (Anders et al. 2013) and EdgeR packages (Robinson et al. 
2010) (R/Bioconductor) with α=5% and |log2(fold change)| ≥ 1. The heatmap graphic was 
generated based on z-score values calculated from FPKMs (Fragments Per Kilobase Million) 
values of DEG using R package “pheatmap”. DEG between C-O and C-F clones were submitted 
to functional annotation tool of DAVID program (Database for Annotation, Visualization and 
Integrated Discovery), version 6.8 (https://david.ncifcrf.gov/) (Sharan et al. 2003), in order to 
identify enriched terms of Gene Ontology (GO). GO analysis was generated by the DAVID 
software based on biological processes (GO_TERM_BP_2 database). Pathway 
overrepresentation analysis was performed in Panther Classification System 
(http://pantherdb.org/). We only considered the enriched GO terms and pathways generated by 
modified Fisher Exact test followed by the Bonferroni test and p value threshold of < 0.05. 
For other experiments, the data were expressed as mean ± standard deviation (SD).  
t-test was used to analyze differences between two groups, and  analysis of variance (ANOVA) 
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one-way or two-way were used to analyze difference among three or more groups. p values of 
<0.05 were considered statistically significant. 
 
Results 
The PDL CD105+-enriched population exhibited high proportion of cells that 
expressed mesenchymal stem cell (MSC)-related markers (Appendix Figure 1A). Since we 
aimed to isolated clones with distinct O/C differentiation potentials from PDL CD105+-
enriched population, the biomineralization potential of this population was evaluated and 
compared to the total pool of cells obtained from PDL from third molars. The PDL CD105+-
enriched population displayed capacity of biomineralization similar to the unsorted population 
(PDL) (Appendix Figure 1B and 1C).  
 
PDL clones present distinct hability to form mineralized matrix in vitro 
A total of 46 cell clones were obtained from PDL CD105+ mesenchymal progenitor 
population. According to the AR-S assay, two of the 46 clones demonstrated significant higher 
potential to form mineralized matrix in vitro under OM induction, namely G13 and G48, and 
were denominated as clones of O/C phenotype (C-O) (Figure 1A). The remaining 44 clones 
showed lower ability to form mineralized matrix in vitro, and were classified as clones of 
fibroblastic phenotype (C-F). Among the C-F group, two clones that rapidly expanded during 
the isolation and expansion periods were selected to represent the C-F counterpart, namely 
clones G16 and G23 (Figure 1A). The C-F and C-O groups were evaluated for their metabolic 
activity and did not show significant difference in each time point evaluated. Both clone groups 
showed increased metabolic activity at day 3 (Figure 1B).  
 
C-O and C-F clones present different transcriptome profile  
By the FastQC analysis, around 84% of the reads were at optimum quality and 
aligned to human genome (Appendix Table 2). Only the aligned portions to the genome were 
retained for subsequent analysis. As the heatmap shows, C-O clones presented a higher 
transcriptional activity (Figure 2). From a total of 235 DEG, from which 193 genes were 
significantly up-regulated in C-O group when compared to C-F, and 42 genes were significantly 
down-regulated in C-O group (Figure 2). The detailed lists of up- and downregulated genes are 
described in Appendix Table 3 and 4, respectively.  
Functional classification shows distinct profile of DEG in C-O and C-F clones 
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To investigate the differences between C-O and C-F clones, DEG were analyzed 
for pathway overrepresentation. C-O clones showed upregulated genes related to 55 pathways 
(Appendix Table 5), from which Cadherin signaling pathway (P00012) and Wnt signaling 
pathway (P00057) were significantly enriched according to Panther Classification System 
(Table 1). Downregulated genes in C-O clones were related to 10 pathways, but no significantly 
overrepresented pathway was observed compared to Homo sapiens genome background 
(Appendix Table 6).  
To understand the biological context of DEG, Gene Ontology (GO) analysis was 
used to map the biological process enrichment related to DEG. Genes up-regulated in C-O 
clones showed significant enrichment in 20 biological processes compared to Homo sapiens 
genome background (Figure 3A). Downregulated genes in C-O clones were related to 
significant enrichment of 9 biological processes (Figure 3B). Among the significant enriched 
biological processes in C-O clones compared to C-F clones, the biological process “anatomical 
structure development” (GO: 0048856) harbored genes related to Wnt pathway: WNT2, 
WNT2B, WNT16, and WIF1 (Figure 3C), and the biological process “cell adhesion” 
(GO:0007155) presented the gene PCDHGA10, related to Cadherin pathway, and BMP4 related 
to TGFβ/BMP pathway (Figure 3D). 
 
WNT2, WNT16, and WIF1 were validated to be upregulated by qRT-PCR 
The significantly upregulated genes WNT2, WNT2B, WNT16, WIF1, PCDHGA10, 
and BMP4 observed in RNA-seq were selected to be validated by qRT-PCR because they were 
related to signaling mechanisms previously reported in the literature as related to osteoblastic 
differentiation, and were  related to significantly overrepresented pathways Wnt and Cadherin, 
and significantly enriched biological processes anatomical structure development or cell 
adhesion. We validated RNA-seq results that C-O clones presented significantly higher 
expression of  WNT2, WNT16, and WIF1 (Figures 4A-4C), but, although the trend of higher 
expression in C-O clones could be observed, the genes WNT2B, PCDHGA10, and BMP4 did 
not showed statistical significant difference (Figures 4D-4F). 
 
Discussion 
Although it has been reported that PDL contains heterogeneous cell subpopulations 
(Fujii et al. 2008), the molecular characteristics that distinguish these subpopulations still not 
well elucidated.  In our previous study, we had characterized primary PDL cell clones from a 
PDL CD105+ progenitor population and observed that this enriched population remains 
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heterogeneous. Further, this cell population was composed by PDL cell clones committed to 
O/C phenotype (C-O) or fibroblastic phenotype (C-F) clones (Saito et al., 2014). The isolation 
of cell clones allowed the analysis of highly purified cell populations, circumventing the 
heterogeneity of cell types that constitute the PDL (Barkana et al. 2007; Liu et al. 1997; Saito 
et al. 2014; Tomokiyo et al. 2008). Although CD105 has been considered as a maker of multi-
lineage potential for bone MSCs (Rallapalli et al. 2009), our present study confirmed previous 
report (Saito et al. 2014) that CD105-enriched cell population from human PDL present 
subtypes with distinct O/C differentiation commitment.   
Since it is known that the characteristics of a given cell is determined by the 
combination pattern of its expressed gene (Yamada et al. 2016), in this study, we expanded our 
investigation about PDL clones using a next-generation sequencing technology (RNa-seq) to 
explore the differential transcriptomic profile between C-O and C-F clones. The use of a label-
free approach enables the most inclusive and unbiased description of genes, and it has been 
used to describe many types of cells, including osteoblasts (Ayturk et al. 2013; Twine et al. 
2014) and MSC (De Luca et al. 2014; Jaager et al. 2012). In this context, this investigation 
aimed to identify the transcriptome profile associated to O/C compared to fibroblastic 
phenotypes in PDL by RNA-seq. Although research about a group of transcripts important to 
PDL have been previously described (Yamada et al. 2016), the investigation of high throughput 
analysis of human PDL clones with distinct differentiation capacity has not yet been explored. 
To our knowledge, this is the first study to analyze primary human PDL cell clones on 
comprehensive scale using RNA-seq.  
This study revealed that, in a heterogeneous cells population derived from PDL, 
cell clones prone to differentiate into O/C phenotype (C-O clones) have a more complex 
transcriptional profile compared to clones related to fibroblastic phenotype (C-F clones). 
Furthermore, genes related to biological process described as “anatomical structure 
development”, and the Cadherin and Wnt signaling pathways (WNT2, WNT16 and WIF1), were 
identified as significantly important to distinguish PDL cells with higher potential to 
commitment to O/C phenotype. 
Wnt signaling has been reported to be important in the regulation of homeostasis of 
craniofacial tissue, including PDL and alveolar bone (Lim et al. 2015). It has been reported that 
the Wnt/β-catenin signaling pathway is important to direct mesenchymal progenitor cell 
differentiation toward osteoblastic phenotype, by inhibition of chondroblastic differentiation 
(Kook et al. 2016). According to some studies, when cells are in a more immature stage, the 
activation of Wnt/β-catenin signaling pathway may be important to direct cell fate toward 
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osteoblast phenotype, but after osteoblastic differentiation, there is a down-regulation of Wnt 
signaling, and continuous stimulation of Wnt pathway may inhibit mineralization (Eijken et al. 
2008; Regard et al. 2012). It has been reported that up-regulation of WNT2 in dental follicles 
cells in early time point may be related to promotion of  commitment to O/C progeny, prior to 
acquisition of a more mature phenotype (Park et al. 2015). Further, WNT16 has been reported 
to be related to regulation of cortical bone homeostasis (Gori et al. 2015), and to induce 
expression of osteoprotegerin, suggesting that WNT16 expression can inhibit osteoclastogenesis 
(Kobayashi et al. 2015). Accordingly, we observed that periodontal ligament cells more prone 
to differentiate into O/C phenotype presented higher expression of WNT2 and WNT16, 
demonstrating the importance of the expression of these genes to initial commitment toward 
O/C progeny in our study. Additionally, the gene TNFRSF11B, that encodes osteoprotegerin, 
was also significantly up-regulated in our C-O clones. In our study, WIF1 was one of the most 
significantly upregulated gene in C-O clones compared to C-F clones. Although Panther 
analysis did not classified this gene as related to Wnt signaling pathway, the literature report 
this molecule as a Wnt antagonist (Jia et al. 2013). In a recent study comparing murine 
osteoblasts and cementoblasts, the inhibitor of Wnt pathway, Wif1, was reported to be more 
expressed in cementoblasts than osteoblasts and poorly expressed in PDL (Matthews et al. 
2016). By this data, it is possible to suppose that C-O clones are more committed to differentiate 
toward a cementoblast phenotype, although our study has assessed the transcriptome profile 
from human cells.  
It has also been declared that Wnt pathway alone may not enough for mature bone, 
and other signaling pathways, such as TGFβ/BMPs and Cadherin pathways may interact with 
Wnt pathway to control O/C differentiation (Castro et al. 2004; Romanos 2016). In our previous 
study, it was demonstrated that BMP2 requires the activation of canonical Wnt signaling at the 
early stage of differentiation of murine dental follicle cell line (SVF4 cells) along O/C 
phenotype (Silverio et al. 2012). On the other hand, at the time of follicle cell maturation, BMP2 
promotes a negative Wnt-feedback loop by increasing expression of Wnt pathway inhibitors, 
including Wif1, Dkk1 and Sfrp4 (Silverio et al. 2012). The results of present study showed that 
the expression of BMP4 was constitutively increased about six-fold in C-O clones compared to 
C-F clone cells. Similar findings were found in immortalized PDL cell clones, in which clones 
that possess high expression of BMP4 showed intrinsic ability to form mineralized tissue in 
vitro, whereas another clone that did not expressed BMP4 was unable to form mineral nodules 
(Tomokiyo et al. 2008). BMP4, another member of TGF/BMPs superfamily, plays an important 
role in the process of bone nodule formation as already described to BMP2 (Chen et al. 2012; 
22 
 
 
2
2
 
Yamaguchi et al. 2008), and  BMP4 is considered one of the most predictive gene expression 
markers of in vivo bone formation potential according to a recent RNA-seq analysis (Twine et 
al. 2014). Also, it has been reported that BMP4 also interacts with Wnt signaling pathway 
during tooth organogenesis (Jia et al. 2016; Jia et al. 2013), where higher BMP4 levels showed 
to be important to overcome the inhibitory effects of Wnt antagonists, such as WIF1 and DKK2, 
during tooth development beyond bud stage (Jia et al. 2013). Take this findings together, it is 
possible to speculate that BMP4 expression in C-O clone cells might to be related to the capacity 
of these clones to acquire O/C phenotype through of functional interactions with Wnt signaling 
pathway. However, additional experiments must be performed to elucidate how Wnt-BMP 
interactions work to drive the O/C maturation process in these clone cells.      
 Cadherin superfamily was another significantly overrepresented signaling pathway in 
clones with potential to differentiate into O/C phenotype. Studies have reported that cross-talk 
between Cadherin and Wnt signaling regulates the mechanism underlining osteoblast 
differentiation ( Castro et al. 2004; Hay et al. 2014; Marie et al. 2014). Some evidences revealed 
that Cadherins bind to β-catenin, hindering its translocation to the nucleus (Marie et al. 2014) 
and then, causing the reduction of canonical Wnt signaling. Additionally, Cadherins have also 
been reported to interact with Wnt co-receptor lipoprotein receptor-related protein 5 (LRP5) 
(Hay et al. 2014), which is important to regulate bone mass (Jacobsen et al. 2014). In agreement 
with these findings, our study showed that C-O clone cells presented nine upregulated genes 
common between Cadherin and Wnt pathways, suggesting an interaction of these two pathways 
in the regulation of osteoblast/cementoblast cell lineage commitment localized into periodontal 
dental ligament. 
Here we provide a comprehensive assessment of the transcriptome of human PDL 
progenitor cell clones with high O/C differentiation potential using a next-generation 
sequencing technology (RNA-seq). This data shows potential genes and pathways associated 
to PDL cells with potential commitment into O/C phenotype. Together, these findings provide 
evidence that genes related to Wnt pathway are important for commitment of PDL cells toward 
O/C differentiation. However, subsequent studies are necessary to better understand the 
mechanisms of action and extent of this process of differentiation. We expect that better 
understating of molecular regulation of PDL cells committed to O/C phenotype can be 
potentially used to promote better protocols for periodontal regenerative therapies in the future. 
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Figures 
 
Figure 1. PDL CD105+- derived cell clones. A: Alizarin Red Stain (AR-S) assay showed that 
G16 and G23 clones were not able to form mineralized deposits in vitro, whereas G13 and G48 
clones displayed capacity of biomineralization in vitro when cultivated under osteogenic 
induction (OM). Clones G13 and G48 showed significant fold change of AR-S in OM/control 
medium when compared to other all clones, and were considered as clones with potential to 
differentiate into osteoblastic/cementoblastic phenotype (C-O). Clones G16 and G23 were 
selected as counterpart of fibroblastic phentopype (C-F) clones to be compared to C-O clones. 
Distinct letters represent significant difference (One way ANOVA/Tukey. P<0.05). B: Cell 
metabolic activity of between C-O and C-F clones did not show significant difference in each 
time point evaluated. Both clone types showed increased metabolic activity at day 3.  Distinct 
uppercase letters represent significant difference (p<0.05) intragroup, and distinct lowercase 
letters represent significant difference (p<0.05) intergroup (Two-way Anova/Tukey test).  
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Figure 2. Heatmap of differentially 2 
expressed genes of C-O and C-F clones. A 3 
total of 235 DEG were observed between C-4 
O and C-F clones. 193 genes were 5 
significantly up-regulated in C-O group, 6 
and 42 genes were significantly down-7 
regulated in C-O group (up-regulated in C-8 
F) (|log2(fold change)| ≥ 2; p <0.05). 9 
 
 
 
Figure 3. Gene Ontology (GO) of Biological Processes (BP) enrichment analysis of the list of 
differentially expressed genes between C-O and C-F clones. GO analysis was generated by 
the DAVID software based on biological processes (GO_TERM_BP_2 database). A:  GO BP 
analysis from upregulated genes in C-O clones. B:  GO BP analysis from downregulated 
genes in C-O clones. C: Barplot of FPKM of upregulated genes in C-O clones present GO BP 
anatomical structure development. D: Barplot of FPKM of upregulated genes in C-O clones 
present GO BP and cell adhesion. Mean ± standard deviation and p-value determined by 
negative binomial statistical test (DESEQ) in C and D barplots.  
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Figure 4. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) showed that 
the expression of WNT2 (A), WNT16 (B) and WIF1 (C) was significantly higher in C-O clones 
than in C-F clones. The expression of WNT2B (D), PCDHGA10 (E) and BMP4 (F) was not 
statistically significantly up-regulaed in C-O clones (* represents p <0.05, t-Test). 
 
Table 
Table 1. Significantly overrepresented pathways and respective upregulated genes in clones 
with potential to differentiate into osteoblastic/cementoblastic phenotype (C-O clones). 
Pathway (code) p value Gene ID 
Wnt signaling pathway 
(P00057) 
5.70E-04 
 
ADSSL1; PCDH18; PCDHB2; PCDHGA6; 
PCDHGA10; PCDHGB2; PCDHGB4; PRKCD; 
PRKCZ; SFRP2; WNT16; WNT2; WNT2B 
Cadherin signaling 
pathway (P00012) 
1.73E-03 
 
PCDH18; PCDHB2; PCDHB4; PCDHGA6; 
PCDHGA10; PCDHGB2; WNT16; WNT2; WNT2B 
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Appendix: Differential Transcriptome profile of periodontal ligament cell clones 
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Appendix Table 1. Specific primer sequence for quantitative Polymerase Chain Reaction (qPCR). 
Gene ID Primers (5’ 3’) 
GAPDH Forward: ACATCATCCCTGCCTCTAC; Reverse:  CCACCTTCTTGATGTCATCATATTTG 
WNT2 Forward: TTTGGCAGGGTCCTACTCC; Reverse: CCTGGTGATGGCAAATACAA 
WNT2B Forward: AACTTACATAATAACCGCTGTGGTC; Reverse: ACTCACGCCATGGCACTT 
WNT16 Forward: CAATGAACCTACATAACAATGAAGC; Reverse: CAGCGGCAGTCTACTGACAT 
WIF1 Forward: CCAGGGAGACCTCTGTTCAA; Reverse: TTGGGTTCATGGCAGGTT 
PCDHGA10 Forward: ATTTGCCTGTGGGCACTC; Reverse: CACTTCTCCATTGGCACCTT 
BMP4 Forward: CTGCAACCGTTCAGAGGTC; Reverse: TGCTCGGGATGGCACTAC 
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Appendix Table 2. Summary of mapping results. 
 R1 R2 Total 
Sample Name # Total reads # aligned # Total reads # aligned # Total reads # aligned 
G13 (C-O) 22485809 
18775954 
(83.5%) 
22485809 
 18836596 
(83.8%) 
44971618 
37612550 
(83.6%) 
G48 (C-O) 22914459 
19092937 
(83.3%) 
22914459 
19145870 
(83.6%) 
45828918 
38238807 
(83.4%) 
G16 (C-F) 26335319 
22241223 
(84.5%) 
26335319 
22332183 
(84.8%) 
52670638 
44573406 
(84.6%) 
G23 (C-F) 26435828 
22233598 
(84.1%) 
26435828 
22329638 
(84.5%) 
52871656 
44563236 
(84.3%) 
C-O: clone with potential to differentiate into osteo/cementoblastic phenotype; C-F: clone that shows fibroblastic phenotype 
 
Appendix Table 3. Significantly upregulated genes of C-O clones (clones with potential to differentiate into osteo/cementoblastic phenotype) 
compared to C-F clones (clones that shows fibroblastic phenotype). 
Gene ID Gene_description |log2FoldChange| p value 
PCDHGA10 protocadherin gamma subfamily A, 10 [Source:HGNC Symbol;Acc:HGNC:8697] 4.24549 1.05462E-46 
CBLN2 cerebellin 2 precursor [Source:HGNC Symbol;Acc:HGNC:1544] 3.56478 1.52284E-35 
PDPN podoplanin [Source:HGNC Symbol;Acc:HGNC:29602] 3.95217 1.9629E-30 
ITIH5 inter-alpha-trypsin inhibitor heavy chain family, member 5 [Source:HGNC 
Symbol;Acc:HGNC:21449] 
3.13118 2.75103E-28 
SDK1 sidekick cell adhesion molecule 1 [Source:HGNC Symbol;Acc:HGNC:19307] 3.22717 7.94864E-26 
WIF1 WNT inhibitory factor 1 [Source:HGNC Symbol;Acc:HGNC:18081] 3.39957 3.67738E-22 
CYP26B1 cytochrome P450, family 26, subfamily B, polypeptide 1 [Source:HGNC 
Symbol;Acc:HGNC:20581] 
2.36631 2.43062E-21 
CD4 CD4 molecule [Source:HGNC Symbol;Acc:HGNC:1678] 3.13156 2.85121E-19 
PCDHGB4 protocadherin gamma subfamily B, 4 [Source:HGNC Symbol;Acc:HGNC:8711] 2.79096 5.56668E-19 
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IL12RB2 interleukin 12 receptor, beta 2 [Source:HGNC Symbol;Acc:HGNC:5972] 4.57954 3.56492E-16 
EPB41L3 erythrocyte membrane protein band 4.1-like 3 [Source:HGNC Symbol;Acc:HGNC:3380] 3.01442 5.69076E-15 
CTAG2 cancertestis antigen 2 [Source:HGNC Symbol;Acc:HGNC:2492] 3.53231 7.41633E-15 
ARHGAP28 Rho GTPase activating protein 28 [Source:HGNC Symbol;Acc:HGNC:25509] 2.99542 4.98714E-13 
PTPRN protein tyrosine phosphatase, receptor type, N [Source:HGNC Symbol;Acc:HGNC:9676] 1.76435 4.75154E-13 
CYP7B1 cytochrome P450, family 7, subfamily B, polypeptide 1 [Source:HGNC 
Symbol;Acc:HGNC:2652] 
3.23889 1.32703E-12 
CCL11 chemokine (C-C motif) ligand 11 [Source:HGNC Symbol;Acc:HGNC:10610] 3.46256 1.72989E-12 
GPRC5B G protein-coupled receptor, class C, group 5, member B [Source:HGNC 
Symbol;Acc:HGNC:13308] 
1.85847 2.47654E-12 
HGF hepatocyte growth factor (hepapoietin A; scatter factor) [Source:HGNC 
Symbol;Acc:HGNC:4893] 
1.64454 3.9322E-12 
RGS5 regulator of G-protein signaling 5 [Source:HGNC Symbol;Acc:HGNC:10001] 2.07866 1.00855E-11 
RARRES2 retinoic acid receptor responder (tazarotene induced) 2 [Source:HGNC 
Symbol;Acc:HGNC:9868] 
1.90944 1.78452E-11 
PRKAR2B protein kinase, cAMP-dependent, regulatory, type II, beta [Source:HGNC 
Symbol;Acc:HGNC:9392] 
1.78616 3.79563E-11 
STC1 stanniocalcin 1 [Source:HGNC Symbol;Acc:HGNC:11373] 1.56167 3.73425E-11 
ATP8B4 ATPase, class I, type 8B, member 4 [Source:HGNC Symbol;Acc:HGNC:13536] 1.68163 4.77333E-11 
RASSF2 Ras association (RalGDSAF-6) domain family member 2 [Source:HGNC 
Symbol;Acc:HGNC:9883] 
1.55265 1.31829E-10 
RGS2 regulator of G-protein signaling 2 [Source:HGNC Symbol;Acc:HGNC:9998] 1.91296 2.27637E-10 
FER1L4 fer-1-like family member 4, pseudogene (functional) [Source:HGNC Symbol;Acc:HGNC:15801] 1.87366 2.54745E-10 
CPE carboxypeptidase E [Source:HGNC Symbol;Acc:HGNC:2303] 1.53984 3.20492E-10 
RDH10 retinol dehydrogenase 10 (all-trans) [Source:HGNC Symbol;Acc:HGNC:19975] 1.48357 7.37919E-10 
PCDHB2 protocadherin beta 2 [Source:HGNC Symbol;Acc:HGNC:8687] 2.35028 1.32862E-09 
SLC40A1 solute carrier family 40 (iron-regulated transporter), member 1 [Source:HGNC 
Symbol;Acc:HGNC:10909] 
1.89721 1.32381E-09 
GPRASP1 G protein-coupled receptor associated sorting protein 1 [Source:HGNC 
Symbol;Acc:HGNC:24834] 
1.58206 2.06756E-09 
TMEFF2 transmembrane protein with EGF-like and two follistatin-like domains 2 [Source:HGNC 
Symbol;Acc:HGNC:11867] 
2.58703 3.76804E-09 
GPRC5C G protein-coupled receptor, class C, group 5, member C [Source:HGNC 
Symbol;Acc:HGNC:13309] 
5.00989 5.99626E-09 
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ANGPTL4 angiopoietin-like 4 [Source:HGNC Symbol;Acc:HGNC:16039] 1.46281 6.57978E-09 
ACSL4 acyl-CoA synthetase long-chain family member 4 [Source:HGNC Symbol;Acc:HGNC:3571] 1.36068 7.19252E-09 
BMP4 bone morphogenetic protein 4 [Source:HGNC Symbol;Acc:HGNC:1071] 1.54228 7.05132E-09 
ADRA2A adrenoceptor alpha 2A [Source:HGNC Symbol;Acc:HGNC:281] 1.94034 1.41308E-08 
MSX1 msh homeobox 1 [Source:HGNC Symbol;Acc:HGNC:7391] 1.36846 1.64356E-08 
RGCC regulator of cell cycle [Source:HGNC Symbol;Acc:HGNC:20369] 1.61296 3.14662E-08 
CXCL3 chemokine (C-X-C motif) ligand 3 [Source:HGNC Symbol;Acc:HGNC:4604] 1.32072 3.40575E-08 
HMOX1 heme oxygenase (decycling) 1 [Source:HGNC Symbol;Acc:HGNC:5013] 1.36216 3.87512E-08 
JUP junction plakoglobin [Source:HGNC Symbol;Acc:HGNC:6207] 3.50483 5.79384E-08 
RASL12 RAS-like, family 12 [Source:HGNC Symbol;Acc:HGNC:30289] 1.99066 5.84738E-08 
ABCA1 ATP-binding cassette, sub-family A (ABC1), member 1 [Source:HGNC Symbol;Acc:HGNC:29] 1.5986 6.86385E-08 
PPFIA4 protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), 
alpha 4 [Source:HGNC Symbol;Acc:HGNC:9248] 
1.47638 7.11774E-08 
SNED1 sushi, nidogen and EGF-like domains 1 [Source:HGNC Symbol;Acc:HGNC:24696] 1.27218 7.33975E-08 
SDPR serum deprivation response [Source:HGNC Symbol;Acc:HGNC:10690] 1.34845 8.59599E-08 
DPP4 dipeptidyl-peptidase 4 [Source:HGNC Symbol;Acc:HGNC:3009] 2.33549 8.89398E-08 
ADAMTS9-AS2 ADAMTS9 antisense RNA 2 [Source:HGNC Symbol;Acc:HGNC:42435] 2.37547 1.13482E-07 
CPZ carboxypeptidase Z [Source:HGNC Symbol;Acc:HGNC:2333] 1.30417 1.65588E-07 
KCNJ2 potassium inwardly-rectifying channel, subfamily J, member 2 [Source:HGNC 
Symbol;Acc:HGNC:6263] 
1.31047 1.7474E-07 
FHL1 four and a half LIM domains 1 [Source:HGNC Symbol;Acc:HGNC:3702] 1.22027 2.26562E-07 
CLEC2B C-type lectin domain family 2, member B [Source:HGNC Symbol;Acc:HGNC:2053] 1.45914 2.67557E-07 
WSB1 WD repeat and SOCS box containing 1 [Source:HGNC Symbol;Acc:HGNC:19221] 1.21971 2.71196E-07 
RP11-574K11.31 Bifunctional heparan sulfate N-deacetylaseN- sulfotransferase 2 
{ECO:0000313|Ensembl:ENSP00000475031} [Source:UniProtKBTrEMBL;Acc:S4R438] 
1.33573 3.11273E-07 
ROR2 receptor tyrosine kinase-like orphan receptor 2 [Source:HGNC Symbol;Acc:HGNC:10257] 2.90473 3.78578E-07 
MEG3 maternally expressed 3 (non-protein coding) [Source:HGNC Symbol;Acc:HGNC:14575] 1.18855 3.84665E-07 
NABP1 nucleic acid binding protein 1 [Source:HGNC Symbol;Acc:HGNC:26232] 1.27097 3.97971E-07 
RORB RAR-related orphan receptor B [Source:HGNC Symbol;Acc:HGNC:10259] 1.38769 4.15514E-07 
TNFRSF11B tumor necrosis factor receptor superfamily, member 11b [Source:HGNC 
Symbol;Acc:HGNC:11909] 
1.63493 6.18438E-07 
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WNT2 wingless-type MMTV integration site family member 2 [Source:HGNC 
Symbol;Acc:HGNC:12780] 
1.60302 6.22446E-07 
WNT2B wingless-type MMTV integration site family, member 2B [Source:HGNC 
Symbol;Acc:HGNC:12781] 
1.24416 6.52856E-07 
ABCA7 ATP-binding cassette, sub-family A (ABC1), member 7 [Source:HGNC Symbol;Acc:HGNC:37] 1.80062 7.49863E-07 
TAC3 tachykinin 3 [Source:HGNC Symbol;Acc:HGNC:11521] 4.07224 7.51049E-07 
COL27A1 collagen, type XXVII, alpha 1 [Source:HGNC Symbol;Acc:HGNC:22986] 1.20662 7.86327E-07 
AREG amphiregulin [Source:HGNC Symbol;Acc:HGNC:651] 1.69621 8.32209E-07 
HMGN2P5 high mobility group nucleosomal binding domain 2 pseudogene 5 [Source:HGNC 
Symbol;Acc:HGNC:33568] 
3.29067 9.62166E-07 
PCDHGA9 protocadherin gamma subfamily A, 9 [Source:HGNC Symbol;Acc:HGNC:8707] 1.96426 9.95279E-07 
RSPO1 R-spondin 1 [Source:HGNC Symbol;Acc:HGNC:21679] 2.33933 1.04161E-06 
TMEM178B transmembrane protein 178B [Source:HGNC Symbol;Acc:HGNC:44112] 1.5176 1.05343E-06 
ADHFE1 alcohol dehydrogenase, iron containing, 1 [Source:HGNC Symbol;Acc:HGNC:16354] 1.66859 1.34897E-06 
NEAT1 nuclear paraspeckle assembly transcript 1 (non- protein coding) [Source:HGNC 
Symbol;Acc:HGNC:30815] 
1.11941 1.64333E-06 
TMEM150C transmembrane protein 150C [Source:HGNC Symbol;Acc:HGNC:37263] 1.63538 1.78918E-06 
SLC27A6 solute carrier family 27 (fatty acid transporter), member 6 [Source:HGNC 
Symbol;Acc:HGNC:11000] 
2.1816 1.9993E-06 
MN1 meningioma (disrupted in balanced translocation) 1 [Source:HGNC Symbol;Acc:HGNC:7180] 1.34167 2.19509E-06 
PCDHGA6 protocadherin gamma subfamily A, 6 [Source:HGNC Symbol;Acc:HGNC:8704] 1.85145 2.40947E-06 
LAMA5 laminin, alpha 5 [Source:HGNC Symbol;Acc:HGNC:6485] 1.55834 2.44561E-06 
ARHGAP6 Rho GTPase activating protein 6 [Source:HGNC Symbol;Acc:HGNC:676] 1.32046 2.52235E-06 
CHL1 cell adhesion molecule L1-like [Source:HGNC Symbol;Acc:HGNC:1939] 4.08022 2.5772E-06 
MST1 macrophage stimulating 1 (hepatocyte growth factor- like) [Source:HGNC 
Symbol;Acc:HGNC:7380] 
1.37764 2.76513E-06 
ATHL1 ATH1, acid trehalase-like 1 (yeast) [Source:HGNC Symbol;Acc:HGNC:26210] 1.36577 2.95143E-06 
SHANK2 SH3 and multiple ankyrin repeat domains 2 [Source:HGNC Symbol;Acc:HGNC:14295] 1.24192 3.24887E-06 
CLCA2 chloride channel accessory 2 [Source:HGNC Symbol;Acc:HGNC:2016] 1.13126 4.00996E-06 
SPAG4 sperm associated antigen 4 [Source:HGNC Symbol;Acc:HGNC:11214] 1.4616 4.41202E-06 
PRR5 proline rich 5 (renal) [Source:HGNC Symbol;Acc:HGNC:31682] 1.68234 5.02727E-06 
PCDH18 protocadherin 18 [Source:HGNC Symbol;Acc:HGNC:14268] 1.09425 5.43378E-06 
LINC01305 long intergenic non-protein coding RNA 1305 [Source:HGNC Symbol;Acc:HGNC:27690] 2.66685 6.958E-06 
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UCP2 uncoupling protein 2 (mitochondrial, proton carrier) [Source:HGNC Symbol;Acc:HGNC:12518] 1.71815 7.1711E-06 
WNT16 wingless-type MMTV integration site family, member 16 [Source:HGNC 
Symbol;Acc:HGNC:16267] 
1.945 7.7253E-06 
PTGS2 prostaglandin-endoperoxide synthase 2 (prostaglandin GH synthase and cyclooxygenase) 
[Source:HGNC Symbol;Acc:HGNC:9605] 
1.04232 7.79974E-06 
HSPA2 heat shock 70kDa protein 2 [Source:HGNC Symbol;Acc:HGNC:5235] 1.13304 8.69472E-06 
HILPDA hypoxia inducible lipid droplet-associated [Source:HGNC Symbol;Acc:HGNC:28859] 1.42496 8.76722E-06 
APLP1 amyloid beta (A4) precursor-like protein 1 [Source:HGNC Symbol;Acc:HGNC:597] 1.16054 9.23808E-06 
LINC00663 long intergenic non-protein coding RNA 663 [Source:HGNC Symbol;Acc:HGNC:28609] 2.06331 9.60987E-06 
MIR210HG MIR210 host gene (non-protein coding) [Source:HGNC Symbol;Acc:HGNC:39524] 1.26344 9.63018E-06 
CYR61 cysteine-rich, angiogenic inducer, 61 [Source:HGNC Symbol;Acc:HGNC:2654] 1.02409 1.10586E-05 
MMP12 matrix metallopeptidase 12 (macrophage elastase) [Source:HGNC Symbol;Acc:HGNC:7158] 1.3208 1.3066E-05 
TNFSF10 tumor necrosis factor (ligand) superfamily, member 10 [Source:HGNC 
Symbol;Acc:HGNC:11925] 
1.87505 1.29981E-05 
GALNTL6 polypeptide N-acetylgalactosaminyltransferase-like 6 [Source:HGNC 
Symbol;Acc:HGNC:33844] 
1.42258 1.31939E-05 
INHBE inhibin, beta E [Source:HGNC Symbol;Acc:HGNC:24029] 1.92796 1.37312E-05 
PTHLH parathyroid hormone-like hormone [Source:HGNC Symbol;Acc:HGNC:9607] 1.04103 1.59472E-05 
TBX1 T-box 1 [Source:HGNC Symbol;Acc:HGNC:11592] 2.82073 1.6372E-05 
ABCA8 ATP-binding cassette, sub-family A (ABC1), member 8 [Source:HGNC Symbol;Acc:HGNC:38] 1.33572 1.75245E-05 
GULP1 GULP, engulfment adaptor PTB domain containing 1 [Source:HGNC 
Symbol;Acc:HGNC:18649] 
1.08536 1.81815E-05 
ITGB8 integrin, beta 8 [Source:HGNC Symbol;Acc:HGNC:6163] 1.0853 2.13288E-05 
RASL11A RAS-like, family 11, member A [Source:HGNC Symbol;Acc:HGNC:23802] 1.58981 2.15851E-05 
FILIP1L filamin A interacting protein 1-like [Source:HGNC Symbol;Acc:HGNC:24589] 1.0124 2.1855E-05 
LIMCH1 LIM and calponin homology domains 1 [Source:HGNC Symbol;Acc:HGNC:29191] 2.45246 2.31835E-05 
MOCOS molybdenum cofactor sulfurase [Source:HGNC Symbol;Acc:HGNC:18234] 1.13597 2.36632E-05 
TLR2 toll-like receptor 2 [Source:HGNC Symbol;Acc:HGNC:11848] 1.50532 2.39797E-05 
FENDRR FOXF1 adjacent non-coding developmental regulatory RNA [Source:HGNC 
Symbol;Acc:HGNC:43894] 
1.25891 2.55299E-05 
MPP2 membrane protein, palmitoylated 2 (MAGUK p55 subfamily member 2) [Source:HGNC 
Symbol;Acc:HGNC:7220] 
2.63995 2.74966E-05 
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ABCC6 ATP-binding cassette, sub-family C (CFTRMRP), member 6 [Source:HGNC 
Symbol;Acc:HGNC:57] 
1.43449 2.86218E-05 
NEDD9 neural precursor cell expressed, developmentally down-regulated 9 [Source:HGNC 
Symbol;Acc:HGNC:7733] 
1.23603 3.02056E-05 
MIR210 microRNA 210 [Source:HGNC Symbol;Acc:HGNC:31587] 1.53024 3.19208E-05 
SH3BGRL2 SH3 domain binding glutamate-rich protein like 2 [Source:HGNC Symbol;Acc:HGNC:15567] 1.29476 3.69352E-05 
REC8 REC8 meiotic recombination protein [Source:HGNC Symbol;Acc:HGNC:16879] 1.31485 4.6937E-05 
NR4A3 nuclear receptor subfamily 4, group A, member 3 [Source:HGNC Symbol;Acc:HGNC:7982] 1.01179 4.75244E-05 
ADM2 adrenomedullin 2 [Source:HGNC Symbol;Acc:HGNC:28898] 1.29248 4.97492E-05 
CHRNA7 cholinergic receptor, nicotinic, alpha 7 (neuronal) [Source:HGNC Symbol;Acc:HGNC:1960] 3.406 5.15205E-05 
KBTBD11 kelch repeat and BTB (POZ) domain containing 11 [Source:HGNC Symbol;Acc:HGNC:29104] 1.37209 5.49048E-05 
ARMC4 armadillo repeat containing 4 [Source:HGNC Symbol;Acc:HGNC:25583] 1.2362 6.00187E-05 
CORO6 coronin 6 [Source:HGNC Symbol;Acc:HGNC:21356] 1.05161 6.18401E-05 
ABCA6 ATP-binding cassette, sub-family A (ABC1), member 6 [Source:HGNC Symbol;Acc:HGNC:36] 1.06436 6.37063E-05 
INMT indolethylamine N-methyltransferase [Source:HGNC Symbol;Acc:HGNC:6069] 1.71313 6.76701E-05 
ROBO3 roundabout, axon guidance receptor, homolog 3 (Drosophila) [Source:HGNC 
Symbol;Acc:HGNC:13433] 
1.10175 8.53108E-05 
COLEC10 collectin sub-family member 10 (C-type lectin) [Source:HGNC Symbol;Acc:HGNC:2220] 1.76357 9.96863E-05 
ENTPD1 ectonucleoside triphosphate diphosphohydrolase 1 [Source:HGNC Symbol;Acc:HGNC:3363] 1.01319 0.000103996 
BGN biglycan [Source:HGNC Symbol;Acc:HGNC:1044] 2.38082 0.000105983 
TNFRSF10C tumor necrosis factor receptor superfamily, member 10c, decoy without an intracellular domain 
[Source:HGNC Symbol;Acc:HGNC:11906] 
1.1611 0.000108966 
SLC9A9 solute carrier family 9, subfamily A (NHE9, cation proton antiporter 9), member 9 
[Source:HGNC Symbol;Acc:HGNC:20653] 
1.03802 0.000113679 
MASP1 mannan-binding lectin serine peptidase 1 (C4C2 activating component of Ra-reactive factor) 
[Source:HGNC Symbol;Acc:HGNC:6901] 
2.01426 0.000116068 
CPAMD8 C3 and PZP-like, alpha-2-macroglobulin domain containing 8 [Source:HGNC 
Symbol;Acc:HGNC:23228] 
1.85271 0.000116631 
ICAM5 intercellular adhesion molecule 5, telencephalin [Source:HGNC Symbol;Acc:HGNC:5348] 1.9301 0.000119378 
SCN2B sodium channel, voltage-gated, type II, beta subunit [Source:HGNC Symbol;Acc:HGNC:10589] 1.70566 0.000128748 
NUDT10 nudix (nucleoside diphosphate linked moiety X)-type motif 10 [Source:HGNC 
Symbol;Acc:HGNC:17621] 
2.05949 0.000141662 
OLFML2A olfactomedin-like 2A [Source:HGNC Symbol;Acc:HGNC:27270] 1.82282 0.000140823 
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PCDHGB2 protocadherin gamma subfamily B, 2 [Source:HGNC Symbol;Acc:HGNC:8709] 2.38447 0.000152631 
SP9 Sp9 transcription factor [Source:HGNC Symbol;Acc:HGNC:30690] 2.44408 0.000160934 
ODF3B outer dense fiber of sperm tails 3B [Source:HGNC Symbol;Acc:HGNC:34388] 1.61834 0.000169382 
PIM1 Pim-1 proto-oncogene, serinethreonine kinase [Source:HGNC Symbol;Acc:HGNC:8986] 1.00963 0.000171383 
MYO15B myosin XVB pseudogene [Source:HGNC Symbol;Acc:HGNC:14083] 2.7617 0.000211859 
PSAT1 phosphoserine aminotransferase 1 [Source:HGNC Symbol;Acc:HGNC:19129] 1.22993 0.000233103 
ARHGEF19 Rho guanine nucleotide exchange factor (GEF) 19 [Source:HGNC Symbol;Acc:HGNC:26604] 1.01813 0.000265419 
CMKLR1 chemokine-like receptor 1 [Source:HGNC Symbol;Acc:HGNC:2121] 3.8077 0.000275864 
BNC1 basonuclin 1 [Source:HGNC Symbol;Acc:HGNC:1081] 1.4185 0.000301962 
SLC2A1-AS1 SLC2A1 antisense RNA 1 [Source:HGNC Symbol;Acc:HGNC:44187] 1.68598 0.000311853 
B3GALT4 UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 4 [Source:HGNC 
Symbol;Acc:HGNC:919] 
1.51923 0.000333388 
FAM115C family with sequence similarity 115, member C [Source:HGNC Symbol;Acc:HGNC:26878] 1.32815 0.000337956 
ACSS1 acyl-CoA synthetase short-chain family member 1 [Source:HGNC Symbol;Acc:HGNC:16091] 1.36572 0.00036002 
MX2 MX dynamin-like GTPase 2 [Source:HGNC Symbol;Acc:HGNC:7533] 1.35949 0.000369066 
C1QL1 complement component 1, q subcomponent-like 1 [Source:HGNC Symbol;Acc:HGNC:24182] 1.41448 0.000389667 
TNFSF15 tumor necrosis factor (ligand) superfamily, member 15 [Source:HGNC 
Symbol;Acc:HGNC:11931] 
1.90156 0.00041443 
FOXL1 forkhead box L1 [Source:HGNC Symbol;Acc:HGNC:3817] 1.56737 0.000434715 
PLA2G6 phospholipase A2, group VI (cytosolic, calcium- independent) [Source:HGNC 
Symbol;Acc:HGNC:9039] 
1.09882 0.000436934 
ADSSL1 adenylosuccinate synthase like 1 [Source:HGNC Symbol;Acc:HGNC:20093] 1.18365 0.00045484 
NIPSNAP3B nipsnap homolog 3B (C. elegans) [Source:HGNC Symbol;Acc:HGNC:23641] 1.72535 0.000497826 
PAPLN papilin, proteoglycan-like sulfated glycoprotein [Source:HGNC Symbol;Acc:HGNC:19262] 1.51116 0.000494175 
PPARG peroxisome proliferator-activated receptor gamma [Source:HGNC Symbol;Acc:HGNC:9236] 1.04788 0.0004889 
RGS4 regulator of G-protein signaling 4 [Source:HGNC Symbol;Acc:HGNC:10000] 2.19792 0.000491326 
TM4SF1 transmembrane 4 L six family member 1 [Source:HGNC Symbol;Acc:HGNC:11853] 1.34867 0.00049749 
MEG9 maternally expressed 9 (non-protein coding) [Source:HGNC Symbol;Acc:HGNC:43874] 1.13738 0.000525 
NRCAM neuronal cell adhesion molecule [Source:HGNC Symbol;Acc:HGNC:7994] 1.00905 0.000553536 
PENK proenkephalin [Source:HGNC Symbol;Acc:HGNC:8831] 2.75415 0.000548842 
LBP lipopolysaccharide binding protein [Source:HGNC Symbol;Acc:HGNC:6517] 1.85026 0.000555541 
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KNDC1 kinase non-catalytic C-lobe domain (KIND) containing 1 [Source:HGNC 
Symbol;Acc:HGNC:29374] 
1.8114 0.000597758 
KCNJ2-AS1 KCNJ2 antisense RNA 1 (head to head) [Source:HGNC Symbol;Acc:HGNC:43720] 1.42512 0.000616035 
SFRP2 secreted frizzled-related protein 2 [Source:HGNC Symbol;Acc:HGNC:10777] 1.21626 0.000619934 
HSF4 heat shock transcription factor 4 [Source:HGNC Symbol;Acc:HGNC:5227] 1.13413 0.000661941 
CD40 CD40 molecule, TNF receptor superfamily member 5 [Source:HGNC 
Symbol;Acc:HGNC:11919] 
1.38645 0.000705633 
MIR503HG MIR503 host gene (non-protein coding) [Source:HGNC Symbol;Acc:HGNC:28258] 1.44105 0.000725127 
ASMTL-AS1 ASMTL antisense RNA 1 [Source:HGNC Symbol;Acc:HGNC:25811] 1.1478 0.000738242 
CLUHP3 clustered mitochondria (cluACLU1) homolog pseudogene 3 [Source:HGNC 
Symbol;Acc:HGNC:28447] 
1.09777 0.000747621 
SEPP1 selenoprotein P, plasma, 1 [Source:HGNC Symbol;Acc:HGNC:10751] 1.63958 0.000761785 
PRKCZ protein kinase C, zeta [Source:HGNC Symbol;Acc:HGNC:9412] 1.15858 0.000789937 
EEPD1 endonucleaseexonucleasephosphatase family domain containing 1 [Source:HGNC 
Symbol;Acc:HGNC:22223] 
1.14009 0.000807002 
LINC00672 long intergenic non-protein coding RNA 672 [Source:HGNC Symbol;Acc:HGNC:44353] 1.53192 0.000834011 
CMAHP cytidine monophospho-N-acetylneuraminic acid hydroxylase, pseudogene [Source:HGNC 
Symbol;Acc:HGNC:2098] 
1.17126 0.001014205 
SIX2 SIX homeobox 2 [Source:HGNC Symbol;Acc:HGNC:10888] 1.22528 0.001017085 
LPHN3 latrophilin 3 [Source:HGNC Symbol;Acc:HGNC:20974] 1.15322 0.001039395 
OR7E155P olfactory receptor, family 7, subfamily E, member 155 pseudogene [Source:HGNC 
Symbol;Acc:HGNC:31310] 
2.48421 0.001047946 
DNER Delta notch-like EGF repeat containing [Source:HGNC Symbol;Acc:HGNC:24456] 2.10309 0.001052827 
PDK4 pyruvate dehydrogenase kinase, isozyme 4 [Source:HGNC Symbol;Acc:HGNC:8812] 1.47279 0.001062613 
LINC00958 long intergenic non-protein coding RNA 958 [Source:HGNC Symbol;Acc:HGNC:48671] 2.21984 0.001074528 
DLL1 delta-like 1 (Drosophila) [Source:HGNC Symbol;Acc:HGNC:2908] 1.31061 0.001120041 
MAP3K1 mitogen-activated protein kinase kinase kinase 1, E3 ubiquitin protein ligase [Source:HGNC 
Symbol;Acc:HGNC:6848] 
1.04849 0.001185829 
ENO3 enolase 3 (beta, muscle) [Source:HGNC Symbol;Acc:HGNC:3354] 1.04416 0.001240996 
ARHGEF35 Rho guanine nucleotide exchange factor (GEF) 35 [Source:HGNC Symbol;Acc:HGNC:33846] 1.03407 0.001277462 
MATN3 matrilin 3 [Source:HGNC Symbol;Acc:HGNC:6909] 1.10179 0.001354113 
ZFPM2 zinc finger protein, FOG family member 2 [Source:HGNC Symbol;Acc:HGNC:16700] 1.07328 0.001356613 
MYO3B myosin IIIB [Source:HGNC Symbol;Acc:HGNC:15576] 1.27057 0.001409756 
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Appendix Table 4. Significantly downregulated genes of C-O clones (clones with potential to differentiate into osteo/cementoblastic phenotype) 
compared to C-F (clones that shows fibroblastic phenotype). 
Gene ID Gene_description |log2FoldChange| p  value  
GABRB3 gamma-aminobutyric acid (GABA) A receptor, beta 3 [Source:HGNC Symbol;Acc:HGNC:4083] 2.578126 1.59258E-13 
TAGLN transgelin [Source:HGNC Symbol;Acc:HGNC:11553] 1.639792 3.93602E-12 
INSIG1 insulin induced gene 1 [Source:HGNC Symbol;Acc:HGNC:6083] 1.657435 2.74927E-11 
TM4SF20 transmembrane 4 L six family member 20 [Source:HGNC Symbol;Acc:HGNC:26230] 2.860736 2.39859E-10 
SULF1 sulfatase 1 [Source:HGNC Symbol;Acc:HGNC:20391] 1.835271 2.53653E-10 
TUBB3 tubulin, beta 3 class III [Source:HGNC Symbol;Acc:HGNC:20772] 1.509186 2.7384E-10 
IRAK1 interleukin-1 receptor-associated kinase 1 [Source:HGNC Symbol;Acc:HGNC:6112] 1.481092 7.32617E-10 
LINC01444 long intergenic non-protein coding RNA 1444 [Source:HGNC Symbol;Acc:HGNC:50769] 2.080967 1.84299E-09 
LDLR low density lipoprotein receptor [Source:HGNC Symbol;Acc:HGNC:6547] 1.698726 1.08937E-08 
PHLDA2 pleckstrin homology-like domain, family A, member 2 [Source:HGNC 
Symbol;Acc:HGNC:12385] 
1.405997 3.00783E-08 
PMEPA1 prostate transmembrane protein, androgen induced 1 [Source:HGNC Symbol;Acc:HGNC:14107] 1.563129 7.72665E-08 
MRPL2 mitochondrial ribosomal protein L2 [Source:HGNC Symbol;Acc:HGNC:14056] 1.998278 1.0772E-07 
PLXNC1 plexin C1 [Source:HGNC Symbol;Acc:HGNC:9106] 1.259832 1.46288E-07 
DHCR24 24-dehydrocholesterol reductase [Source:HGNC Symbol;Acc:HGNC:2859] 1.16178 8.26376E-07 
TUBA1A tubulin, alpha 1a [Source:HGNC Symbol;Acc:HGNC:20766] 1.129236 1.2827E-06 
LAMA1 laminin, alpha 1 [Source:HGNC Symbol;Acc:HGNC:6481] 1.643878 1.8498E-06 
KRT34 keratin 34 [Source:HGNC Symbol;Acc:HGNC:6452] 1.826842 5.46012E-06 
COPRS coordinator of PRMT5, differentiation stimulator [Source:HGNC Symbol;Acc:HGNC:28848] 1.058071 1.38316E-05 
LRP8 low density lipoprotein receptor-related protein 8, apolipoprotein e receptor [Source:HGNC 
Symbol;Acc:HGNC:6700] 
1.225934 1.46044E-05 
CMSS1 cms1 ribosomal small subunit homolog (yeast) [Source:HGNC Symbol;Acc:HGNC:28666] 1.17734 1.90063E-05 
FDPS farnesyl diphosphate synthase [Source:HGNC Symbol;Acc:HGNC:3631] 1.02293 1.95916E-05 
BHLHE41 basic helix-loop-helix family, member e41 [Source:HGNC Symbol;Acc:HGNC:16617] 1.161356 2.77057E-05 
KDR kinase insert domain receptor (a type III receptor tyrosine kinase) [Source:HGNC 
Symbol;Acc:HGNC:6307] 
1.499663 2.92042E-05 
CTPS1 CTP synthase 1 [Source:HGNC Symbol;Acc:HGNC:2519] 1.215288 3.41216E-05 
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CCDC85A coiled-coil domain containing 85A [Source:HGNC Symbol;Acc:HGNC:29400] 2.3642 5.15725E-05 
RPL36A-HNRNPH2 RPL36A-HNRNPH2 readthrough [Source:HGNC Symbol;Acc:HGNC:48349] 2.969909 5.57432E-05 
EBP emopamil binding protein (sterol isomerase) [Source:HGNC Symbol;Acc:HGNC:3133] 1.086353 9.28651E-05 
LINC01443 long intergenic non-protein coding RNA 1443 [Source:HGNC Symbol;Acc:HGNC:50768] 1.892397 0.000100212 
SPECC1L-ADORA2A SPECC1L-ADORA2A readthrough (NMD candidate) [Source:HGNC 
Symbol;Acc:HGNC:49185] 
1.489043 0.000100812 
ANKRD35 ankyrin repeat domain 35 [Source:HGNC Symbol;Acc:HGNC:26323] 2.082923 0.000125709 
PRELP Proline arginine-rich end leucine-rich repeat protein [Source:HGNC Symbol;Acc:HGNC:9357] 1.257404 0.000130688 
FAM53B family with sequence similarity 53, member B [Source:HGNC Symbol;Acc:HGNC:28968] 4.140408 0.000137422 
LRRC8E leucine rich repeat containing 8 family, member E [Source:HGNC Symbol;Acc:HGNC:26272] 1.132353 0.00014194 
HSD3B7 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7 [Source:HGNC 
Symbol;Acc:HGNC:18324] 
1.422454 0.000161714 
NCR3LG1 natural killer cell cytotoxicity receptor 3 ligand 1 [Source:HGNC Symbol;Acc:HGNC:42400] 1.029262 0.000202593 
CLCN5 chloride channel, voltage-sensitive 5 [Source:HGNC Symbol;Acc:HGNC:2023] 1.113708 0.00020509 
ACAT2 acetyl-CoA acetyltransferase 2 [Source:HGNC Symbol;Acc:HGNC:94] 1.001669 0.000228977 
DCTPP1 dCTP pyrophosphatase 1 [Source:HGNC Symbol;Acc:HGNC:28777] 1.005396 0.000252872 
MARCH3 membrane-associated ring finger (C3HC4) 3, E3 ubiquitin protein ligase [Source:HGNC 
Symbol;Acc:HGNC:28728] 
1.089764 0.000328179 
FAM225A family with sequence similarity 225, member A (non- protein coding) [Source:HGNC 
Symbol;Acc:HGNC:27855] 
1.603495 0.000433013 
IDI1 isopentenyl-diphosphate delta isomerase 1 [Source:HGNC Symbol;Acc:HGNC:5387] 1.055258 0.00059642 
NME1 NMENM23 nucleoside diphosphate kinase 1 [Source:HGNC Symbol;Acc:HGNC:7849] 1.016969 0.00072965 
 
Appendix Table 5. Pathways related to upregulated genes in C-O clones (clones with potential to differentiate into osteo/cementoblastic 
phenotype).  
Pathway (code) Fold 
Enrichment 
p value Gene ID 
5HT1 type receptor mediated signaling pathway (P04373) 2.53 1.00E+00 PRKAR2B 
5HT2 type receptor mediated signaling pathway (P04374) 3.48 1.00E+00 PRKCD; PRKCZ 
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Acetate utilization (P02722) 38.84 1.00E+00 ACSS1 
Adrenaline and noradrenaline biosynthesis (P00001) 3.88 1.00E+00 INMT 
Alpha adrenergic receptor signaling pathway (P00002) 9.32 1.00E+00 ADRA2A; PRKCD 
Alzheimer disease-amyloid secretase pathway (P00003) 5.14 1.00E+00 CHRNA7; PRKCD; PRKCZ 
Alzheimer disease-presenilin pathway (P00004) 4.7 7.24E-01 JUP; MMP12; WNT16; WNT2; WNT2B; 
Angiogenesis (P00005) 4.63 1.42E-01 DLL1; MAP3K1; PRKCD; PRKCZ; PRR5; WNT2; WNT2B 
Apoptosis signaling pathway (P00006) 4.78 6.77E-01 HSPA2; MAP3K1; PRKCD; TNFRDF10C; TNFSF10; 
Axon guidance mediated by Slit/Robo (P00008) 4.48 1.00E+00 ROBD3 
B cell activation (P00010) 1.62 1.00E+00 PRKCD 
Beta1 adrenergic receptor signaling pathway (P04377) 2.53 1.00E+00 PRKAR2B 
Beta2 adrenergic receptor signaling pathway (P04378) 2.53 1.00E+00 PRKAR2B 
Cadherin signaling pathway (P00012)* 6.64 1.73E-03 PCDH18; PCDHB2; PCDHB4; PCDHGA6; PCDHGA10; 
PCDHGB2; WNT16; WNT2; WNT2B 
CCKR signaling map (P06959) 3.37 1.00E+00 CPE; PPARG; PRKCD; PTGS2; RGS2 
Cytoskeletal regulation by Rho GTPase (P00016) 2.81 1.00E+00 MYO3B; PRR5 
De novo purine biosynthesis (P02738) 3.88 1.00E+00 ADSSL1 
Dopamine receptor mediated signaling pathway (P05912) 3.95 1.00E+00 EPB41L3; PRKAR2B 
EGF receptor signaling pathway (P00018) 4.19 1.00E+00 AREG; MAP3K1; 
PRKCD; PRKCZ 
Endothelin signaling pathway (P00019) 5.42 1.00E+00 PRKAR2B; PRKCD ; PRKCZ; PTGS2 
Enkephalin release (P05913) 6.66 1.00E+00 PENK; PRKA2B 
FGF signaling pathway (P00021) 2.82 1.00E+00 MAP3K1; PRKCD; PRKCZ 
GABA-B receptor II signaling (P05731) 3.07 1.00E+00 PRKAR2B 
Gonadotropin-releasing hormone receptor pathway (P06664) 2.97 1.00E+00 BMP4; MAP3K1; PLA2G6; PPARG; PRKCD; PRKCZ 
Hedgehog signaling pathway (P00025) 5.55 1.00E+00 PRKAR2B 
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha 
mediated pathway (P00026) 
3.55 1.00E+00 ADRA2A; PRKAR2B; RGS2; RGS4; RGS5 
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha 
mediated pathway (P00027) 
4.74 7.00E-01 RGS2; RGS4; RGS5; PRKCD; PRKCZ 
Histamine H1 receptor mediated signaling pathway (P04385) 5.3 1.00E+00 PRKCD; PRKCZ 
Histamine H2 receptor mediated signaling pathway (P04386) 4.48 1.00E+00 PRKA2B 
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Inflammation mediated by chemokine and cytokine signaling 
pathway (P00031) 
2.23 1.00E+00 AGS4; CLL11; MYO3B; PRKCZ; PTGS2 
Integrin signaling pathway (P00034) 2.43 1.00E+00 LAMA5; COL27A1; ITGB8; MAP3K1 
Interleukin signaling pathway (P00036) 1.19 1.00E+00 IL12RB2 
Ionotropic glutamate receptor pathway (P00037) 2.33 1.00E+00 SHANK2 
Metabotropic glutamate receptor group II pathway (P00040) 2.43 1.00E+00 PRKAR2B 
Metabotropic glutamate receptor group III pathway (P00039) 1.69 1.00E+00 PRKAR2B 
Muscarinic acetylcholine receptor 1 and 3 signaling pathway 
(P00042) 
3.88 1.00E+00 PRKCD; PRKCZ 
Muscarinic acetylcholine receptor 2 and 4 signaling pathway 
(P00043) 
1.82 1.00E+00 PRKAR2B 
Nicotine degradation (P05914) 10.59 1.00E+00 INMT 
Nicotinic acetylcholine receptor signaling pathway (P00044) 2.31 1.00E+00 CHRAN7; MYO3B 
Notch signaling pathway (P00045) 2.65 1.00E+00 DLL1 
Opioid proenkephalin pathway (P05915) 3.43 1.00E+00 PENK 
Oxytocin receptor mediated signaling pathway (P04391) 4.02 1.00E+00 PRKCZ; SDK1 
Parkinson disease (P00049) 1.17 1.00E+00 HSPA2 
PDGF signaling pathway (P00047) 1.56 1.00E+00 ARHGAP6; PRR5 
Pyridoxal-5-phosphate biosynthesis (P02759) 58.26 1.00E+00 PSAT1 
Ras Pathway (P04393) 1.53 1.00E+00 MAP3K1 
Serine glycine biosynthesis (P02776) 23.3 1.00E+00 PSAT1 
T cell activation (P00053) 1.21 1.00E+00 MAP3K1 
TGF-beta signaling pathway (P00052) 2.26 1.00E+00 BMP4; INHBE 
Thyrotropin-releasing hormone receptor signaling pathway (P04394) 3.88 1.00E+00 PRKCD; PRKCZ 
Toll receptor signaling pathway (P00054) 5.83 1.00E+00 MAP3K1; TLR2; PTGS2 
Transcription regulation by bZIP transcription factor (P00055) 2.08 1.00E+00 PRKAR2B 
Vasopressin synthesis (P04395) 8.96 1.00E+00 CPE 
VEGF signaling pathway (P00056) 4.85 1.00E+00 PRKCD; PRKCZ; PRR5 
Vitamin B6 metabolism (P02787) 29.13 1.00E+00 PSAT1 
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Wnt signaling pathway (P00057) * 4.87 5.70E-04 ADSSL1; PCDH18; PCDHB2; PCDHGA6; PCDHGA10; 
PCDHGB2; PCDHGB4; PRKCD; PRKCZ; SFRP2; WNT16; 
WNT2; WNT2B 
Pathways in bold were pathways that presented both upregulated as downregulated genes in C-O clones (See Appendix Table 6). 
*: represent significantly overrepresented pathways compared to Homo sapiens genome background (See Table 1).  
 
Appendix Table 6. Pathways related to downregulated genes in C-O clones (clones with potential to differentiate into osteo/cementoblastic 
phenotype).  
Pathway (code) Fold Enrichment p value Gene ID 
Androgen/estrogene/progesterone biosynthesis (P02727) 76.82 5.14E-02 HDS3B7; SOAT2 
Angiogenesis (P00005) 2.84 1.00E+00 KDR 
Cholesterol biosynthesis (P00014) 76.82 5.14E-02 FDPS; IDI1 
Cytoskeletal regulation by Rho GTPase (P00016) 6.02 1.00E+00 TUBB3 
De novo purine biosynthesis (P02738) 16.64 1.00E+00 NME1 
De novo pyrimidine deoxyribonucleotide biosynthesis (P02739) 38.41 1.00E+00 NME1 
De novo pyrimidine ribonucleotides biosythesis (P02740) 71.33 5.96E-02 CTS1; NME1 
Gonadotropin-releasing hormone receptor pathway (P06664) 2.12 1.00E+00 TUBA1A 
Huntington disease (P00029) 3.59 1.00E+00 TUBB3 
Integrin signalling pathway (P00034) 2.6 1.00E+00 LAMA1 
Toll receptor signaling pathway (P00054) 8.32 1.00E+00 IRAK1 
VEGF signaling pathway (P00056) 6.94 1.00E+00 KDR 
Pathways in bold were pathways that presented both upregulated as downregulated genes in C-O clones (See Appendix Table 5). 
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Appendix Figure 1. Periodontal ligament derived (PDL) CD105+-enriched population characterization. A: Flow cytometric analysis of PDL 
CD105+-enriched population. The relative levels of cell surface expression was analyzed using CD105, CD146, CD166, STRO-1, CD34 and CD45 
antibodies (red histograms) and their isotype-matched antibodies as control (black histograms). Note that the purification process by magnetic cell 
sorting was efficient, since 99.85% of cells were positive for CD105. Cells also expressed other mesenchymal cell-related surface markers, such 
as CD166, STRO-1 and CD146, and did not expressed hematopoietic related markers CD34 and CD45. B: Alizarin Red Stain (AR-S) assay 
demonstrated that PDL CD105+-enriched population (105+) showed similar potential of biomineralization as the unsorted population (PDL) when 
cultivated under osteogenic induction (OM). Quantification AR-S demonstrated that both PDL CD105+-enriched population and unsorted PDL 
presented significant increase of AR-S when cultivated in OM comparing control medium, but no statistical significant difference between PDL 
CD105+-enriched population and unsorted PDL was observed in OM. Distinct uppercase letters represent significant difference (p<0.05) intragroup, 
and distinct lowercase letters represent significant difference (p<0.05) intergroup (Two-way Anova/Tukey test).  
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2.2. Artigo 2: Transcriptomic profile of human periodontal ligament cell clones in 
osteoblastic/cementoblastic (O/C) differentiation  
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Abstract 
 
The periodontium is composed by heterogeneous cell populations, comprising cells related to 
the periodontal ligament and gingiva, non-mineralized tissues, and other two mineralized 
tissues, cementum and alveolar bone. When the periodontium is destructed in periodontitis, the 
regeneration of lost tissues is very difficult to obtain. Recently, regenerative approaches based 
on biological knowledge of tissue formation have been investigated. However, the 
understanding of commitment of periodontal ligament cells to form different tissues still not 
been fully elucidated. To better define the gene expression in differentiating periodontal cells, 
here we compared the transcriptomic profile of primary cell clones committed to 
osteoblastic/cementoblastic (O/C) differentiation (C-O clones) and clones committed to 
fibroblastic phenotype (C-F clones) using next-generation sequencing technology (RNA-seq) 
when cultivated under O/C differentiation induction condition (OM) in vitro. Some genes 
commonly reported in many biological processes and pathways were investigated in 
immortalized cell clones with correlated phenotypes during the process of differentiation 
induction to validate the RNA-seq. The C-O clones showed higher number of up-regulated 
differentially expressed genes (DEG) than C-F clones. The up-regulated genes in C-O clones 
were related to many biological processes, including “mesenchymal cell differentiation”, 
“regulation of osteoblast differentiation”, “regulation of ossification”, “mesenchyme 
development”, and “vasculature development”. The “angiogenesis” and “CCKR signaling” 
pathways were significantly overrepresented in C-O clones compared to C-F clones. The genes 
BMP4, WNT2, WNT5A and WIF1 showed to be differentially expressed between periodontal 
ligament clones with distinct differentiation commitment potential, both in primary as in 
immortalized cell clones. The up-regulation of these genes involved to those biological 
processes and pathways are related to higher commitment to O/C differentiation in cells of 
periodontal ligament.  
 
Keywords: periodontal ligament cells, differentiation, mineralization, high-throughput 
transcriptome sequencing, differential gene expression, pathway analysis.  
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Introduction  
Periodontitis is a polimicrobial infection-induced inflammatory disease in the 
periodontium characterized by connective attachment loss and alveolar bone destruction 
(Armitage, 1999). Epidemiological studies show that periodontitis still a prevalent disease 
world-wide (Dye, 2012), and that this periodontal disease may lead to functionally comprised 
dentition and affect the quality of life of many subjects (Meusel et al., 2015; Mourao et al., 
2015).  
For the last decades, many attempts have been made in order to regenerate the 
tissues destroyed by periodontitis, including bone replacement grafts, guided tissue 
regeneration, enamel matrix derivative, and combination of  them (Susin & Wikesjo, 2013; 
Avila-Ortiz et al., 2015; Kao et al., 2015). However, these current clinical approaches have not 
shown complete and predictable regeneration of periodontal tissues, i.e., formation of 
cementum, periodontal ligament (PDL), and alveolar bone in a similar pattern as previously to 
the periodontal disease occurrence (Susin & Wikesjo, 2013; Avila-Ortiz et al., 2015; Kao et al., 
2015; Lin et al., 2015). Therefore, emerging regenerative approaches based on a sound 
biological rationale have been proposed to achieve improved clinical outcomes (Macneil & 
Somerman, 1999; Ivanovski et al., 2014; Lin et al., 2015).  
The periodontium is a complex structure composed by mineralized (cementum and 
alveolar bone) and non-mineralized tissues (PDL and gingiva) in an intimate relationship. 
Consequently, the regeneration of the periodontium demands a well-coordinated process of cell 
differentiation to form these tissues. Although we know that PDL is constituted by 
heterogeneous cell populations, comprising fibroblastic and mineralized tissue-forming 
progenitor cells (Liu et al., 1997; Seo et al., 2004; Barkana et al., 2007; Fujii et al., 2008; Saito 
et al., 2014), the mechanisms that regulate the differentiation process are not fully understood 
(Fujii et al., 2008; Han et al., 2015). Here we purified PDL cell clones committed to O/C 
phenotype (C-O clones) and clones committed to fibroblastic phenotype (C-F clones), and 
explored their transcriptome, using a next-generation sequencing technology (RNA-seq) , when 
cultivated under osteogenic induction factors. The present study aimed to describe the 
transcriptional profile involved in O/C differentiation of PDL cell clones. To our knowledge, 
this is the first study to analyze O/C differentiation in human PDL cell clones on comprehensive 
scale using high-throughput transcriptome sequencing.  
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Material and Methods 
Cell culture and induction of O/C differentiation 
The procedures of this study was approved by Institutional Review Board of 
Piracicaba Dental School – University of Campinas (#053/2013) and informed consent was 
obtained from patients. Culture of PDL-derived cells and magnetic-activated cell sorting 
(MACS) to obtain a CD105+ enriched population were performed as previously described 
(Silverio et al., 2010). Isolation of single cell–derived colonies (clones) from a CD105-enriched 
PDL progenitor cell population was performed by the ring-cloning technique as previously 
described (Saito et al., 2014).   
Two primary cell clones that showed the potential to differentiate into O/C 
phenotype (G13 and G48 clones), named C-O clones, and two primary cell clones that did not 
showed this potential, defined as presenting fibroblastic phenotype (G16 and G23 clones), 
named C-F clones, by our previous studies were selected to have their RNA extracted after 
cultivation in O/C induction medium for 14 days and be analyzed by RNA-seq. One 
immortalized cell clone with characteristic of C-O clone (named 2-14), and one immortalized 
cell clone with characteristics of C-F clone (named 2-52) were used to validate the data by 
quantitative reverse transcription-polymerase chain reaction (qRT-PCR).  
For in vitro biomineralization assay, each cell clone were seeded (2x105cells/well) 
in 24-well plates with Dulbecco’s modified Eagle medium high glucose (Gibco, Cat #1199-
065,USA) supplemented with 10% Fetal Bovine Serum (FBS) (Gibco, Cat #10500-064, USA), 
1% Anti-Anti (Gibco, Cat #15240-062, USA) (DMEM) and incubated for 24 hours. After this 
period, cells were cultivated in osteogenic medium (OM) composed by  DMEM supplemented 
with 50 mg/mL ascorbic acid (Sigma-Aldrich, Cat #A4544, China) 10 mM b-glycerophosphate 
(Sigma-Aldrich, Cat #G9422, USA), and 10-8 M dexamethasone (Sigma-Aldrich, Cat #D2915, 
USA) for 21 days (immortalized clones) or 28 days (primary clones) with media change twice 
per week. At the end of the induction period, the Alizarin Red staining (AR-S) assay was 
performed as previously described (Zhao et al., 2015). Primary and immortalized cell clones 
were cultivated in control (DMEM) and O/C induction medium (OM), and confirmed their 
phenotype as C-O and C-F clones (Figure 1).  
 
RNA extraction 
For RNA isolation, each cell clone were seeded (2x105cells/well) in 6-well plates 
with DMEM and incubated for 24 hours. After this period, the medium was replaced by OM. 
Cells were cultured for 14 days, with media changes twice weekly. At the established period 
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(3, 7 or 14 days), cells were lyzed for total RNA extraction using TRIzol reagent (Invitrogen, 
Cat #15596-018, USA), as previously described (Saito et al., 2014), followed by a 
phenol/chloroform extraction, and isopropanol precipitation. RNA samples were treated with 
Turbo DNA-free to remove genomic DNA (Ambion, Cat #1907, USA). 
 
RNA deep sequencing (RNA-seq) 
RNA-seq was performed using Illumina TruSeq RNA Sample Preparation kit v2 
(Illumina, Cat# RS-122-2002, USA), according to the manufacturer’s instruction. Briefly, 1 µg 
total DNA-free RNA samples obtained after cultivation of primary cell clones during 14 in OM 
were processed to purify mRNA molecules. mRNA was fragmented and copied into first strand 
cDNA, followed by second strand cDNA synthesis. cDNA fragments were submitted to end 
repair process, addition of single adenosine base and adapter ligation. Finally, processed cDNA 
were amplified by 15 PCR cycles to create de cDNA library. Library was read in HiSeq 2500 
(v3) (Illumina, San Diego, CA, USA). 
 
Analysis of RNA-seq data 
Raw data quality was evaluated by FastQC 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/), and filtered reads of RNA library 
were mapped against the human genome (GRCh38) using the pipeline Tophat2-Cufflinks 
(Trapnell et al., 2012). Fragments per kilobase of transcript per million (FPKM) mapped reads 
were calculated by RSEM program (Li & Dewey, 2011). Differentially expressed genes (DEG) 
between C-O and C-F clones cultivated in OM were obtained by DESeq and EdgeR packages 
(R/Bioconductor)(Anders et al., 2013) with α=5% and |log2(fold change)| ≥ 1 . The heatmap 
graphic was generated based on z-score values calculated from FPKMs values of DEG between 
C-F versus C-O, using R package “pheatmap”. 
DEG between C-O versus C-F were evaluated for gene ontology (GO) 
overrepresentation analysis (http://amigo.geneontology.org) compared to Homo sapiens genome 
background (Ashburner et al., 2000; Mao et al., 2015), and pathway overrepresentation in 
Panther Classification System (http://pantherdb.org/), using Bonferroni correction for multiple 
tests to calculate p-value. 
 
Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) 
Single-stranded complementary DNA (cDNA) was synthesized from 0.5 µg total 
DNA-free RNA using ExScript RTase kit (Takara Biotechnology Co., P.R. China), following 
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the manufacturer’s recommendations. qRT-PCR was performed using the samples of cDNA 
and SYBR Green II  (Takara Biotechnology Co., P.R. China) on the Thermal Cycler Dice Real 
Time System Takara Biotechnology Co., P.R. China)  under the following conditions: 95°C for 
10 s (initial denaturation), then 40 cycles at [95°C for 5 s and 60°C for 30 s], followed by a 
dissociation program at 95°C for 15 s, 60°C for 30 s, and 95°C for 15 s, using  primers sequences 
BMP4, WNT2, WNT5A, WIF1 and GAPDH (Table 1). Relative quantification of reactions 
products was accomplished to GAPDH and calculated by the ΔCT-method. 
 
Statistical Analysis 
The data were expressed as mean ± standard deviation (SD), two-way analysis of 
variance (ANOVA) were used to analyze difference among three or more 
groups.Transformation of data was used when necessary. P values of <0.05 were considered 
significant. 
 
Results and discussion 
The lack of characterization of different cell populations and markers of commited 
progenitors has hampered a faster development of tissue engineering approaches (Menicanin et 
al., 2009). “–omics” has emerged as tool for comprehensively understand the biological events 
that occur in certain processes or diseases (Kebschull et al., 2017). This is the first report of 
transcriptomic profile of purified cell clones from PDL during differentitation into O/C 
phenotype. The isolation of cell clones allowed the analysis of purified cell populations that 
constitute the PDL (Liu et al., 1997; Barkana et al., 2007; Tomokiyo et al., 2008; Saito et al., 
2014). The RNA-seq analysis allows to describe the range of transcripts without the need for a 
priori target specification, leading to an unbiased approach to find novel genes important for 
cell commitment (Ayturk et al., 2013; Twine et al., 2014).   
RNA collected from primary PDL cell clones were submitted to RNA-seq analysis. 
By the FastQC analysis, around 84% of the reads were at optimum quality and aligned to human 
genome (Appendix Table 1). Only the aligned portions to the genome were retained for 
subsequent analysis. The heatmap shows the total gene expression pattern of C-O clones 
compared to C-F clones  when cultivated in OM for 14 days, illustrating that C-O clones present 
higher numbers of up-regulated genes (388) than down-regulated genes (84) when inducted to 
O/C differentiation (Figure 2) (list of up-regulated and down-regulated genes in Appendix 
Tables 2 and 3, respectively).  
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To understand the biological context of DEG, Gene Ontology (GO) analysis was 
used to map the biological process overrepresentation related to the up-regulated genes in C-O 
clones and C-F clones cultivated during 14 days in OM, GO analysis showed that there was 
239 biological processes enriched compared to Homo sapiens genome (Appendix Table 4), 
whereas no overrepresented biological process was observed when down-regulated genes in C-
O clones cultivated in OM were evaluated. Among the 239 biological processes 
overrepresented in C-O clones, we found out biological processes that are related to 
mesenchymal and osteoblastic differentiation and angiogenesis, such as “mesenchymal cell 
differentiation” (GO: 0048762), “regulation of osteoblast differentiation” (GO: 0045667), 
“regulation of ossification” (GO: 0030278), “mesenchyme development” (GO: 0060485), and 
“vasculature development” (GO: 0001944). These genes related to these biological processes 
are shown in Table 2.  
To further investigate the differences between C-O and C-F clones, the DEG were 
analyzed for pathway overrepresentation. C-O clones exhibited a significantly enrichement of 
up-regulated genes in two pathways: “Angiogenesis” (P00005) and “CCKR signaling map” 
(P06959) (Table 3), and none significantly overrepresented pathway was detected in down-
regulated genes of C-O clones. Although “Cadherin signaling pathway” (P00012), 
“Inflammation mediated by chemokine and cytokine signaling pathway” (P00031), and “Wnt 
signaling pathway” (P00057) were not considered statistically enriched pathways in C-O 
clones, they showed 10 or more genes related to these pathways (Appendix Table 5). Certain 
genes related to mineralized tissue formation (Yan et al., 2009; Lan et al., 2014), such as TGF-
β/BMPs (BMP2, BMP4), Wnt family (WNT2, WNT5A, WIF1), and Angiogenesis (PDGFRA, 
VEGFA, WNT5A) were up-regulated in C-O clones, and the expression of these genes may 
favor the commitment to O/C differentiation of these C-O clones.  
The up-regulation of genes related to Angiogenesis pathway in O/C differentiation 
of C-O clones is in accordance to previous report describing bone mesenchymal stem cell 
differentiation into osteoblastic phenotype (Granchi et al., 2010), suggesting that expression of 
these genes are important to bone formation. The up-regulation of VEGFA was also recently 
reported in a RNA-seq analysis of genes related to osteoblast differentiation (Twine et al., 
2014). ANGPT1 is also related to angiogenesis in angiopoetin-dependent pathway. Although 
the expression of genes related to this pathway have been reported in bone cells, the role in 
bone cell development is not clear (Granchi et al., 2010). AMIGO2 is another gene that was 
described to be up-regulated in our primary C-O clones compared to C-F clones (Appendix 
Table 2). Previous report had also shown that the expression of this gene was higher in 
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osteoblast differentiating cells (Granchi et al., 2010). At the time of publication, Granchi et al. 
could not describe the function of AMIGO2 in osteoblast differentiation, but a recent report 
described that AMIGO2 interact with PDK1 and they are related to cell survival and 
angiogenesis (Park et al., 2015a). In fact, the gene PDK1 was also up-regulated in our C-O 
clones (Appendix Table 2) and is related to many pathways, including the significant enriched 
“CCKR signaling pathway”, as well as other pathways such as “Inflammation mediated by 
chemokine and cytokine signaling pathway” and “PDGF signaling pathway” (Appendix Table 
5).  
The gene CPE was up-regulated to primary C-O clones and is related to “CCKR 
signaling pathway”. CPE was reported to interact with Wnt signaling pathway (Skalka et al., 
2013). Wnt signaling has been classically divided into canonical/β-catenin and non-canonical 
pathways (Ling et al., 2009), but a cross-talk between these two Wnt pathways is important for 
osteoblastic differentiation (Baksh et al., 2007). Although Wnt signaling pathway was not 
considered significantly enriched in C-O clones when cultivated in OM, it was noticed that 
some genes related to angiogenesis pathway (SFRP1, WNT2, WNT2B and WNT5A) were also 
present in Wnt signaling pathway. Therefore, we speculate that even though the up-regulation 
of these genes were important to commitment of C-O clones into O/C phenotype, the Wnt 
signaling pathway was not considered enriched by Panther Classification System because the 
number of genes expected to be up-regulated in Homo sapiens genome for Wnt pathway was 
higher (309 genes) than for the other pathways (176, and 173 for Angiogenesis, and CCKR 
signaling, respectively), therefore, the number of up-regulated genes was not sufficient to 
achieve statistical significance.  
The expression of genes WNT2, WIF1, BMP4, and WNT5A were selected to be 
analyzed by qRT-PCR during the process of differentiation in immortalized periodontal cell 
clones that present similar distinct phenotypes of C-O and C-F clones as primary clones to 
validate the RNA-seq analysis. These genes had been commonly related to biological processes 
and pathways significantly overrepresented in C-O clones compared to C-F clones when 
cultivated under O/C differentiation induction, and had been previously shown to be up-
regulated in C-O clones in cultivation without induction in our previous study (data not shown). 
Among the up-regulated genes in C-O clones cultivated in differentiating O/C medium 
induction, WNT2, WIF1, and BMP4 were transcripts that were previously noticed to be also up-
regulated in C-O clones compared to C-F clones when cultivated without stimulation in our 
previous study (data not shown). WNT5A was not observed in C-O clones cultivated without 
O/C induction, but it was significantly expressed in C-O clones compared to C-F clones in 
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differentiation induction, and it has demonstrated to influence PDL cells (Hasegawa et al., 
2015), therefore, it was also investigated during osteogenic induction of the immortalized 
clones that presented O/C phenotype (2-14) and fibroblastic phenotype (2-52).  
WNT2 had a significant increase at day 14 of differentiation induction in 2-14 
compared to 2-52 (Figure 3A). The gradual increase in expression of Wnt related genes, 
including WNT2, was also reported in osteoblast differentiation (Zhong et al., 2012), and in 
human dental papilla cells treated with osteogenic medium associated with dental pulp cell-
conditioned medium (Park et al., 2015b). 
WIF1 presented a different behavior comparing 2-14 and 2-52 by qRT-PCR to 
primary C-O and C-F clones analyzed by RNA-seq. WIF1 was also detected to be up-regulated 
in primary C-O clones by RNA-seq, but no difference was detected between 2-14 and 2-52 by 
qRT-PCR at 14 days of induction, and in earlier time points, the expression of WIF1 was higher 
in 2-52 than 2-14 (Figure 3B). The expression of WIF1 has been reported in different types of 
cells in the literature. It has been reported to be expressed in CD271+ mesenchymal stromal 
cells (Churchman et al., 2012) and to be higher expressed in cementoblast compared to 
osteoblasts (Matthews et al., 2016). WIF1 is increased in late phases of osteoblast maturation, 
as a feedback loop that controls osteoblast maturation (Vaes et al., 2005). Therefore, we can 
suggest that expression of WIF1can be both related to inhibition of commitment to osteoblastic 
phenotype, as well as downregulation of Wnt pathway after maturation of mineralizing 
phenotype in O/C cells.  
BMP4 was up-regulated in C-O clone (2-14) compared to C-F clone (2-52) in all 
evaluated periods (Figure 3C). Previous study showed that expression of BMP4 is higher in 
immortalized cell clones that present capacity to differentiate into O/C than clones that present 
less capacity (Tomokiyo et al., 2008). BMP4 was also shown to be one of the most predictive 
gene expression markers of in vivo bone formation potential according to a recent RNA-seq 
analysis (Twine et al., 2014). BMP4 has also been reported to necessary to act synergically with 
VEGF to enhance bone formation (Peng et al., 2002).  
WNT5A was up-regulated in 2-14 in all periods, but the expression was higher in 
the initial period of O/C induction and decreased through time (Figure 3D). Studies have shown 
that bone marrow commitment to osteoblast differentiation is regulated by a switch from Wnt 
canonical to non-canonical signaling (Baksh et al., 2007), in which WNT5A is considered one 
of the main Wnt non-canonical molecules that regulate osteoblast differentiation (Baksh et al., 
2007; Hay et al., 2014; Kobayashi et al., 2015).  
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In conclusion, by the comparison of transcriptional profile between PDL cell clones 
that were able to differentiate into O/C phenotype (C-O clones) and clones that were not able 
to differentiate into O/C phenotype (fibroblastic committed) (C-F clones) using RNA-seq 
technology, we demonstrate that angiogenesis and CCKR signaling pathways, and genes related 
to Wnt signaling pathway are important to commitment of PDL cells to O/C phenotype and that 
the biological processes “mesenchymal cell differentiation”, “regulation of osteoblast 
differentiation”, “regulation of ossification”, “mesenchyme development”, and “vasculature 
development” are involved in this differentiation process. The genes BMP4, WNT2, WNT5A 
and WIF1 showed to be differentially expressed between PDL clones with distinct 
differentiation commitment potential, both in primary cell clones or immortalized clones. The 
up-regulation of these genes involved to those biological processes and pathways are related to 
higher commitment to O/C differentiation in cells of periodontal ligament. We expect that the 
knowledge of these biological processes and pathways involved in regulation of PDL cells 
committed to O/C phenotype serve as basis for promoting new therapies for periodontal 
regeneration.  
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Figures 
 
Figure 1. A. Alizarin Red Stain (AR-S) assay of primary periodontal ligament clones 
demonstrated that clones G13 and G48 were able to form minerals in vitro, and they were named 
as osteo/cementoblastic clones (C-O clones), whereas G16 and G23 were not able to form 
minerals in vitro, and were named as fibroblastic clones (C-F clones).  B. AR-S assay of 
immortalized cell 2-14 and 2-52, showed two distincts phenotypes of C-O and C-F clones, 
respectively.  
 
 
 
Figure 2. C-O clones showed a higher 
trancriptional activity when cultivated in 
osteoblastic/cementoblastic induction 
medium. C-O clones presented 388 genes 
up-regulated compared to C-F clones, and 
only 84 down-regulated genes.  
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 2 
Figure 3.  Gene 3 
expression analyzed by 4 
qRT-PCR in immortalized 5 
cell clones expressing 6 
distinct phenotypes: 2-14 7 
present is a clone with 8 
potential to differentiate 9 
into osteo/cementoblastic 10 
phenotype (C-O), and 2-11 
52 is a clone that express a 12 
fibroblastic phenotype (C-13 
F). Different uppercase 14 
letters represent 15 
significant difference 16 
(p<0.05) in the same 17 
period (inter-group). 18 
Different lowercase letters 19 
represent significant 20 
difference (p<0.05) in the 21 
same clone and condition 22 
along the time (intra-23 
group). 24 
25 
Tables 26 
Table 1. Specific primer sequence for qRT-PCR. 27 
 28 
 29 
 30 
 31 
 32 
 33 
Gene ID Primers (5’ 3’) 
BMP4 
Forward: CTGCAACCGTTCAGAGGTC 
Reverse: TGCTCGGGATGGCACTAC 
GAPDH 
Forward: GTCAGTGGTGGACCTGACC 
Reverse: TGCTGTAGCCAAATTCGTTG 
WIF1 
Forward: CCAGGGAGACCTCTGTTCAA 
Reverse: TTGGGTTCATGGCAGGTT 
WNT2 
Forward: TTTGGCAGGGTCCTACTCC 
Reverse: CCTGGTGATGGCAAATACAA 
WNT5A 
Forward: CTGCAGCCAACTGGCAGGACT 
Reverse: CGCGGCTGCCTATCTGCATCA 
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Table 2. Overrepresented biological processes related mesenchymal differentiation, ossification 1 
and angiogenesis and respective up-regulated genes in C-O clones compared to C-F clones. 2 
(For additional overrepresented biological processes, see Appendix Table 4).  3 
GO biological process  
Fold 
Enrichment 
p-value Gene Symbol 
mesenchymal cell 
differentiation 
(GO:0048762) 
5.81 7.21E-04 
BMP2; BMP4;FAM83D; EDNRB; 
EFNB1; HGF; LAMA5; MSX1; 
SEMA3B; SEMA4D; SEMA4G; 
SFRP1; TGFB2; WNT2; WNT5A 
regulation of osteoblast 
differentiation 
(GO:0045667) 
5.65 1.87E-02 
AREG; BMP2; BMP4; CEBPD;  
FAM20C; HDAC4; HGF; IL6; PTCH1; 
RORB; SEMA4D; SFRP1 
regulation of 
ossification 
(GO:0030278) 
4.6 5.88E-03 
AREG; BMP2; BMP4; CEBPD; ENPP1; 
FAM20C; HDAC4; HGF; IL6; PTCH1; 
RORB; SEMA4D; SFRP1;SOST; 
TGFB2; WNT5A 
mesenchyme 
development 
(GO:0060485) 
4.35 1.21E-02 
BMP2; BMP4; EDNRB; EFNB1; 
FAM83D; FOXF1; HGF; LAMA5; 
MSX1; SEMA3B; SEMA4D; SEMA4G; 
SFRP1; TGFB2; WNT2; WNT5A 
vasculature 
development 
(GO:0001944) 
2.79 4.77E-02 
ACKR3; ANGPT1; APOE; BMP4; 
DLL1; EPHB2; FOXF1; HMOX1; 
ITGB3; LAMA4; LAMA5; PDGFRA; 
PDPN; PGF; PLAU; PRDM1; 
PRICKLE1; PTGS2;  RSPO3; SAT1; 
SOX4; TGFB2;  THSD7A; VEGFA; 
WNT2 
 4 
Table 3. Significantly overrepresented pathways related to up-regulated genes in C-O clones 5 
compared to C-F clones. (For additional pathways related to up-regulated genes in C-O clones 6 
compared to C-F clones, see Appendix Table 5). 7 
PANTHER 
Pathways 
Fold 
Enrichment 
p-value Gene Symbol 
Angiogenesis 
(P00005) 
4.96 4.09E-05 
ANGPT1; BIRC5; DLL1; EFNB1; EPBH2; 
FOS; MAPK10; PDGFRA; PLD1; PRR5; 
RERG; SFRP1; VEGFA; WNT2; WNT2B; 
WNT5A 
CCKR 
signaling map 
(P06959) 
4.1 3.95E-03 
CCK; CPE; CXCL1; FOS; IRS1; ITPR1; 
MAP2K6; MAPK10; MMP3; PDK1; PLAU; 
PTGS2; RGS2 
 8 
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Appendix: Transcriptomic profile of human periodontal ligament cell clones in osteoblastic/cementoblastic (O/C) differentiation 
Appendix Table 1.  Summary of mapping results for RNA sequencing. 
 R1 R2 Total 
Sample Name # Total reads # aligned # Total reads # aligned # Total reads # aligned 
G13 (C-O) 20209360 16988331 (84.1%) 20209360 17039626 (84.3%) 40418720 34027957 (84.2%) 
G48 (C-O) 26359512 22089457 (83.8%) 26359512 22150373 (84.0%) 52719024 44239830 (83.9%) 
G16 (C-F) 30410108 25617082 (84.2%) 30410108 25688051 (84.5%) 60820216 51305133 (84.4%) 
G23 (C-F) 22090731 18685570 (84.6%) 22090731 18774559 (85.0%) 44181462 37460129 (84.8%) 
C-O: clone that shows osteo/cementoblastic phenotype. C-F: clone that shows fibroblastic phenotype.  
 
Appendix Table 2. Significantly upregulated genes of C-O clones (clones with potential to differentiate into osteo/cementoblastic phenotype) 
compared to C-F clones (clones that shows fibroblastic phenotype). 
Gene Symbol Gene_description |log2FoldChange| p value 
TRPA1 
transient receptor potential cation channel, subfamily A, member 1 [Source:HGNC 
Symbol;Acc:HGNC:497] 
4.21649655 1.00426E-59 
PDPN podoplanin [Source:HGNC Symbol;Acc:HGNC:29602] 4.324237457 9.07393E-51 
HGF hepatocyte growth factor (hepapoietin A; scatter factor) [Source:HGNC Symbol;Acc:HGNC:4893] 3.66951968 8.54089E-51 
CMKLR1 chemokinelike receptor 1 [Source:HGNC Symbol;Acc:HGNC:2121] 4.163665165 1.29748E-44 
CSGALNACT1 
chondroitin sulfate N acetylgalactosaminyltransferase 1 [Source:HGNC 
Symbol;Acc:HGNC:24290] 
3.318636751 5.17146E-42 
EPB41L3 erythrocyte membrane protein band 4.1like 3 [Source:HGNC Symbol;Acc:HGNC:3380] 3.305274542 1.44924E-40 
ADAMTS3 
ADAM metallopeptidase with thrombospondin type 1 motif, 3 [Source:HGNC 
Symbol;Acc:HGNC:219] 
3.200155681 2.33735E-40 
RGS18 regulator of Gprotein signaling 18 [Source:HGNC Symbol;Acc:HGNC:14261] 6.693539068 6.38254E-40 
FGF7 fibroblast growth factor 7 [Source:HGNC Symbol;Acc:HGNC:3685] 3.17190694 7.92897E-40 
NR4A2 nuclear receptor subfamily 4, group A, member 2 [Source:HGNC Symbol;Acc:HGNC:7981] 3.74913379 7.7205E-37 
LHCGR luteinizing hormonechoriogonadotropin receptor [Source:HGNC Symbol;Acc:HGNC:6585] 4.245053308 3.15217E-32 
AREG amphiregulin [Source:HGNC Symbol;Acc:HGNC:651] 3.618408623 8.71715E-31 
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MMP3 
matrix metallopeptidase 3 (stromelysin 1, progelatinase) [Source:HGNC 
Symbol;Acc:HGNC:7173] 
3.054328931 8.73493E-28 
COL4A5 collagen, type IV, alpha 5 [Source:HGNC Symbol;Acc:HGNC:2207] 5.490336479 2.15604E-27 
TMEM56 transmembrane protein 56 [Source:HGNC Symbol;Acc:HGNC:26477] 4.769031722 1.35167E-26 
ARHGAP28 Rho GTPase activating protein 28 [Source:HGNC Symbol;Acc:HGNC:25509] 4.083128281 1.43592E-26 
SLC19A3 
solute carrier family 19 (thiamine transporter), member 3 [Source:HGNC 
Symbol;Acc:HGNC:16266] 
4.023590091 2.59961E-26 
MMD monocyte to macrophage differentiationassociated [Source:HGNC Symbol;Acc:HGNC:7153] 2.535636734 9.53298E-26 
FAM198B family with sequence similarity 198, member B [Source:HGNC Symbol;Acc:HGNC:25312] 2.882541658 8.33889E-25 
PTGS2 
prostaglandinendoperoxide synthase 2 (prostaglandin GH synthase and cyclooxygenase) 
[Source:HGNC Symbol;Acc:HGNC:9605] 
3.620794815 2.00243E-24 
SLC16A4 solute carrier family 16, member 4 [Source:HGNC Symbol;Acc:HGNC:10925] 3.480164431 2.63153E-24 
CCL7 chemokine (CC motif) ligand 7 [Source:HGNC Symbol;Acc:HGNC:10634] 4.371943978 1.98785E-23 
STC1 stanniocalcin 1 [Source:HGNC Symbol;Acc:HGNC:11373] 3.018735604 2.27611E-23 
TGFB2 transforming growth factor, beta 2 [Source:HGNC Symbol;Acc:HGNC:11768] 2.214200564 7.38027E-23 
CD4 CD4 molecule [Source:HGNC Symbol;Acc:HGNC:1678] 3.163178679 2.15262E-22 
JUP junction plakoglobin [Source:HGNC Symbol;Acc:HGNC:6207] 3.419476403 3.53123E-22 
CXCL6 chemokine (CXC motif) ligand 6 [Source:HGNC Symbol;Acc:HGNC:10643] 2.569295411 4.05242E-21 
GNLY granulysin [Source:HGNC Symbol;Acc:HGNC:4414] 5.190535331 7.16559E-21 
SLC1A3 
solute carrier family 1 (glial high affinity glutamate transporter), member 3 [Source:HGNC 
Symbol;Acc:HGNC:10941] 
2.420942616 7.87067E-21 
CPE carboxypeptidase E [Source:HGNC Symbol;Acc:HGNC:2303] 2.346388261 1.05747E-20 
PTPN22 
protein tyrosine phosphatase, nonreceptor type 22 (lymphoid) [Source:HGNC 
Symbol;Acc:HGNC:9652] 
2.969498831 9.45935E-20 
SAA1 serum amyloid A1 [Source:HGNC Symbol;Acc:HGNC:10513] 2.453562632 3.45584E-19 
SMOX spermine oxidase [Source:HGNC Symbol;Acc:HGNC:15862] 2.121291769 5.73511E-19 
ITPRIP inositol 1,4,5trisphosphate receptor interacting protein [Source:HGNC Symbol;Acc:HGNC:29370] 2.00799316 7.07928E-19 
PAPPA pregnancyassociated plasma protein A, pappalysin 1 [Source:HGNC Symbol;Acc:HGNC:8602] 1.897929577 2.32977E-18 
PGF placental growth factor [Source:HGNC Symbol;Acc:HGNC:8893] 3.307071944 3.22074E-18 
HMOX1 heme oxygenase (decycling) 1 [Source:HGNC Symbol;Acc:HGNC:5013] 2.028589502 4.00601E-18 
ACSL4 acylCoA synthetase longchain family member 4 [Source:HGNC Symbol;Acc:HGNC:3571] 2.748965521 8.22625E-18 
TMEM176B transmembrane protein 176B [Source:HGNC Symbol;Acc:HGNC:29596] 5.934031412 8.73013E-18 
CSF3 colony stimulating factor 3 (granulocyte) [Source:HGNC Symbol;Acc:HGNC:2438] 3.266833782 9.6259E-18 
FIBIN fin bud initiation factor homolog (zebrafish) [Source:HGNC Symbol;Acc:HGNC:33747] 2.190914109 1.44041E-17 
RRAD Rasrelated associated with diabetes [Source:HGNC Symbol;Acc:HGNC:10446] 2.165021051 1.55056E-17 
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PCDHGB4 protocadherin gamma subfamily B, 4 [Source:HGNC Symbol;Acc:HGNC:8711] 2.461232656 1.86373E-17 
MSX1 msh homeobox 1 [Source:HGNC Symbol;Acc:HGNC:7391] 1.898931149 4.56856E-17 
ISYNA1 inositol3phosphate synthase 1 [Source:HGNC Symbol;Acc:HGNC:29821] 2.342154833 5.45923E-17 
SDPR serum deprivation response [Source:HGNC Symbol;Acc:HGNC:10690] 2.171792735 5.40222E-17 
ACSL1 acylCoA synthetase longchain family member 1 [Source:HGNC Symbol;Acc:HGNC:3569] 1.893307986 6.55049E-17 
STOM stomatin [Source:HGNC Symbol;Acc:HGNC:3383] 2.008867676 1.07826E-16 
MAP2K6 mitogenactivated protein kinase kinase 6 [Source:HGNC Symbol;Acc:HGNC:6846] 3.185003939 1.14815E-16 
KIF20A kinesin family member 20A [Source:HGNC Symbol;Acc:HGNC:9787] 2.140542708 1.23745E-16 
TNFRSF11B 
tumor necrosis factor receptor superfamily, member 11b [Source:HGNC 
Symbol;Acc:HGNC:11909] 
1.873706737 1.4462E-16 
CHRM2 cholinergic receptor, muscarinic 2 [Source:HGNC Symbol;Acc:HGNC:1951] 2.297458874 1.78018E-16 
FLRT2 fibronectin leucine rich transmembrane protein 2 [Source:HGNC Symbol;Acc:HGNC:3761] 1.962986885 3.7985E-16 
TIMP3 TIMP metallopeptidase inhibitor 3 [Source:HGNC Symbol;Acc:HGNC:11822] 2.288169091 4.28681E-16 
RGS2 regulator of Gprotein signaling 2 [Source:HGNC Symbol;Acc:HGNC:9998] 4.735975619 4.80133E-16 
VWA5A von Willebrand factor A domain containing 5A [Source:HGNC Symbol;Acc:HGNC:6658] 1.899373513 1.56438E-15 
SAA2 serum amyloid A2 [Source:HGNC Symbol;Acc:HGNC:10514] 3.263441845 2.97818E-15 
PDE4D phosphodiesterase 4D, cAMPspecific [Source:HGNC Symbol;Acc:HGNC:8783] 1.948567676 3.64869E-15 
RGS4 regulator of Gprotein signaling 4 [Source:HGNC Symbol;Acc:HGNC:10000] 3.036383283 3.8428E-15 
NR4A3 nuclear receptor subfamily 4, group A, member 3 [Source:HGNC Symbol;Acc:HGNC:7982] 2.252211504 7.30706E-15 
SEPP1 selenoprotein P, plasma, 1 [Source:HGNC Symbol;Acc:HGNC:10751] 2.20515054 7.81288E-15 
SLC30A1 solute carrier family 30 (zinc transporter), member 1 [Source:HGNC Symbol;Acc:HGNC:11012] 1.765628193 8.3085E-15 
SOST sclerostin [Source:HGNC Symbol;Acc:HGNC:13771] 4.430660028 1.4857E-14 
TMEM176A transmembrane protein 176A [Source:HGNC Symbol;Acc:HGNC:24930] 5.069130021 1.63279E-14 
BDNF brain derived neurotrophic factor [Source:HGNC Symbol;Acc:HGNC:1033] 1.847804442 2.05988E-14 
CXCL3 chemokine (CXC motif) ligand 3 [Source:HGNC Symbol;Acc:HGNC:4604] 1.742513308 2.99741E-14 
PDE4B phosphodiesterase 4B, cAMPspecific [Source:HGNC Symbol;Acc:HGNC:8781] 1.708385286 7.0452E-14 
MCTP2 multiple C2 domains, transmembrane 2 [Source:HGNC Symbol;Acc:HGNC:25636] 1.772164178 8.86118E-14 
LPAR3 lysophosphatidic acid receptor 3 [Source:HGNC Symbol;Acc:HGNC:14298] 2.978249892 1.2615E-13 
IGDCC4 
immunoglobulin superfamily, DCC subclass, member 4 [Source:HGNC 
Symbol;Acc:HGNC:13770] 
1.748262392 1.8247E-13 
CDCP1 CUB domain containing protein 1 [Source:HGNC Symbol;Acc:HGNC:24357] 1.810342323 1.92947E-13 
ARHGEF19 Rho guanine nucleotide exchange factor (GEF) 19 [Source:HGNC Symbol;Acc:HGNC:26604] 1.79837438 4.30573E-13 
MMP8 matrix metallopeptidase 8 (neutrophil collagenase) [Source:HGNC Symbol;Acc:HGNC:7175] 2.52411215 4.41003E-13 
TOP2A topoisomerase (DNA) II alpha 170kDa [Source:HGNC Symbol;Acc:HGNC:11989] 1.634300664 5.38791E-13 
MXRA5 matrixremodelling associated 5 [Source:HGNC Symbol;Acc:HGNC:7539] 1.871050754 5.67624E-13 
63 
 
 
6
3 
CLCA2 chloride channel accessory 2 [Source:HGNC Symbol;Acc:HGNC:2016] 3.259014639 8.57007E-13 
EYA4 EYA transcriptional coactivator and phosphatase 4 [Source:HGNC Symbol;Acc:HGNC:3522] 2.212032438 8.76573E-13 
MIR503HG MIR503 host gene (nonprotein coding) [Source:HGNC Symbol;Acc:HGNC:28258] 2.711206864 9.00472E-13 
LAMA5 laminin, alpha 5 [Source:HGNC Symbol;Acc:HGNC:6485] 2.68100409 8.9872E-13 
THSD7A thrombospondin, type I, domain containing 7A [Source:HGNC Symbol;Acc:HGNC:22207] 2.841772773 1.29305E-12 
VEGFA vascular endothelial growth factor A [Source:HGNC Symbol;Acc:HGNC:12680] 1.552659519 1.83052E-12 
RGCC regulator of cell cycle [Source:HGNC Symbol;Acc:HGNC:20369] 1.684500949 2.4316E-12 
PTCH1 patched 1 [Source:HGNC Symbol;Acc:HGNC:9585] 2.005248988 3.33122E-12 
ARHGAP6 Rho GTPase activating protein 6 [Source:HGNC Symbol;Acc:HGNC:676] 1.98545695 3.83891E-12 
SOCS2 suppressor of cytokine signaling 2 [Source:HGNC Symbol;Acc:HGNC:19382] 1.676574815 3.81419E-12 
PTPRN protein tyrosine phosphatase, receptor type, N [Source:HGNC Symbol;Acc:HGNC:9676] 3.447409141 4.11218E-12 
ITPR1 inositol 1,4,5trisphosphate receptor, type 1 [Source:HGNC Symbol;Acc:HGNC:6180] 1.741698296 4.80942E-12 
GALNT15 polypeptide Nacetylgalactosaminyltransferase 15 [Source:HGNC Symbol;Acc:HGNC:21531] 2.525662474 4.99756E-12 
DPP4 dipeptidylpeptidase 4 [Source:HGNC Symbol;Acc:HGNC:3009] 3.949441641 5.32477E-12 
TAC3 tachykinin 3 [Source:HGNC Symbol;Acc:HGNC:11521] 4.42383963 5.74089E-12 
ASPM 
asp (abnormal spindle) homolog, microcephaly associated (Drosophila) [Source:HGNC 
Symbol;Acc:HGNC:19048] 
1.700495081 7.37928E-12 
SLC12A8 solute carrier family 12, member 8 [Source:HGNC Symbol;Acc:HGNC:15595] 1.75035337 8.68104E-12 
FAM20C family with sequence similarity 20, member C [Source:HGNC Symbol;Acc:HGNC:22140] 1.458081035 1.08488E-11 
TNFRSF21 
tumor necrosis factor receptor superfamily, member 21 [Source:HGNC 
Symbol;Acc:HGNC:13469] 
1.681113361 1.69523E-11 
FOS FBJ murine osteosarcoma viral oncogene homolog [Source:HGNC Symbol;Acc:HGNC:3796] 3.103318957 1.79732E-11 
PRICKLE1 prickle homolog 1 (Drosophila) [Source:HGNC Symbol;Acc:HGNC:17019] 2.165648594 2.85314E-11 
STAMBPL1 STAM binding proteinlike 1 [Source:HGNC Symbol;Acc:HGNC:24105] 1.581298796 4.47907E-11 
UCN2 urocortin 2 [Source:HGNC Symbol;Acc:HGNC:18414] 1.744251996 5.10948E-11 
CYGB cytoglobin [Source:HGNC Symbol;Acc:HGNC:16505] 1.823961005 5.45157E-11 
COL24A1 collagen, type XXIV, alpha 1 [Source:HGNC Symbol;Acc:HGNC:20821] 2.261294922 5.73269E-11 
DENND2A DENNMADD domain containing 2A [Source:HGNC Symbol;Acc:HGNC:22212] 2.139410589 5.75875E-11 
PSD3 pleckstrin and Sec7 domain containing 3 [Source:HGNC Symbol;Acc:HGNC:19093] 1.707283735 5.92625E-11 
ITGA2 
integrin, alpha 2 (CD49B, alpha 2 subunit of VLA2 receptor) [Source:HGNC 
Symbol;Acc:HGNC:6137] 
1.486573976 6.41165E-11 
PTHLH parathyroid hormonelike hormone [Source:HGNC Symbol;Acc:HGNC:9607] 3.404326849 7.66624E-11 
PTPRU protein tyrosine phosphatase, receptor type, U [Source:HGNC Symbol;Acc:HGNC:9683] 1.916804796 1.21008E-10 
IL1R1 interleukin 1 receptor, type I [Source:HGNC Symbol;Acc:HGNC:5993] 1.855668092 1.22792E-10 
ATP8B4 ATPase, class I, type 8B, member 4 [Source:HGNC Symbol;Acc:HGNC:13536] 4.971171415 1.4224E-10 
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ABCA1 ATPbinding cassette, subfamily A (ABC1), member 1 [Source:HGNC Symbol;Acc:HGNC:29] 1.477832629 1.62023E-10 
GABARAPL1 GABA(A) receptorassociated protein like 1 [Source:HGNC Symbol;Acc:HGNC:4068] 1.490389882 1.96763E-10 
SORBS2 sorbin and SH3 domain containing 2 [Source:HGNC Symbol;Acc:HGNC:24098] 1.793331848 1.99933E-10 
CDC20 cell division cycle 20 [Source:HGNC Symbol;Acc:HGNC:1723] 1.629434875 2.19268E-10 
GPRC5B 
G proteincoupled receptor, class C, group 5, member B [Source:HGNC 
Symbol;Acc:HGNC:13308] 
2.106186142 2.34158E-10 
ADCY4 adenylate cyclase 4 [Source:HGNC Symbol;Acc:HGNC:235] 1.656931068 2.37539E-10 
GPCPD1 
glycerophosphocholine phosphodiesterase GDE1 homolog (S. cerevisiae) [Source:HGNC 
Symbol;Acc:HGNC:26957] 
1.482577861 2.89792E-10 
FILIP1L filamin A interacting protein 1like [Source:HGNC Symbol;Acc:HGNC:24589] 1.476925205 2.98764E-10 
F2RL2 coagulation factor II (thrombin) receptorlike 2 [Source:HGNC Symbol;Acc:HGNC:3539] 1.860601817 3.57435E-10 
KLHL13 kelchlike family member 13 [Source:HGNC Symbol;Acc:HGNC:22931] 1.705466466 4.55878E-10 
FAM83D family with sequence similarity 83, member D [Source:HGNC Symbol;Acc:HGNC:16122] 1.786297671 5.21611E-10 
CEMIP cell migration inducing protein, hyaluronan binding [Source:HGNC Symbol;Acc:HGNC:29213] 1.903902854 5.7319E-10 
DLGAP5 discs, large (Drosophila) homologassociated protein 5 [Source:HGNC Symbol;Acc:HGNC:16864] 1.705830509 5.851E-10 
SNCAIP synuclein, alpha interacting protein [Source:HGNC Symbol;Acc:HGNC:11139] 1.91755483 7.61386E-10 
PTGS1 
Prostaglandin endoperoxide synthase 1 (prostaglandin GH synthase and cyclooxygenase) 
[Source:HGNC Symbol;Acc:HGNC:9604] 
2.043696928 8.45086E-10 
LINC00958 long intergenic non protein coding RNA 958 [Source:HGNC Symbol;Acc:HGNC:48671] 2.919983058 8.76039E-10 
PCDHGA10 protocadherin gamma subfamily A, 10 [Source:HGNC Symbol;Acc:HGNC:8697] 3.388749349 1.01781E-09 
SFRP1 secreted frizzledrelated protein 1 [Source:HGNC Symbol;Acc:HGNC:10776] 1.705009476 1.30541E-09 
COL7A1 collagen, type VII, alpha 1 [Source:HGNC Symbol;Acc:HGNC:2214] 1.348567895 1.3713E-09 
BEX4 brain expressed, Xlinked 4 [Source:HGNC Symbol;Acc:HGNC:25475] 1.546952275 1.46354E-09 
NEK2 NIMArelated kinase 2 [Source:HGNC Symbol;Acc:HGNC:7745] 2.104326295 1.99235E-09 
GNA14 
guanine nucleotide binding protein (G protein), alpha 14 [Source:HGNC 
Symbol;Acc:HGNC:4382] 
2.035774327 2.30309E-09 
AVPI1 arginine vasopressininduced 1 [Source:HGNC Symbol;Acc:HGNC:30898] 1.453807607 2.50823E-09 
IQGAP3 IQ motif containing GTPase activating protein 3 [Source:HGNC Symbol;Acc:HGNC:20669] 1.572280749 2.75851E-09 
PLAU plasminogen activator, urokinase [Source:HGNC Symbol;Acc:HGNC:9052] 1.830372034 2.78833E-09 
PCDH18 protocadherin 18 [Source:HGNC Symbol;Acc:HGNC:14268] 2.122606247 2.89371E-09 
CLEC2B Ctype lectin domain family 2, member B [Source:HGNC Symbol;Acc:HGNC:2053] 1.791336775 3.02486E-09 
ABCC3 
ATPbinding cassette, subfamily C (CFTRMRP), member 3 [Source:HGNC 
Symbol;Acc:HGNC:54] 
2.787034468 3.16498E-09 
RARRES2 retinoic acid receptor responder (tazarotene induced) 2 [Source:HGNC Symbol;Acc:HGNC:9868] 3.285761806 3.827E-09 
FBXO32 Fbox protein 32 [Source:HGNC Symbol;Acc:HGNC:16731] 1.315865 3.98873E-09 
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SLC2A10 
solute carrier family 2 (facilitated glucose transporter), member 10 [Source:HGNC 
Symbol;Acc:HGNC:13444] 
1.303207083 3.96644E-09 
NAMPTP1 nicotinamide phosphoribosyltransferase pseudogene 1 [Source:HGNC Symbol;Acc:HGNC:17633] 1.73429841 4.40552E-09 
KIF14 kinesin family member 14 [Source:HGNC Symbol;Acc:HGNC:19181] 1.775793858 4.91223E-09 
ENC1 ectodermalneural cortex 1 (with BTB domain) [Source:HGNC Symbol;Acc:HGNC:3345] 1.348325772 4.90009E-09 
PRKAR2B 
protein kinase, cAMPdependent, regulatory, type II, beta [Source:HGNC 
Symbol;Acc:HGNC:9392] 
1.725208207 6.87641E-09 
LMO4 LIM domain only 4 [Source:HGNC Symbol;Acc:HGNC:6644] 1.360684149 7.63884E-09 
ALDH2 aldehyde dehydrogenase 2 family (mitochondrial) [Source:HGNC Symbol;Acc:HGNC:404] 1.428064032 7.76486E-09 
CENPF centromere protein F, 350400kDa [Source:HGNC Symbol;Acc:HGNC:1857] 1.303436867 8.18009E-09 
EDNRB endothelin receptor type B [Source:HGNC Symbol;Acc:HGNC:3180] 3.171377182 8.27407E-09 
CYFIP2 cytoplasmic FMR1 interacting protein 2 [Source:HGNC Symbol;Acc:HGNC:13760] 1.644783233 1.00764E-08 
HMMR hyaluronanmediated motility receptor (RHAMM) [Source:HGNC Symbol;Acc:HGNC:5012] 1.762205503 1.01712E-08 
PDE7B phosphodiesterase 7B [Source:HGNC Symbol;Acc:HGNC:8792] 1.283788247 1.19074E-08 
HSPA2 heat shock 70kDa protein 2 [Source:HGNC Symbol;Acc:HGNC:5235] 1.242422195 1.57994E-08 
TROAP trophinin associated protein [Source:HGNC Symbol;Acc:HGNC:12327] 1.854611031 1.58991E-08 
SOCS1 suppressor of cytokine signaling 1 [Source:HGNC Symbol;Acc:HGNC:19383] 1.669405258 2.02308E-08 
NID2 nidogen 2 (osteonidogen) [Source:HGNC Symbol;Acc:HGNC:13389] 1.491401821 2.04943E-08 
SLC26A6 solute carrier family 26 (anion exchanger), member 6 [Source:HGNC Symbol;Acc:HGNC:14472] 1.330668649 2.62253E-08 
ANGPT1 angiopoietin 1 [Source:HGNC Symbol;Acc:HGNC:484] 1.224820703 3.09235E-08 
LAMA4 laminin, alpha 4 [Source:HGNC Symbol;Acc:HGNC:6484] 1.25661684 3.18819E-08 
DEPDC1 DEP domain containing 1 [Source:HGNC Symbol;Acc:HGNC:22949] 1.548820713 3.38718E-08 
PDK4 pyruvate dehydrogenase kinase, isozyme 4 [Source:HGNC Symbol;Acc:HGNC:8812] 4.209496208 3.52732E-08 
GK glycerol kinase [Source:HGNC Symbol;Acc:HGNC:4289] 2.426186978 5.15383E-08 
SLC40A1 
solute carrier family 40 (ironregulated transporter), member 1 [Source:HGNC 
Symbol;Acc:HGNC:10909] 
2.070115603 5.41181E-08 
VCAN versican [Source:HGNC Symbol;Acc:HGNC:2464] 1.507805788 5.56796E-08 
PRDM1 PR domain containing 1, with ZNF domain [Source:HGNC Symbol;Acc:HGNC:9346] 1.456549483 5.68423E-08 
PENK proenkephalin [Source:HGNC Symbol;Acc:HGNC:8831] 2.901042995 6.27906E-08 
C1orf132 chromosome 1 open reading frame 132 [Source:HGNC Symbol;Acc:HGNC:32018] 1.638821486 6.43999E-08 
PMAIP1 phorbol12myristate13acetateinduced protein 1 [Source:HGNC Symbol;Acc:HGNC:9108] 1.293763067 6.48202E-08 
MGC32805 uncharacterized LOC153163 [Source:EntrezGene;Acc:153163] 4.145424887 7.03216E-08 
PLOD2 procollagenlysine, 2oxoglutarate 5dioxygenase 2 [Source:HGNC Symbol;Acc:HGNC:9082] 1.114855511 7.39363E-08 
CDKN3 cyclindependent kinase inhibitor 3 [Source:HGNC Symbol;Acc:HGNC:1791] 1.627406493 7.55941E-08 
CHMP1B charged multivesicular body protein 1B [Source:HGNC Symbol;Acc:HGNC:24287] 1.225146836 7.54475E-08 
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PC pyruvate carboxylase [Source:HGNC Symbol;Acc:HGNC:8636] 1.579060712 8.45907E-08 
PFKFB4 6phosphofructo2kinasefructose2,6biphosphatase 4 [Source:HGNC Symbol;Acc:HGNC:8875] 1.254976385 8.46036E-08 
FENDRR 
FOXF1 adjacent noncoding developmental regulatory RNA [Source:HGNC 
Symbol;Acc:HGNC:43894] 
2.085773935 9.85871E-08 
PRC1 protein regulator of cytokinesis 1 [Source:HGNC Symbol;Acc:HGNC:9341] 1.212973158 1.06201E-07 
ZRANB1 zinc finger, RANbinding domain containing 1 [Source:HGNC Symbol;Acc:HGNC:18224] 1.217890951 1.09978E-07 
ABCC6 
ATPbinding cassette, subfamily C (CFTRMRP), member 6 [Source:HGNC 
Symbol;Acc:HGNC:57] 
2.22466057 1.29247E-07 
ITGB3 
integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) [Source:HGNC 
Symbol;Acc:HGNC:6156] 
1.747713334 1.37456E-07 
SAPCD2 suppressor APC domain containing 2 [Source:HGNC Symbol;Acc:HGNC:28055] 2.159575919 1.49697E-07 
VNN3 vanin 3 [Source:HGNC Symbol;Acc:HGNC:16431] 2.414803419 1.61776E-07 
NAMPT nicotinamide phosphoribosyltransferase [Source:HGNC Symbol;Acc:HGNC:30092] 1.638393886 1.61926E-07 
TNFRSF10C 
tumor necrosis factor receptor superfamily, member 10c, decoy without an intracellular domain 
[Source:HGNC Symbol;Acc:HGNC:11906] 
1.846491343 1.75702E-07 
ENTPD1 ectonucleoside triphosphate diphosphohydrolase 1 [Source:HGNC Symbol;Acc:HGNC:3363] 1.199325313 1.95758E-07 
P2RX6 purinergic receptor P2X, ligandgated ion channel, 6 [Source:HGNC Symbol;Acc:HGNC:8538] 1.953802673 2.001E-07 
NUSAP1 nucleolar and spindle associated protein 1 [Source:HGNC Symbol;Acc:HGNC:18538] 1.35470499 2.00116E-07 
PLEKHA5 
pleckstrin homology domain containing, family A member 5 [Source:HGNC 
Symbol;Acc:HGNC:30036] 
1.265172054 2.01038E-07 
ACKR3 atypical chemokine receptor 3 [Source:HGNC Symbol;Acc:HGNC:23692] 2.772134841 2.12373E-07 
KSR1 kinase suppressor of ras 1 [Source:HGNC Symbol;Acc:HGNC:6465] 1.556125065 2.1211E-07 
ENPP1 ectonucleotide pyrophosphatasephosphodiesterase 1 [Source:HGNC Symbol;Acc:HGNC:3356] 1.274453751 2.14386E-07 
AMIGO2 adhesion molecule with Iglike domain 2 [Source:HGNC Symbol;Acc:HGNC:24073] 1.594583433 2.16611E-07 
CHST7 
carbohydrate (Nacetylglucosamine 6O) sulfotransferase 7 [Source:HGNC 
Symbol;Acc:HGNC:13817] 
1.208381034 2.17176E-07 
CRISPLD1 
cysteinerich secretory protein LCCL domain containing 1 [Source:HGNC 
Symbol;Acc:HGNC:18206] 
1.804681389 3.42482E-07 
BTAF1 
BTAF1 RNA polymerase II, BTFIID transcription factorassociated, 170kDa [Source:HGNC 
Symbol;Acc:HGNC:17307] 
1.182474561 4.07368E-07 
SNCA 
synuclein, alpha (non A4 component of amyloid precursor) [Source:HGNC 
Symbol;Acc:HGNC:11138] 
1.733075528 4.14963E-07 
SLC16A6 solute carrier family 16, member 6 [Source:HGNC Symbol;Acc:HGNC:10927] 1.356662138 4.15107E-07 
SPAG5 sperm associated antigen 5 [Source:HGNC Symbol;Acc:HGNC:13452] 1.230413674 5.11459E-07 
LRCH2 
leucinerich repeats and calponin homology (CH) domain containing 2 [Source:HGNC 
Symbol;Acc:HGNC:29292] 
1.226124286 5.72787E-07 
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BIRC5 baculoviral IAP repeat containing 5 [Source:HGNC Symbol;Acc:HGNC:593] 1.244783767 5.78731E-07 
BUB1 BUB1 mitotic checkpoint serinethreonine kinase [Source:HGNC Symbol;Acc:HGNC:1148] 1.315121102 5.91082E-07 
FOXF1 forkhead box F1 [Source:HGNC Symbol;Acc:HGNC:3809] 1.083640291 6.06579E-07 
EPHB2 EPH receptor B2 [Source:HGNC Symbol;Acc:HGNC:3393] 1.247703175 6.1564E-07 
MKI67 marker of proliferation Ki67 [Source:HGNC Symbol;Acc:HGNC:7107] 1.130632256 6.32318E-07 
SEMA3B 
sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3B 
[Source:HGNC Symbol;Acc:HGNC:10724] 
1.677459794 6.39406E-07 
WSB1 WD repeat and SOCS box containing 1 [Source:HGNC Symbol;Acc:HGNC:19221] 1.138059111 6.50806E-07 
PLD1 phospholipase D1, phosphatidylcholinespecific [Source:HGNC Symbol;Acc:HGNC:9067] 1.339429882 6.54372E-07 
BUB1B BUB1 mitotic checkpoint serinethreonine kinase B [Source:HGNC Symbol;Acc:HGNC:1149] 1.305828303 6.64501E-07 
PPFIA3 
protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), 
alpha 3 [Source:HGNC Symbol;Acc:HGNC:9247] 
1.616135243 6.84246E-07 
AKR1B1 
aldoketo reductase family 1, member B1 (aldose reductase) [Source:HGNC 
Symbol;Acc:HGNC:381] 
1.114712549 6.79505E-07 
PIM1 Pim1 protooncogene, serinethreonine kinase [Source:HGNC Symbol;Acc:HGNC:8986] 1.315021216 6.99665E-07 
ABHD17C abhydrolase domain containing 17C [Source:HGNC Symbol;Acc:HGNC:26925] 1.686965749 7.08784E-07 
ZNF521 zinc finger protein 521 [Source:HGNC Symbol;Acc:HGNC:24605] 1.23303544 7.78081E-07 
SAT1 spermidinespermine N1acetyltransferase 1 [Source:HGNC Symbol;Acc:HGNC:10540] 1.391489748 9.81456E-07 
PPARGC1A 
peroxisome proliferatoractivated receptor gamma, coactivator 1 alpha [Source:HGNC 
Symbol;Acc:HGNC:9237] 
2.146042743 1.06433E-06 
PLK1 pololike kinase 1 [Source:HGNC Symbol;Acc:HGNC:9077] 1.276224646 1.0642E-06 
CXCL1 
chemokine (CXC motif) ligand 1 (melanoma growth stimulating activity, alpha) [Source:HGNC 
Symbol;Acc:HGNC:4602] 
1.090210899 1.08459E-06 
KIF18A kinesin family member 18A [Source:HGNC Symbol;Acc:HGNC:29441] 1.671986214 1.17962E-06 
TSPAN9 tetraspanin 9 [Source:HGNC Symbol;Acc:HGNC:21640] 1.571531798 1.21257E-06 
OSGIN2 
oxidative stress induced growth inhibitor family member 2 [Source:HGNC 
Symbol;Acc:HGNC:1355] 
1.140174953 1.30204E-06 
STEAP2 STEAP family member 2, metalloreductase [Source:HGNC Symbol;Acc:HGNC:17885] 1.239967045 1.33509E-06 
GLIS3 GLIS family zinc finger 3 [Source:HGNC Symbol;Acc:HGNC:28510] 1.640690031 1.34514E-06 
SLC6A9 
solute carrier family 6 (neurotransmitter transporter, glycine), member 9 [Source:HGNC 
Symbol;Acc:HGNC:11056] 
1.446087744 1.39581E-06 
CXCL5 chemokine (CXC motif) ligand 5 [Source:HGNC Symbol;Acc:HGNC:10642] 2.391736847 1.48224E-06 
TNFRSF19 
tumor necrosis factor receptor superfamily, member 19 [Source:HGNC 
Symbol;Acc:HGNC:11915] 
1.117113321 1.49357E-06 
TMEM178A transmembrane protein 178A [Source:HGNC Symbol;Acc:HGNC:28517] 2.261399194 1.61319E-06 
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CHST2 
carbohydrate (Nacetylglucosamine6O) sulfotransferase 2 [Source:HGNC 
Symbol;Acc:HGNC:1970] 
1.063334701 1.77711E-06 
APOE apolipoprotein E [Source:HGNC Symbol;Acc:HGNC:613] 4.55925421 1.79822E-06 
GTSE1 G2 and Sphase expressed 1 [Source:HGNC Symbol;Acc:HGNC:13698] 1.23489859 1.79855E-06 
ELOVL3 ELOVL fatty acid elongase 3 [Source:HGNC Symbol;Acc:HGNC:18047] 2.031871352 1.80481E-06 
ST5 suppression of tumorigenicity 5 [Source:HGNC Symbol;Acc:HGNC:11350] 1.098798492 1.8148E-06 
THBS2 thrombospondin 2 [Source:HGNC Symbol;Acc:HGNC:11786] 2.012547127 1.91027E-06 
DTWD1 DTW domain containing 1 [Source:HGNC Symbol;Acc:HGNC:30926] 1.296894075 2.00567E-06 
ANTXR2 anthrax toxin receptor 2 [Source:HGNC Symbol;Acc:HGNC:21732] 1.061550083 2.04148E-06 
TTK TTK protein kinase [Source:HGNC Symbol;Acc:HGNC:12401] 1.48864736 2.1284E-06 
IRS1 insulin receptor substrate 1 [Source:HGNC Symbol;Acc:HGNC:6125] 1.036704621 2.74635E-06 
FAM64A family with sequence similarity 64, member A [Source:HGNC Symbol;Acc:HGNC:25483] 1.523365644 3.14727E-06 
RGL3 ral guanine nucleotide dissociation stimulator like 3 [Source:HGNC Symbol;Acc:HGNC:30282] 2.230697008 3.28117E-06 
ARID5B AT rich interactive domain 5B (MRF1like) [Source:HGNC Symbol;Acc:HGNC:17362] 1.187164127 3.30693E-06 
TMEM71 transmembrane protein 71 [Source:HGNC Symbol;Acc:HGNC:26572] 2.141125486 3.55432E-06 
CCNB2 cyclin B2 [Source:HGNC Symbol;Acc:HGNC:1580] 1.283573911 3.75697E-06 
KIF2C kinesin family member 2C [Source:HGNC Symbol;Acc:HGNC:6393] 1.394675 3.98097E-06 
ALG9 ALG9, alpha1,2mannosyltransferase [Source:HGNC Symbol;Acc:HGNC:15672] 1.046759341 4.10882E-06 
CEP55 centrosomal protein 55kDa [Source:HGNC Symbol;Acc:HGNC:1161] 1.159765686 4.43337E-06 
HDAC4 histone deacetylase 4 [Source:HGNC Symbol;Acc:HGNC:14063] 1.128993548 4.50451E-06 
SLC16A14 solute carrier family 16, member 14 [Source:HGNC Symbol;Acc:HGNC:26417] 2.144596915 4.5725E-06 
GPRASP1 
G protein coupled receptor associated sorting protein 1 [Source:HGNC 
Symbol;Acc:HGNC:24834] 
1.363079304 5.20293E-06 
SOX4 SRY (sex determining region Y)box 4 [Source:HGNC Symbol;Acc:HGNC:11200] 1.233324103 5.94291E-06 
RNF112 ring finger protein 112 [Source:HGNC Symbol;Acc:HGNC:12968] 1.629687986 6.37066E-06 
MT1F metallothionein 1F [Source:HGNC Symbol;Acc:HGNC:7398] 3.477904877 6.75724E-06 
PCDHGA6 protocadherin gamma subfamily A, 6 [Source:HGNC Symbol;Acc:HGNC:8704] 1.401290882 6.76093E-06 
SLC6A6 
solute carrier family 6 (neurotransmitter transporter), member 6 [Source:HGNC 
Symbol;Acc:HGNC:11052] 
1.037570762 7.01114E-06 
PTGES prostaglandin E synthase [Source:HGNC Symbol;Acc:HGNC:9599] 1.00017664 7.08945E-06 
WNT2 
wingless type MMTV integration site family member 2 [Source:HGNC 
Symbol;Acc:HGNC:12780] 
5.403137697 7.37858E-06 
LPCAT3 lysophosphatidylcholine acyltransferase 3 [Source:HGNC Symbol;Acc:HGNC:30244] 1.038639857 8.0604E-06 
RAPGEF6 Rap guanine nucleotide exchange factor (GEF) 6 [Source:HGNC Symbol;Acc:HGNC:20655] 1.174491113 8.27042E-06 
CES4A carboxylesterase 4A [Source:HGNC Symbol;Acc:HGNC:26741] 1.620285039 9.64275E-06 
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SPAG4 sperm associated antigen 4 [Source:HGNC Symbol;Acc:HGNC:11214] 1.84173251 9.87019E-06 
MBP myelin basic protein [Source:HGNC Symbol;Acc:HGNC:6925] 2.038148774 1.06561E-05 
CFAP69 cilia and flagella associated protein 69 [Source:HGNC Symbol;Acc:HGNC:26107] 1.347983633 1.08398E-05 
FBXO2 Fbox protein 2 [Source:HGNC Symbol;Acc:HGNC:13581] 1.453020508 1.13583E-05 
SPTSSA serine palmitoyltransferase, small subunit A [Source:HGNC Symbol;Acc:HGNC:20361] 1.072893752 1.13999E-05 
CDK14 cyclindependent kinase 14 [Source:HGNC Symbol;Acc:HGNC:8883] 1.010285808 1.15073E-05 
RNF157 ring finger protein 157 [Source:HGNC Symbol;Acc:HGNC:29402] 1.042848633 1.15963E-05 
SOWAHD sosondowah ankyrin repeat domain family member D [Source:HGNC Symbol;Acc:HGNC:32960] 2.316567373 1.19645E-05 
PDGFRA 
platelet derived growth factor receptor, alpha polypeptide [Source:HGNC 
Symbol;Acc:HGNC:8803] 
1.378949526 1.21615E-05 
PF4V1 platelet factor 4 variant 1 [Source:HGNC Symbol;Acc:HGNC:8862] 4.306482632 1.33314E-05 
WNT5A 
winglesstype MMTV integration site family, member 5A [Source:HGNC 
Symbol;Acc:HGNC:12784] 
1.024172763 1.39901E-05 
DIRAS3 DIRAS family, GTPbinding RASlike 3 [Source:HGNC Symbol;Acc:HGNC:687] 2.30478155 1.4319E-05 
WNT2B 
wingless type MMTV integration site family, member 2B [Source:HGNC 
Symbol;Acc:HGNC:12781] 
1.867516939 1.54326E-05 
FAT4 FAT atypical cadherin 4 [Source:HGNC Symbol;Acc:HGNC:23109] 1.172949761 1.56339E-05 
UBE2C ubiquitinconjugating enzyme E2C [Source:HGNC Symbol;Acc:HGNC:15937] 1.237569994 1.63214E-05 
PDK1 pyruvate dehydrogenase kinase, isozyme 1 [Source:HGNC Symbol;Acc:HGNC:8809] 1.148735215 1.64468E-05 
PPFIA4 
protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), 
alpha 4 [Source:HGNC Symbol;Acc:HGNC:9248] 
1.680048063 1.76619E-05 
AZIN2 antizyme inhibitor 2 [Source:HGNC Symbol;Acc:HGNC:29957] 1.419413791 1.77429E-05 
CCNA2 cyclin A2 [Source:HGNC Symbol;Acc:HGNC:1578] 1.070014357 1.77018E-05 
ANKDD1A ankyrin repeat and death domain containing 1A [Source:HGNC Symbol;Acc:HGNC:28002] 1.278757932 1.81391E-05 
LRRC61 leucine rich repeat containing 61 [Source:HGNC Symbol;Acc:HGNC:21704] 4.775020439 1.85561E-05 
OR1J4 olfactory receptor, family 1, subfamily J, member 4 [Source:HGNC Symbol;Acc:HGNC:8211] 2.174744618 1.96131E-05 
GBP5 guanylate binding protein 5 [Source:HGNC Symbol;Acc:HGNC:19895] 1.763714994 2.22009E-05 
CELSR3 cadherin, EGF LAG sevenpass Gtype receptor 3 [Source:HGNC Symbol;Acc:HGNC:3230] 1.214953406 2.21869E-05 
EBF4 early Bcell factor 4 [Source:HGNC Symbol;Acc:HGNC:29278] 1.972078765 2.33083E-05 
MEDAG mesenteric estrogendependent adipogenesis [Source:HGNC Symbol;Acc:HGNC:25926] 2.167338241 2.50592E-05 
DLL1 deltalike 1 (Drosophila) [Source:HGNC Symbol;Acc:HGNC:2908] 1.650923139 2.64175E-05 
EVI2B ecotropic viral integration site 2B [Source:HGNC Symbol;Acc:HGNC:3500] 1.421886873 2.69616E-05 
PELI2 pellino E3 ubiquitin protein ligase family member 2 [Source:HGNC Symbol;Acc:HGNC:8828] 1.16259072 2.92264E-05 
SDC1 syndecan 1 [Source:HGNC Symbol;Acc:HGNC:10658] 1.320591098 2.95094E-05 
PILRA paired immunoglobinlike type 2 receptor alpha [Source:HGNC Symbol;Acc:HGNC:20396] 3.742543317 2.96256E-05 
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BNC1 basonuclin 1 [Source:HGNC Symbol;Acc:HGNC:1081] 1.011140715 3.02685E-05 
SOCS2AS1 SOCS2 antisense RNA 1 [Source:HGNC Symbol;Acc:HGNC:27054] 1.35195257 3.12045E-05 
CCNB1 cyclin B1 [Source:HGNC Symbol;Acc:HGNC:1579] 1.08811855 3.54582E-05 
PRR11 proline rich 11 [Source:HGNC Symbol;Acc:HGNC:25619] 1.054063519 3.73061E-05 
ABTB2 ankyrin repeat and BTB (POZ) domain containing 2 [Source:HGNC Symbol;Acc:HGNC:23842] 1.342472674 3.86044E-05 
KYNU kynureninase [Source:HGNC Symbol;Acc:HGNC:6469] 1.991118689 4.12076E-05 
LINCR0002 uncharacterized LincR0002 [Source:EntrezGene;Acc:103344926] 3.437729207 4.47948E-05 
BMP4 bone morphogenetic protein 4 [Source:HGNC Symbol;Acc:HGNC:1071] 1.652112021 4.49006E-05 
CEBPD CCAATenhancer binding protein (CEBP), delta [Source:HGNC Symbol;Acc:HGNC:1835] 1.207564882 4.64113E-05 
RAC2 
rasrelated C3 botulinum toxin substrate 2 (rho family, small GTP binding protein Rac2) 
[Source:HGNC Symbol;Acc:HGNC:9802] 
2.447864447 4.87689E-05 
PAPLN papilin, proteoglycan like sulfated glycoprotein [Source:HGNC Symbol;Acc:HGNC:19262] 1.263212775 5.43865E-05 
ITGB4 integrin, beta 4 [Source:HGNC Symbol;Acc:HGNC:6158] 1.884599207 5.47162E-05 
RORB RAR related orphan receptor B [Source:HGNC Symbol;Acc:HGNC:10259] 2.331400274 5.52317E-05 
MARCKSL1 MARCKS like 1 [Source:HGNC Symbol;Acc:HGNC:7142] 1.59779248 5.65053E-05 
KCNIP3 Kv channel interacting protein 3, calsenilin [Source:HGNC Symbol;Acc:HGNC:15523] 1.71137176 5.77356E-05 
GABRE 
Gamma aminobutyric acid (GABA) A receptor, epsilon [Source:HGNC 
Symbol;Acc:HGNC:4085] 
1.449332274 6.09851E-05 
RSPO3 R spondin 3 [Source:HGNC Symbol;Acc:HGNC:20866] 2.068738511 6.44541E-05 
TRIM16L tripartite motif containing 16like [Source:HGNC Symbol;Acc:HGNC:32670] 1.150887382 6.83517E-05 
SLITRK2 SLIT and NTRK like family, member 2 [Source:HGNC Symbol;Acc:HGNC:13449] 2.376086464 6.92329E-05 
DEPDC7 DEP domain containing 7 [Source:HGNC Symbol;Acc:HGNC:29899] 1.063258941 6.9459E-05 
PAQR5 progestin and adipoQ receptor family member V [Source:HGNC Symbol;Acc:HGNC:29645] 1.510773339 7.08969E-05 
HNMT histamine Nmethyltransferase [Source:HGNC Symbol;Acc:HGNC:5028] 1.003717959 7.10371E-05 
NEAT1 
nuclear paraspeckle assembly transcript 1 (non protein coding) [Source:  HGNC 
Symbol;Acc:HGNC:30815] 
1.275774158 7.35484E-05 
S100P S100 calcium binding protein P [Source: HGNC Symbol;Acc:HGNC:10504] 3.220309835 7.399E-05 
EFNB1 ephrinB1 [Source: HGNC Symbol;Acc:HGNC:3226] 1.078362317 8.00175E-05 
A2M alpha2macroglobulin [Source: HGNC Symbol;Acc:HGNC:7] 4.678155598 8.11353E-05 
LIPC lipase, hepatic [Source:HGNC Symbol;Acc:HGNC:6619] 1.779447662 8.71711E-05 
RNF175 ring finger protein 175 [Source: HGNC Symbol;Acc:HGNC:27735] 2.182041912 8.81028E-05 
CKAP2L cytoskeleton associated protein 2like [Source: HGNC Symbol;Acc:HGNC:26877] 1.13989413 9.78978E-05 
ABCA10 ATP binding cassette, subfamily A (ABC1), member 10 [Source: HGNC Symbol;Acc:HGNC:30] 1.358625589 9.99564E-05 
ST8SIA4 
ST8 alpha-N-acetyl-neuraminide alpha2,8 sialyl-transferase 4 [Source: HGNC 
Symbol;Acc:HGNC:10871] 
2.305450367 0.000100716 
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RERG RAS like, estrogen regulated, growth inhibitor [Source: HGNC Symbol;Acc:HGNC:15980] 2.280835625 0.000103906 
STYK1 Serine threonine tyrosine kinase 1 [Source: HGNC Symbol;Acc:HGNC:18889] 1.606872728 0.00010525 
C8orf4 chromosome 8 open reading frame 4 [Source: HGNC Symbol;Acc:HGNC:1357] 2.166181154 0.000108917 
ZDHHC23 zinc finger, DHHC-type containing 23 [Source: HGNC Symbol;Acc:HGNC:28654] 1.091480908 0.000110659 
MSI2 musashi RNA binding protein 2 [Source: HGNC Symbol;Acc:HGNC:18585] 1.347729636 0.000116432 
PSRC1 Proline serine rich coiled coil 1 [Source :HGNC Symbol;Acc:HGNC:24472] 1.161852961 0.000121614 
ROBO3 
roundabout, axon guidance receptor, homolog 3 (Drosophila) [Source: HGNC 
Symbol;Acc:HGNC:13433] 
1.266204307 0.000125843 
HHIPL2 HHIP-like 2 [Source: HGNC Symbol;Acc:HGNC:25842] 2.487647866 0.000126516 
ABCA8 ATP binding cassette, subfamily A (ABC1), member 8 [Source :HGNC Symbol;Acc:HGNC:38] 1.996876796 0.000127201 
C1QL1 complement component 1, q sub-component-like 1 [Source: HGNC Symbol;Acc:HGNC:24182] 2.147034497 0.000133948 
PRR5 proline rich 5 (renal) [Source: HGNC Symbol;Acc:HGNC:31682] 1.212140735 0.00013497 
CYP26B1 
cytochrome P450, family 26, subfamily B, polypeptide 1 [Source:  HGNC 
Symbol;Acc:HGNC:20581] 
2.106469377 0.000137015 
GKAS1 GK antisense RNA 1 [Source: HGNC Symbol;Acc:HGNC:40255] 2.809517679 0.000154127 
PCDHB2 protocadherin beta 2 [Source: HGNC Symbol;Acc:HGNC:8687] 1.931861094 0.000160349 
ADAMTS9 
ADAM metallopeptidase with thrombospondin type 1 motif, 9 [Source: HGNC 
Symbol;Acc:HGNC:13202] 
1.04833192 0.00017249 
WIF1 WNT inhibitory factor 1 [Source: HGNC Symbol;Acc:HGNC:18081] 2.598998601 0.000172855 
SNAP25 Synapto-somalassociated protein, 25kDa [Source: HGNC Symbol;Acc:HGNC:11132] 1.310880292 0.000180367 
IL11 interleukin 11 [Source: HGNC Symbol;Acc:HGNC:5966] 1.733467242 0.000180809 
SPON1 spondin 1, extracellular matrix protein [Source: HGNC Symbol;Acc:HGNC:11252] 1.198452072 0.000184374 
PBK PDZ binding kinase [Source: HGNC Symbol;Acc:HGNC:18282] 1.018365077 0.000186442 
MOCOS molybdenum cofactor sulfurase [Source: HGNC Symbol;Acc:HGNC:18234] 1.449957648 0.000191886 
IL1RN interleukin 1 receptor antagonist [Source: HGNC Symbol;Acc:HGNC:6000] 3.756747596 0.000198771 
RP11302B13.5 
ADP-ribosylation factor 3 {ECO:0000313|Ensembl:ENSP00000438507} 
[Source:UniProtKBTrEMBL;Acc:F5H423] 
1.521721905 0.000204409 
PSD pleckstrin and Sec7 domain containing [Source: HGNC Symbol;Acc:HGNC:9507] 1.37258198 0.000219233 
SLC7A11 
solute carrier family 7 (anionic amino acid transporter light chain, xc system), member 11 [Source: 
HGNC Symbol;Acc:HGNC:11059] 
2.095707606 0.000236214 
BDKRB2 bradykinin receptor B2 [Source: HGNC Symbol;Acc:HGNC:1030] 1.932771989 0.000251149 
SELENBP1 selenium binding protein 1 [Source: HGNC Symbol;Acc:HGNC:10719] 1.123837394 0.000273975 
CASC5 cancer susceptibility candidate 5 [Source: HGNC Symbol;Acc:HGNC:24054] 1.02450226 0.000283245 
SEMA4G 
sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic 
domain, (semaphorin) 4G [Source: HGNC Symbol;Acc:HGNC:10735] 
1.450019518 0.00028617 
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CP ceruloplasmin (ferroxidase) [Source: HGNC Symbol;Acc:HGNC:2295] 2.485725196 0.000333143 
CCDC152 Coiled-coil domain containing 152 [Source: HGNC Symbol;Acc:HGNC:34438] 1.956060539 0.00033858 
TSKU tsukushi, small leucine rich proteoglycan [Source: HGNC Symbol;Acc:HGNC:28850] 1.109985687 0.000351772 
HERC5 
HECT and RLD domain containing E3 ubiquitin protein ligase 5 [Source: HGNC 
Symbol;Acc:HGNC:24368] 
1.226108347 0.000359546 
FAM20A family with sequence similarity 20, member A [Source: HGNC Symbol;Acc:HGNC:23015] 2.618007506 0.000366003 
IL6 interleukin 6 [Source: HGNC Symbol;Acc:HGNC:6018] 1.234029155 0.000365548 
SSX2IP synovial sarcoma, X breakpoint 2 interacting protein [Source: HGNC Symbol;Acc:HGNC:16509] 1.206118675 0.000373295 
SHANK2 SH3 and multiple ankyrin repeat domains 2 [Source: HGNC Symbol;Acc:HGNC:14295] 1.136651874 0.000388737 
LINC00472 long intergenic non-protein coding RNA 472 [Source: HGNC Symbol;Acc:HGNC:21380] 1.321400357 0.000419227 
C3 complement component 3 [Source: HGNC Symbol;Acc:HGNC:1318] 1.331880192 0.00042987 
GPX3 glutathione peroxidase 3 (plasma) [Source: HGNC Symbol;Acc:HGNC:4555] 1.548648466 0.000431408 
BMP2 bone morphogenetic protein 2 [Source: HGNC Symbol;Acc:HGNC:1069] 1.248234873 0.000440233 
SCG5 secreto-granin V (7B2 protein) [Source: HGNC Symbol;Acc:HGNC:10816] 1.147846041 0.000453189 
CENPA centromere protein A [Source: HGNC Symbol;Acc:HGNC:1851] 1.266025451 0.000518159 
DLGAP1AS1 DLGAP1 antisense RNA 1 [Source: HGNC Symbol;Acc:HGNC:31676] 1.127883652 0.000519637 
NOL4L nucleolar protein 4like [Source: HGNC Symbol;Acc:HGNC:16106] 1.089428456 0.000526019 
DNAJC22 Dna J (Hsp40) homolog, subfamily C, member 22 [Source: HGNC Symbol;Acc:HGNC:25802] 1.327149867 0.000527532 
MAPK10 mitogenactivated protein kinase 10 [Source:HGNC Symbol;Acc:HGNC:6872] 1.237427446 0.000544489 
TMEM158 transmembrane protein 158 (gene pseudogene) [Source:HGNC Symbol;Acc:HGNC:30293] 1.555254651 0.000548551 
MIR210HG MIR210 host gene (non-protein coding) [Source:HGNC Symbol;Acc:HGNC:39524] 1.735974419 0.000554445 
DENND2D DENNMADD domain containing 2D [Source:HGNC Symbol;Acc:HGNC:26192] 1.453501106 0.000560106 
KCTD4 
potassium channel tetramerization domain containing 4 [Source:HGNC 
Symbol;Acc:HGNC:23227] 
1.420492726 0.000566299 
PCDHGB2 protocadherin gamma subfamily B, 2 [Source:HGNC Symbol;Acc:HGNC:8709] 1.659461911 0.000582496 
CCK cholecystokinin [Source:HGNC Symbol;Acc:HGNC:1569] 2.589527604 0.000587844 
NUF2 NUF2, NDC80 kinetochore complex component [Source:HGNC Symbol;Acc:HGNC:14621] 1.170872491 0.000587484 
APOBEC3B 
apolipoprotein B mRNA editing enzyme, catalytic polypeptidelike 3B [Source:HGNC 
Symbol;Acc:HGNC:17352] 
1.124127398 0.000625331 
CDX1 caudal type homeobox 1 [Source:HGNC Symbol;Acc:HGNC:1805] 2.056462272 0.000751578 
SPIN2A spindlin family, member 2A [Source:HGNC Symbol;Acc:HGNC:20694] 1.630582112 0.000752748 
DUSP16 dual specificity phosphatase 16 [Source:HGNC Symbol;Acc:HGNC:17909] 1.2507682 0.000759462 
SULF2 sulfatase 2 [Source:HGNC Symbol;Acc:HGNC:20392] 2.436767158 0.000784115 
REC8 REC8 meiotic recombination protein [Source:HGNC Symbol;Acc:HGNC:16879] 1.262320225 0.000812165 
CCDC69 Coiled coil domain containing 69 [Source:HGNC Symbol;Acc:HGNC:24487] 1.596606799 0.000829189 
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COL10A1 collagen, type X, alpha 1 [Source:HGNC Symbol;Acc:HGNC:2185] 1.65728122 0.000840403 
CDCA3 cell division cycle associated 3 [Source:HGNC Symbol;Acc:HGNC:14624] 1.034419797 0.000923914 
TEX11 testis expressed 11 [Source:HGNC Symbol;Acc:HGNC:11733] 1.213784013 0.001039721 
SEMA4D 
sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic 
domain, (semaphorin) 4D [Source:HGNC Symbol;Acc:HGNC:10732] 
1.216806783 0.001048128 
ZNF608 zinc finger protein 608 [Source:HGNC Symbol;Acc:HGNC:29238] 1.49685264 0.001060637 
TBX2AS1 TBX2 antisense RNA 1 [Source:HGNC Symbol;Acc:HGNC:50355] 1.439271965 0.001066534 
AFAP1L2 actin filament associated protein 1like 2 [Source:HGNC Symbol;Acc:HGNC:25901] 5.072197481 0.001074663 
HSF4 heat shock transcription factor 4 [Source:HGNC Symbol;Acc:HGNC:5227] 1.220391191 0.001156952 
ELTD1 
EGF, latrophilin and seven transmembrane domain containing 1 [Source:HGNC 
Symbol;Acc:HGNC:20822] 
2.144126507 0.001171717 
SLC26A10 solute carrier family 26, member 10 [Source:HGNC Symbol;Acc:HGNC:14470] 1.425133019 0.001184628 
PIR pirin (ironbinding nuclear protein) [Source:HGNC Symbol;Acc:HGNC:30048] 1.556707387 0.001212117 
CPNE4 copine IV [Source:HGNC Symbol;Acc:HGNC:2317] 2.255603905 0.001218287 
 
 
Appendix Table 3. Significantly downregulated genes of C-O clones (clones with potential to differentiate into osteo/cementoblastic phenotype) 
compared to C-F clones (clones that shows fibroblastic phenotype). 
Gene Symbol Gene_description |log2FoldChange| p value 
LINC01085 long intergenic non-protein coding RNA 1085 [Source:HGNC Symbol;Acc:HGNC:27198] 3.964982 8.78E-21 
RP11-385D13.1 
Uncharacterized protein {ECO:0000313|Ensembl:ENSP00000402644} 
[Source:UniProtKBTrEMBL;Acc:H0Y626] 
2.522707 5.47E-17 
GADD45B growth arrest and DNA-damage-inducible, beta [Source:HGNC Symbol;Acc:HGNC:4096] 1.798697 3.6E-14 
APPL2 
adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper containing 2 
[Source:HGNC Symbol;Acc:HGNC:18242] 
1.713417 4.29E-14 
TUBB3 tubulin, beta 3 class III [Source:HGNC Symbol;Acc:HGNC:20772] 1.708319 1.28E-13 
NPAS1 neuronal PAS domain protein 1 [Source:HGNC Symbol;Acc:HGNC:7894] 3.459166 3.82E-13 
OXTR oxytocin receptor [Source:HGNC Symbol;Acc:HGNC:8529] 2.629509 7.59E-12 
ARHGAP22 Rho GTPase activating protein 22 [Source:HGNC Symbol;Acc:HGNC:30320] 1.521047 7.02E-11 
CDH2 cadherin 2, type 1, N-cadherin (neuronal) [Source:HGNC Symbol;Acc:HGNC:1759] 2.060399 2.03E-10 
IPO4 importin 4 [Source:HGNC Symbol;Acc:HGNC:19426] 1.736697 4.32E-10 
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TNFAIP3 tumor necrosis factor, alpha-induced protein 3 [Source:HGNC Symbol;Acc:HGNC:11896] 1.387013 5.07E-10 
FAM180A family with sequence similarity 180, member A [Source:HGNC Symbol;Acc:HGNC:33773] 1.404615 6.07E-10 
GRIK2 glutamate receptor, ionotropic, kainate 2 [Source:HGNC Symbol;Acc:HGNC:4580] 1.518526 9.26E-10 
FOSL1 FOS-like antigen 1 [Source:HGNC Symbol;Acc:HGNC:13718] 1.372762 1.91E-09 
TUBA1C tubulin, alpha 1c [Source:HGNC Symbol;Acc:HGNC:20768] 1.294287 5.75E-09 
HECW2 
HECT, C2 and WW domain containing E3 ubiquitin protein ligase 2 [Source:HGNC 
Symbol;Acc:HGNC:29853] 
1.600211 3.73E-08 
AFAP1L1 actin filament associated protein 1-like 1 [Source:HGNC Symbol;Acc:HGNC:26714] 1.431046 3.98E-08 
TUBA1A tubulin, alpha 1a [Source:HGNC Symbol;Acc:HGNC:20766] 1.176861 6.58E-08 
BIRC3 baculoviral IAP repeat containing 3 [Source:HGNC Symbol;Acc:HGNC:591] 1.216271 6.71E-08 
ANXA1 annexin A1 [Source:HGNC Symbol;Acc:HGNC:533] 1.173138 6.95E-08 
ERCC6 excision repair cross-complementation group 6 [Source:HGNC Symbol;Acc:HGNC:3438] 2.063832 1.09E-07 
HTRA1 HtrA serine peptidase 1 [Source:HGNC Symbol;Acc:HGNC:9476] 1.119954 1.73E-07 
PRELP prolinearginine-rich end leucine-rich repeat protein [Source:HGNC Symbol;Acc:HGNC:9357] 2.42967 1.97E-07 
C6orf132 chromosome 6 open reading frame 132 [Source:HGNC Symbol;Acc:HGNC:21288] 1.360631 2.28E-07 
AK4P1 adenylate kinase 4 pseudogene 1 [Source:HGNC Symbol;Acc:HGNC:364] 1.533566 2.59E-07 
RCAN2 regulator of calcineurin 2 [Source:HGNC Symbol;Acc:HGNC:3041] 1.549079 2.8E-07 
DSP desmoplakin [Source:HGNC Symbol;Acc:HGNC:3052] 2.387321 3.98E-07 
ADAM23 ADAM metallopeptidase domain 23 [Source:HGNC Symbol;Acc:HGNC:202] 1.994711 5.51E-07 
FOXC2 forkhead box C2 (MFH-1, mesenchyme forkhead 1) [Source:HGNC Symbol;Acc:HGNC:3801] 1.325683 5.85E-07 
TCEAL4 transcription elongation factor A (SII)-like 4 [Source:HGNC Symbol;Acc:HGNC:26121] 1.119773 6.5E-07 
NAV2 neuron navigator 2 [Source:HGNC Symbol;Acc:HGNC:15997] 1.152368 6.69E-07 
HMGA1 high mobility group AT-hook 1 [Source:HGNC Symbol;Acc:HGNC:5010] 1.092109 6.84E-07 
CPNE7 copine VII [Source:HGNC Symbol;Acc:HGNC:2320] 1.131904 7.26E-07 
ASPN asporin [Source:HGNC Symbol;Acc:HGNC:14872] 1.670883 8.88E-07 
AHNAK2 AHNAK nucleoprotein 2 [Source:HGNC Symbol;Acc:HGNC:20125] 1.522171 9.49E-07 
ELN elastin [Source:HGNC Symbol;Acc:HGNC:3327] 2.735783 1.34E-06 
ARHGAP23 Rho GTPase activating protein 23 [Source:HGNC Symbol;Acc:HGNC:29293] 1.058018 1.88E-06 
PTX3 pentraxin 3, long [Source:HGNC Symbol;Acc:HGNC:9692] 1.059165 1.91E-06 
AK4 adenylate kinase 4 [Source:HGNC Symbol;Acc:HGNC:363] 1.179845 2.01E-06 
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ALOX15B arachidonate 15-lipoxygenase, type B [Source:HGNC Symbol;Acc:HGNC:434] 1.622412 2.54E-06 
C11orf68 chromosome 11 open reading frame 68 [Source:HGNC Symbol;Acc:HGNC:28801] 1.064409 2.65E-06 
PMP22 peripheral myelin protein 22 [Source:HGNC Symbol;Acc:HGNC:9118] 1.044198 3.36E-06 
SCFD2 sec1 family domain containing 2 [Source:HGNC Symbol;Acc:HGNC:30676] 1.044562 4.06E-06 
C6orf1 chromosome 6 open reading frame 1 [Source:HGNC Symbol;Acc:HGNC:1340] 1.071357 4.69E-06 
MSMO1 methylsterol monooxygenase 1 [Source:HGNC Symbol;Acc:HGNC:10545] 1.027696 5.58E-06 
BAIAP2 BAI1-associated protein 2 [Source:HGNC Symbol;Acc:HGNC:947] 1.17034 6.05E-06 
MAPKAPK3 
mitogen-activated protein kinase-activated protein kinase 3 [Source:HGNC 
Symbol;Acc:HGNC:6888] 
1.004902 6.12E-06 
TNFAIP8L3 tumor necrosis factor, alpha-induced protein 8-like 3 [Source:HGNC Symbol;Acc:HGNC:20620] 1.590004 6.53E-06 
CYB5D1 cytochrome b5 domain containing 1 [Source:HGNC Symbol;Acc:HGNC:26516] 1.146515 6.68E-06 
FGF1 fibroblast growth factor 1 (acidic) [Source:HGNC Symbol;Acc:HGNC:3665] 1.723254 7.12E-06 
MET MET proto-oncogene, receptor tyrosine kinase [Source:HGNC Symbol;Acc:HGNC:7029] 1.038341 7.86E-06 
CBR3 carbonyl reductase 3 [Source:HGNC Symbol;Acc:HGNC:1549] 1.306181 7.99E-06 
SUGCT succinyl-CoA:glutarate-CoA transferase [Source:HGNC Symbol;Acc:HGNC:16001] 1.052222 8.13E-06 
ALDH4A1 aldehyde dehydrogenase 4 family, member A1 [Source:HGNC Symbol;Acc:HGNC:406] 1.066567 8.42E-06 
MBNL1-AS1 MBNL1 antisense RNA 1 [Source:HGNC Symbol;Acc:HGNC:44584] 1.019527 8.85E-06 
ANK2 ankyrin 2, neuronal [Source:HGNC Symbol;Acc:HGNC:493] 1.070883 1.11E-05 
DRAP1 DR1-associated protein 1 (negative cofactor 2 alpha) [Source:HGNC Symbol;Acc:HGNC:3019] 1.205896 1.13E-05 
NEK10 NIMA-related kinase 10 [Source:HGNC Symbol;Acc:HGNC:18592] 2.214211 1.16E-05 
PTRH1 peptidyl-tRNA hydrolase 1 homolog (S. cerevisiae) [Source:HGNC Symbol;Acc:HGNC:27039] 1.176916 1.19E-05 
APCDD1L adenomatosis polyposis coli down-regulated 1-like [Source:HGNC Symbol;Acc:HGNC:26892] 1.478632 1.36E-05 
EVA1A eva-1 homolog A (C. elegans) [Source:HGNC Symbol;Acc:HGNC:25816] 1.080478 2.67E-05 
KCNQ5 
potassium voltage-gated channel, KQT-like subfamily, member 5 [Source:HGNC 
Symbol;Acc:HGNC:6299] 
2.200169 3.94E-05 
COPS8 COP9 signalosome subunit 8 [Source:HGNC Symbol;Acc:HGNC:24335] 1.121761 4.09E-05 
PPFIA2 
protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), 
alpha 2 [Source:HGNC Symbol;Acc:HGNC:9246] 
2.03639 4.08E-05 
AP1S3 adaptor-related protein complex 1, sigma 3 subunit [Source:HGNC Symbol;Acc:HGNC:18971] 1.475281 4.93E-05 
AXIN2 axin 2 [Source:HGNC Symbol;Acc:HGNC:904] 1.213789 6.17E-05 
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ST6GALNAC5 
ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl- 1,3)-N-acetylgalactosaminide alpha-2,6-
sialyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:19342] 
2.39866 6.37E-05 
KRT19 keratin 19 [Source:HGNC Symbol;Acc:HGNC:6436] 2.984345 0.000103 
PEG10 paternally expressed 10 [Source:HGNC Symbol;Acc:HGNC:14005] 1.130018 0.000118 
NCAM2 neural cell adhesion molecule 2 [Source:HGNC Symbol;Acc:HGNC:7657] 1.713622 0.000183 
MTSS1 metastasis suppressor 1 [Source:HGNC Symbol;Acc:HGNC:20443] 1.441807 0.000215 
MMAB 
methylmalonic aciduria (cobalamin deficiency) cblB type [Source:HGNC 
Symbol;Acc:HGNC:19331] 
1.461812 0.000282 
BMP6 bone morphogenetic protein 6 [Source:HGNC Symbol;Acc:HGNC:1073] 2.575909 0.000362 
FAM53B family with sequence similarity 53, member B [Source:HGNC Symbol;Acc:HGNC:28968] 1.891819 0.000381 
C17orf61-PLSCR3 
Uncharacterized protein {ECO:0000313|Ensembl:ENSP00000468219} 
[Source:UniProtKBTrEMBL;Acc:K7ERE1] 
1.037653 0.000404 
RGMB-AS1 RGMB antisense RNA 1 [Source:HGNC Symbol;Acc:HGNC:48666] 1.135076 0.000422 
RAB4B-EGLN2 RAB4B-EGLN2 readthrough (NMD candidate) [Source:HGNC Symbol;Acc:HGNC:44465] 1.3314 0.000459 
NPTX1 neuronal pentraxin I [Source:HGNC Symbol;Acc:HGNC:7952] 3.03133 0.000483 
CYP19A1 cytochrome P450, family 19, subfamily A, polypeptide 1 [Source:HGNC Symbol;Acc:HGNC:2594] 1.422893 0.000497 
CNNM1 
cyclin and CBS domain divalent metal cation transport mediator 1 [Source:HGNC 
Symbol;Acc:HGNC:102] 
1.276371 0.000534 
ERCC6-PGBD3 ERCC6-PGBD3 readthrough [Source:HGNC Symbol;Acc:HGNC:48347] 1.958482 0.000658 
FAM149A family with sequence similarity 149, member A [Source:HGNC Symbol;Acc:HGNC:24527] 1.390284 0.00067 
C1orf233 chromosome 1 open reading frame 233 [Source:HGNC Symbol;Acc:HGNC:42951] 1.042885 0.000975 
TUBB6 tubulin, beta 6 class V [Source:HGNC Symbol;Acc:HGNC:20776] 1.377469 0.001043 
 
Appendix Table 4. Significantly overrepresented biological processes related to up-regulated genes in C-O clones compared to C-F clones. 
GO biological process complete Fold Enrichment p-value 
spindle assembly checkpoint (GO:0071173) 16.38 1.99E-02 
spindle checkpoint (GO:0031577) 14.7 5.82E-03 
negative regulation of mitotic nuclear division (GO:0045839) 11.95 2.27E-02 
positive chemotaxis (GO:0050918) 11.81 4.77E-03 
regulation of mitotic metaphase/anaphase transition (GO:0030071) 9.5 2.36E-02 
regulation of metaphase/anaphase transition of cell cycle (GO:1902099) 9.3 2.76E-02 
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metaphase plate congression (GO:0051310) 9.27 6.87E-03 
regulation of mitotic sister chromatid separation (GO:0010965) 9.1 3.22E-02 
regulation of morphogenesis of a branching structure (GO:0060688) 8.78 1.08E-02 
positive regulation of leukocyte chemotaxis (GO:0002690) 8.35 8.57E-05 
epithelial to mesenchymal transition (GO:0001837) 8.19 1.88E-02 
mitotic sister chromatid segregation (GO:0000070) 8.19 8.18E-06 
establishment of chromosome localization (GO:0051303) 8.01 1.76E-03 
chromosome localization (GO:0050000) 7.9 2.01E-03 
regulation of chromosome segregation (GO:0051983) 7.9 5.77E-04 
sister chromatid segregation (GO:0000819) 6.98 6.95E-09 
positive regulation of leukocyte migration (GO:0002687) 6.94 7.28E-05 
regulation of leukocyte chemotaxis (GO:0002688) 6.89 7.76E-04 
positive regulation of smooth muscle cell proliferation (GO:0048661) 6.5 3.93E-02 
positive regulation of chemotaxis (GO:0050921) 6.02 1.27E-03 
regulation of nuclear division (GO:0051783) 5.99 2.30E-05 
regulation of mitotic nuclear division (GO:0007088) 5.85 6.59E-04 
mesenchymal cell differentiation (GO:0048762) 5.81 7.21E-04 
sister chromatid cohesion (GO:0007062) 5.75 1.57E-02 
nuclear chromosome segregation (GO:0098813) 5.68 2.14E-08 
regulation of leukocyte migration (GO:0002685) 5.66 1.44E-04 
regulation of osteoblast differentiation (GO:0045667) 5.65 1.87E-02 
response to estradiol (GO:0032355) 5.36 7.89E-04 
cellular response to hypoxia (GO:0071456) 5.31 5.59E-03 
regulation of chemotaxis (GO:0050920) 5.09 2.67E-04 
cellular response to decreased oxygen levels (GO:0036294) 5.03 1.05E-02 
response to glucocorticoid (GO:0051384) 4.99 8.54E-04 
cell chemotaxis (GO:0060326) 4.88 2.71E-03 
morphogenesis of a branching structure (GO:0001763) 4.82 7.41E-03 
chromosome segregation (GO:0007059) 4.81 7.51E-07 
mitotic nuclear division (GO:0007067) 4.75 6.69E-09 
cellular response to oxygen levels (GO:0071453) 4.75 2.02E-02 
morphogenesis of a branching epithelium (GO:0061138) 4.75 2.02E-02 
regulation of ossification (GO:0030278) 4.6 5.88E-03 
response to corticosteroid (GO:0031960) 4.6 2.67E-03 
response to reactive oxygen species (GO:0000302) 4.51 3.48E-03 
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positive regulation of peptidyl-tyrosine phosphorylation (GO:0050731) 4.47 3.99E-02 
positive regulation of cell migration (GO:0030335) 4.45 7.27E-09 
mesenchyme development (GO:0060485) 4.35 1.21E-02 
positive regulation of cell motility (GO:2000147) 4.3 1.89E-08 
positive regulation of cellular component movement (GO:0051272) 4.3 8.99E-09 
renal system development (GO:0072001) 4.28 1.74E-04 
response to hypoxia (GO:0001666) 4.27 1.95E-05 
nuclear division (GO:0000280) 4.24 6.20E-10 
chemotaxis (GO:0006935) 4.17 4.77E-09 
taxis (GO:0042330) 4.16 5.06E-09 
positive regulation of locomotion (GO:0040017) 4.16 2.24E-08 
response to decreased oxygen levels (GO:0036293) 4.14 3.56E-05 
regulation of peptidyl-tyrosine phosphorylation (GO:0050730) 4.11 1.21E-02 
response to oxygen levels (GO:0070482) 4.07 2.43E-05 
carboxylic acid transport (GO:0046942) 4.03 1.94E-03 
organelle fission (GO:0048285) 4 3.65E-09 
organic acid transport (GO:0015849) 3.99 2.30E-03 
urogenital system development (GO:0001655) 3.98 3.07E-04 
response to lipopolysaccharide (GO:0032496) 3.95 1.75E-04 
kidney development (GO:0001822) 3.93 5.62E-03 
regulation of epithelial cell proliferation (GO:0050678) 3.88 9.35E-04 
extracellular matrix organization (GO:0030198) 3.86 9.87E-04 
extracellular structure organization (GO:0043062) 3.85 1.04E-03 
regulation of organ morphogenesis (GO:2000027) 3.84 1.52E-02 
regulation of cell migration (GO:0030334) 3.84 7.14E-12 
response to molecule of bacterial origin (GO:0002237) 3.79 3.74E-04 
response to steroid hormone (GO:0048545) 3.75 1.26E-04 
response to oxidative stress (GO:0006979) 3.7 1.64E-04 
activation of protein kinase activity (GO:0032147) 3.68 7.87E-03 
regulation of cell motility (GO:2000145) 3.65 2.58E-11 
positive regulation of response to external stimulus (GO:0032103) 3.61 3.49E-02 
regulation of cellular component movement (GO:0051270) 3.61 2.80E-12 
cell division (GO:0051301) 3.6 7.03E-06 
regulation of protein serine/threonine kinase activity (GO:0071900) 3.55 1.76E-05 
positive regulation of kinase activity (GO:0033674) 3.54 5.54E-06 
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regulation of locomotion (GO:0040012) 3.5 3.55E-11 
blood coagulation (GO:0007596) 3.49 3.05E-02 
coagulation (GO:0050817) 3.47 3.36E-02 
positive regulation of protein kinase activity (GO:0045860) 3.46 5.57E-05 
negative regulation of protein phosphorylation (GO:0001933) 3.45 1.14E-03 
hemostasis (GO:0007599) 3.44 3.86E-02 
response to acid chemical (GO:0001101) 3.42 4.12E-03 
regulation of protein kinase activity (GO:0045859) 3.38 8.92E-09 
response to lipid (GO:0033993) 3.37 1.46E-11 
response to organic cyclic compound (GO:0014070) 3.36 2.53E-12 
regulation of kinase activity (GO:0043549) 3.33 2.67E-09 
positive regulation of transferase activity (GO:0051347) 3.31 1.01E-06 
negative regulation of phosphorylation (GO:0042326) 3.26 1.80E-03 
cellular response to lipid (GO:0071396) 3.26 2.15E-04 
regulation of cell cycle phase transition (GO:1901987) 3.25 4.88E-02 
cellular response to organic cyclic compound (GO:0071407) 3.21 3.02E-04 
gland development (GO:0048732) 3.2 2.64E-03 
cellular response to organonitrogen compound (GO:0071417) 3.18 1.04E-03 
positive regulation of protein phosphorylation (GO:0001934) 3.17 1.69E-09 
positive regulation of cell proliferation (GO:0008284) 3.17 5.18E-09 
inflammatory response (GO:0006954) 3.17 1.13E-03 
wound healing (GO:0042060) 3.16 1.17E-03 
positive regulation of phosphorylation (GO:0042327) 3.15 7.69E-10 
response to drug (GO:0042493) 3.14 2.26E-03 
tube development (GO:0035295) 3.1 1.33E-04 
positive regulation of phosphorus metabolic process (GO:0010562) 3.1 5.62E-11 
positive regulation of phosphate metabolic process (GO:0045937) 3.1 5.62E-11 
response to hormone (GO:0009725) 3.09 6.49E-08 
mitotic cell cycle process (GO:1903047) 3.09 8.95E-07 
regulation of protein phosphorylation (GO:0001932) 3.05 9.75E-14 
regulation of transferase activity (GO:0051338) 3.03 5.56E-09 
regulation of body fluid levels (GO:0050878) 2.99 3.43E-03 
response to wounding (GO:0009611) 2.99 4.98E-04 
response to extracellular stimulus (GO:0009991) 2.99 5.82E-03 
mitotic cell cycle (GO:0000278) 2.98 2.68E-06 
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cell proliferation (GO:0008283) 2.96 3.43E-05 
regulation of mitotic cell cycle (GO:0007346) 2.96 6.78E-03 
regulation of phosphorylation (GO:0042325) 2.96 9.84E-14 
cellular response to nitrogen compound (GO:1901699) 2.95 1.81E-03 
regulation of cell cycle process (GO:0010564) 2.94 1.15E-03 
response to nutrient levels (GO:0031667) 2.94 1.94E-02 
cellular response to oxygen-containing compound (GO:1901701) 2.94 3.33E-07 
cell migration (GO:0016477) 2.94 4.06E-06 
response to inorganic substance (GO:0010035) 2.91 5.80E-03 
cellular response to hormone stimulus (GO:0032870) 2.87 3.13E-03 
negative regulation of phosphate metabolic process (GO:0045936) 2.83 6.56E-03 
localization of cell (GO:0051674) 2.83 3.19E-06 
cell motility (GO:0048870) 2.83 3.19E-06 
negative regulation of phosphorus metabolic process (GO:0010563) 2.82 6.80E-03 
positive regulation of protein modification process (GO:0031401) 2.81 5.83E-09 
tissue morphogenesis (GO:0048729) 2.81 1.80E-02 
locomotion (GO:0040011) 2.8 2.68E-08 
vasculature development (GO:0001944) 2.79 4.77E-02 
regulation of response to external stimulus (GO:0032101) 2.79 2.84E-05 
regulation of phosphorus metabolic process (GO:0051174) 2.78 5.93E-14 
transmembrane receptor protein tyrosine kinase signaling pathway (GO:0007169) 2.76 3.73E-02 
negative regulation of protein modification process (GO:0031400) 2.71 1.54E-02 
response to oxygen-containing compound (GO:1901700) 2.7 3.28E-11 
regulation of phosphate metabolic process (GO:0019220) 2.7 1.30E-12 
response to bacterium (GO:0009617) 2.68 4.19E-02 
response to organonitrogen compound (GO:0010243) 2.67 1.51E-04 
response to nitrogen compound (GO:1901698) 2.66 1.99E-05 
regulation of cell proliferation (GO:0042127) 2.65 3.37E-11 
regulation of cell cycle (GO:0051726) 2.64 7.45E-06 
regulation of cell adhesion (GO:0030155) 2.64 7.82E-03 
cell-cell signaling (GO:0007267) 2.62 5.36E-07 
regulation of protein modification process (GO:0031399) 2.59 1.86E-11 
regulation of MAPK cascade (GO:0043408) 2.58 8.21E-03 
animal organ morphogenesis (GO:0009887) 2.52 6.92E-04 
response to cytokine (GO:0034097) 2.51 7.08E-03 
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cell cycle process (GO:0022402) 2.51 2.80E-05 
response to endogenous stimulus (GO:0009719) 2.48 3.66E-08 
response to external stimulus (GO:0009605) 2.46 4.53E-11 
regulation of secretion (GO:0051046) 2.45 3.50E-02 
enzyme linked receptor protein signaling pathway (GO:0007167) 2.45 3.60E-02 
cellular response to endogenous stimulus (GO:0071495) 2.45 1.22E-04 
anatomical structure formation involved in morphogenesis (GO:0048646) 2.44 6.48E-03 
chemical homeostasis (GO:0048878) 2.43 8.88E-04 
positive regulation of cellular protein metabolic process (GO:0032270) 2.41 6.22E-07 
positive regulation of transport (GO:0051050) 2.39 1.99E-03 
negative regulation of multicellular organismal process (GO:0051241) 2.37 9.21E-04 
response to abiotic stimulus (GO:0009628) 2.35 4.10E-04 
positive regulation of catalytic activity (GO:0043085) 2.35 4.30E-07 
movement of cell or subcellular component (GO:0006928) 2.34 1.58E-05 
circulatory system development (GO:0072359) 2.32 4.15E-02 
positive regulation of protein metabolic process (GO:0051247) 2.31 2.61E-06 
cell cycle (GO:0007049) 2.3 6.13E-05 
regulation of anatomical structure morphogenesis (GO:0022603) 2.29 8.02E-03 
tissue development (GO:0009888) 2.29 3.47E-06 
positive regulation of intracellular signal transduction (GO:1902533) 2.24 3.60E-02 
positive regulation of molecular function (GO:0044093) 2.21 3.79E-07 
cellular response to organic substance (GO:0071310) 2.2 1.32E-07 
regulation of multicellular organismal development (GO:2000026) 2.2 2.40E-06 
positive regulation of developmental process (GO:0051094) 2.19 2.30E-03 
cell surface receptor signaling pathway (GO:0007166) 2.19 9.40E-09 
positive regulation of signal transduction (GO:0009967) 2.19 1.78E-04 
positive regulation of cell communication (GO:0010647) 2.19 3.94E-05 
positive regulation of multicellular organismal process (GO:0051240) 2.18 1.48E-04 
positive regulation of signaling (GO:0023056) 2.18 4.66E-05 
positive regulation of cellular component organization (GO:0051130) 2.18 3.90E-03 
regulation of multicellular organismal process (GO:0051239) 2.17 2.58E-11 
reproductive process (GO:0022414) 2.17 5.90E-04 
response to organic substance (GO:0010033) 2.16 4.37E-11 
reproduction (GO:0000003) 2.16 6.18E-04 
positive regulation of response to stimulus (GO:0048584) 2.15 4.12E-07 
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regulation of localization (GO:0032879) 2.14 8.36E-10 
regulation of developmental process (GO:0050793) 2.12 3.63E-08 
regulation of immune system process (GO:0002682) 2.11 7.78E-04 
regulation of intracellular signal transduction (GO:1902531) 2.1 5.50E-05 
cell development (GO:0048468) 2.1 9.09E-04 
cell adhesion (GO:0007155) 2.1 6.34E-03 
negative regulation of molecular function (GO:0044092) 2.1 4.07E-02 
cellular response to chemical stimulus (GO:0070887) 2.1 2.89E-08 
biological adhesion (GO:0022610) 2.09 6.92E-03 
defense response (GO:0006952) 2.08 1.41E-02 
regulation of cell differentiation (GO:0045595) 2.06 7.52E-04 
regulation of cellular protein metabolic process (GO:0032268) 2.03 5.72E-07 
anatomical structure morphogenesis (GO:0009653) 2.02 4.88E-05 
regulation of cell communication (GO:0010646) 2.01 6.57E-10 
regulation of catalytic activity (GO:0050790) 2.01 1.32E-06 
regulation of signal transduction (GO:0009966) 1.99 3.52E-08 
regulation of molecular function (GO:0065009) 1.98 1.55E-08 
regulation of protein metabolic process (GO:0051246) 1.98 5.94E-07 
regulation of signaling (GO:0023051) 1.98 1.94E-09 
regulation of transport (GO:0051049) 1.95 1.28E-03 
regulation of cellular component organization (GO:0051128) 1.93 3.06E-05 
system development (GO:0048731) 1.93 9.92E-13 
response to chemical (GO:0042221) 1.9 2.78E-11 
response to stress (GO:0006950) 1.89 1.84E-08 
regulation of response to stimulus (GO:0048583) 1.88 4.66E-10 
animal organ development (GO:0048513) 1.87 2.32E-06 
nervous system development (GO:0007399) 1.86 5.95E-04 
cell differentiation (GO:0030154) 1.86 1.35E-07 
immune system process (GO:0002376) 1.84 3.22E-03 
multicellular organism development (GO:0007275) 1.83 1.76E-12 
single-multicellular organism process (GO:0044707) 1.83 4.55E-16 
cellular developmental process (GO:0048869) 1.83 2.71E-07 
positive regulation of cellular metabolic process (GO:0031325) 1.81 4.67E-05 
anatomical structure development (GO:0048856) 1.81 5.40E-13 
positive regulation of cellular process (GO:0048522) 1.8 1.47E-11 
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single-organism developmental process (GO:0044767) 1.77 8.50E-13 
positive regulation of macromolecule metabolic process (GO:0010604) 1.75 3.53E-04 
regulation of biological quality (GO:0065008) 1.75 3.48E-06 
developmental process (GO:0032502) 1.74 4.95E-12 
positive regulation of metabolic process (GO:0009893) 1.73 2.69E-04 
negative regulation of biological process (GO:0048519) 1.72 7.09E-09 
positive regulation of biological process (GO:0048518) 1.72 5.71E-11 
signaling (GO:0023052) 1.72 9.15E-11 
single organism signaling (GO:0044700) 1.71 1.94E-10 
signal transduction (GO:0007165) 1.69 1.30E-08 
cell communication (GO:0007154) 1.69 4.17E-10 
multicellular organismal process (GO:0032501) 1.68 6.54E-14 
negative regulation of cellular process (GO:0048523) 1.67 1.92E-06 
cellular response to stimulus (GO:0051716) 1.55 4.80E-08 
localization (GO:0051179) 1.55 4.69E-05 
single-organism cellular process (GO:0044763) 1.52 6.09E-16 
response to stimulus (GO:0050896) 1.47 1.63E-08 
single-organism process (GO:0044699) 1.37 1.06E-16 
regulation of cellular process (GO:0050794) 1.35 1.93E-08 
regulation of biological process (GO:0050789) 1.32 1.97E-07 
biological regulation (GO:0065007) 1.32 7.65E-09 
cellular process (GO:0009987) 1.16 4.15E-03 
biological_process (GO:0008150) 1.13 2.07E-05 
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Appendix Table 5. Pathways related to up-regulated genes in C-O clones compared to C-F clones. 
PANTHER Pathways #genes 
Fold 
Enrichment 
p-value Gene Symbol 
Angiogenesis (P00005) 16 4.96 4.09E-05 
ANGPT1; BIRC5; DLL1; EFNB1; EPBH2; FOS; MAPK10; 
PDGFRA;PLD1; PRR5; RERG; SFRP1; VEGFA; WNT2; WNT2B; 
WNT5A 
CCKR signaling map (P06959) 13 4.1 3.95E-03 
CCK; CPE; CXCL1; FOS; IRS1; ITPR1; MAP2K6; MAPK10; MMP3; 
PDK1; PLAU; PTGS2;  RGS2 
Cadherin signaling pathway (P00012) 10 3.46 1.25E-01 
CELSR3; WNT2; WNT2B;WNT5A; PCDH18; PCDHGA6; PCDHGA10; 
PCDHGB2; PCDHGB4 
Inflammation mediated by chemokine and 
cytokine signaling pathway (P00031) 
12 2.51 5.72E-01 
CCL7; GNA14; IL6; ITGA2; ITPR1; PDK1;PF4V1; PTGS1;
 PTGS2; RAC2; RGS4; RGS18 
Plasminogen activating cascade (P00050) 3 9.1 7.33E-01 MMP3; MMP8; PLAU 
Endothelin signaling pathway (P00019) 6 3.81 8.67E-01 ADCY4; EDNRB; GNA14; ITPR1; PTGS2; PRKAR2B 
Wnt signaling pathway (P00057) 13 2.28 8.69E-01 
CELSR3; GNA14; ITPR1; PCDH18; PCDHB2; PCDHGA6; PCDHGA10; 
PCDHGB2; PCDHGB4; SFRP1; WNT2; WNT2B; WNT5A 
Alzheimer disease-amyloid secretase 
pathway (P00003) 
2 1.61 1.00E+00 CHRM2; MAPK10 
Alpha adrenergic receptor signaling 
pathway (P00002) 
2 4.37 1.00E+00 ITPR1; SNAP25 
Adrenaline and noradrenaline biosynthesis 
(P00001) 
1 1.82 1.00E+00 SANP25 
Triacylglycerol metabolism (P02782) 1 27.31 1.00E+00 LIPC 
Synaptic vesicle trafficking (P05734) 1 1.88 1.00E+00 SNAP25 
GABA-B receptor II signaling (P05731) 2 2.87 1.00E+00 ADCY4; PRKAR2B 
Pyruvate metabolism (P02772) 1 4.96 1.00E+00 PC 
p38 MAPK pathway (P05918) 3 3.9 1.00E+00 IL1R1; MAP2K6; RAC2 
Opioid proopiomelanocortin pathway 
(P05917) 
1 1.61 1.00E+00 SNAP25 
Opioid prodynorphin pathway (P05916) 1 1.65 1.00E+00 SANP25 
Opioid proenkephalin pathway (P05915) 2 3.21 1.00E+00 PENK; SNAP25 
Enkephalin release (P05913) 2 3.12 1.00E+00 PENK; PRKAR2B 
Dopamine receptor mediated signaling 
pathway (P05912) 
3 2.78 1.00E+00 EPB41L3; PRKAR2B; SNAP25 
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Angiotensin II-stimulated signaling 
through G proteins and beta-arrestin 
(P05911) 
1 1.4 1.00E+00 ITPR1 
Ornithine degradation (P02758) 1 13.65 1.00E+00 AZIN2 
Ubiquitin proteasome pathway (P00060) 1 0.83 1.00E+00 UBE2C 
p53 pathway (P00059) 4 2.48 1.00E+00 CCNB1; GTSE1; PDK1; PMAIP1 
VEGF signaling pathway (P00056) 4 3.03 1.00E+00 PRR5; RAC2; RERG; VEGFA 
Transcription regulation by bZIP 
transcription factor (P00055) 
1 0.98 1.00E+00 PRKAR2B 
Toll receptor signaling pathway (P00054) 2 1.82 1.00E+00 MAPK10; PTGS2 
T cell activation (P00053) 4 2.28 1.00E+00 FOS; ITPR1; MAPK10; RAC2; 
p53 pathway feedback loops 2 (P04398) 2 2.06 1.00E+00 CCNA2; PDK1 
TGF-beta signaling pathway (P00052) 5 2.65 1.00E+00 BMP2; BMP4; MAPK10; RERG; TGFB2 
Vasopressin synthesis (P04395) 1 4.2 1.00E+00 CPE 
Thyrotropin-releasing hormone receptor 
signaling pathway (P04394) 
2 1.82 1.00E+00 GNA14; SNAP25 
Ras Pathway (P04393) 5 3.59 1.00E+00 MAPK10; MAP2K6; PDK1; PLD1; RAC2 
Oxytocin receptor mediated signaling 
pathway (P04391) 
2 1.88 1.00E+00 GNA14; SNAP25 
Parkinson disease (P00049) 4 2.18 1.00E+00 MAPK10; HSPA2; SNCA; SNCAIP; 
PI3 kinase pathway (P00048) 3 2.98 1.00E+00 GNA14; IRS1; PDK1 
PDGF signaling pathway (P00047) 8 2.93 1.00E+00 ARHGAP6; FOS; ITPR1; MAPK10; PDK1;  PRR5;  RERG; PDGFRA 
Oxidative stress response (P00046) 3 2.93 1.00E+00 DUSP16; MAPK10; MAP2K6; 
Notch signaling pathway (P00045) 1 1.24 1.00E+00 DLL1 
Nicotinic acetylcholine receptor signaling 
pathway (P00044) 
1 0.54 1.00E+00 SNAP25 
Muscarinic acetylcholine receptor 2 and 4 
signaling pathway (P00043) 
3 2.56 1.00E+00 CHRM2; PRKAR2B; SNAP25 
Muscarinic acetylcholine receptor 1 and 3 
signaling pathway (P00042) 
3 2.73 1.00E+00 GNA; ITPR1; SNAP25 
Metabotropic glutamate receptor group I 
pathway (P00041) 
1 2.1 1.00E+00 ITPR1 
Histamine H2 receptor mediated signaling 
pathway (P04386) 
1 2.1 1.00E+00 PRKAR2B 
Metabotropic glutamate receptor group II 
pathway (P00040) 
3 3.41 1.00E+00 BDNF; PRKAR2B; SNAP25 
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Histamine H1 receptor mediated signaling 
pathway (P04385) 
2 2.48 1.00E+00 GNA14; ITPR1 
Cortocotropin releasing factor receptor 
signaling pathway (P04380) 
2 3.41 1.00E+00 GNA; SNAP25 
Metabotropic glutamate receptor group III 
pathway (P00039) 
3 2.37 1.00E+00 BDNF; PRKAR2B; SNAP25 
JAK/STAT signaling pathway (P00038) 1 3.21 1.00E+00 SOCS1 
Ionotropic glutamate receptor pathway 
(P00037) 
3 3.28 1.00E+00 SHANK2; SLC1A3; SNAP25 
Interleukin signaling pathway (P00036) 5 2.79 1.00E+00 FOS; IL6; IL11; IRS1; PDK1 
Interferon-gamma signaling pathway 
(P00035) 
2 3.64 1.00E+00 MAPK10; SOCS2 
Integrin signalling pathway (P00034) 8 2.28 1.00E+00 COL4A5; COL10A1; ITGA2; ITGB3; ITGB4;LAMA5; MAPK10; RAC2 
Beta3 adrenergic receptor signaling 
pathway (P04379) 
1 1.95 1.00E+00 SNAP25 
Insulin/IGF pathway-protein kinase B 
signaling cascade (P00033) 
2 2.66 1.00E+00 IRS1; PDK1 
Gonadotropin-releasing hormone receptor 
pathway (P06664) 
8 1.86 1.00E+00 BMP2; BMP4; FOS; IRS1; ITPR1; KSR1;  MAP2K6; TGFB2 
Beta2 adrenergic receptor signaling 
pathway (P04378) 
2 2.37 1.00E+00 SNAP25 
Insulin/IGF pathway-mitogen activated 
protein kinase kinase/MAP kinase cascade 
(P00032) 
2 3.31 1.00E+00 IRS1; PDK1 
Beta1 adrenergic receptor signaling 
pathway (P04377) 
2 2.37 1.00E+00 PRKAR2B; SNAP25 
5HT4 type receptor mediated signaling 
pathway (P04376) 
1 1.65 1.00E+00 SNAP25 
5HT3 type receptor mediated signaling 
pathway (P04375) 
1 3.21 1.00E+00 SNAP25 
5HT2 type receptor mediated signaling 
pathway (P04374) 
2 1.63 1.00E+00 GNA14; SNAP25 
5HT1 type receptor mediated signaling 
pathway (P04373) 
2 2.37 1.00E+00 PRKAR2B; SNAP25 
5-Hydroxytryptamine degredation 
(P04372) 
1 2.6 1.00E+00 ALDH2 
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Huntington disease (P00029) 4 1.57 1.00E+00 BDNF; CYFIP2; FOS; RAC2 
Heterotrimeric G-protein signaling 
pathway-Gq alpha and Go alpha mediated 
pathway (P00027) 
7 3.11 1.00E+00 BDKRB2; CHRM2; GNA14; ITPR1; RGS2; RGS4; RGS18 
Heterotrimeric G-protein signaling 
pathway-Gi alpha and Gs alpha mediated 
pathway (P00026) 
6 2 1.00E+00 ADCY4; CHRM2; PRKAR2B; RGS2; RGS4; RGS18 
Hedgehog signaling pathway (P00025) 2 5.2 1.00E+00 PRKAR2B; PTCH1 
FGF signaling pathway (P00021) 5 2.2 1.00E+00 FGF7; MAPK10; MAP2K6; RAC2; RERG 
FAS signaling pathway (P00020) 1 1.61 1.00E+00 MAPK10 
EGF receptor signaling pathway (P00018) 5 2.36 1.00E+00 AREG; MAPK10; MAP2K6; RAC2; RERG 
DNA replication (P00017) 1 1.56 1.00E+00 TOP2A 
Cytoskeletal regulation by Rho GTPase 
(P00016) 
2 1.32 1.00E+00 PRR5; RAC2 
Cell cycle (P00013) 1 2.48 1.00E+00 CCNB1 
Blood coagulation (P00011) 4 4.65 1.00E+00 A2M; F2RL2; ITGB3; PLAU 
B cell activation (P00010) 4 3.03 1.00E+00 FOS; ITPR1; MAPK10;RAC2 
Axon guidance mediated by netrin 
(P00009) 
1 1.56 1.00E+00 RAC2 
Axon guidance mediated by Slit/Robo 
(P00008) 
2 4.2 1.00E+00 RAC2; ROBO3 
Axon guidance mediated by semaphorins 
(P00007) 
2 4.75 1.00E+00 RAC2; SEMA4D 
Apoptosis signaling pathway (P00006) 4 1.79 1.00E+00 FOS; HSPA2; MAPK10; TNFRSF10C 
Alzheimer disease-presenilin pathway 
(P00004) 
5 2.2 1.00E+00 JUP; MMP8; WNT2; WNT2B; WNT5A 
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3 DISCUSSÃO 
O presente estudo avaliou o transcriptoma de populações homogêneas (clones) do 
ligamento periodontal com alto potencial para diferenciação O/C comparado com clones sem 
este potencial, a fim de identificar genes que possam caracterizar populações do ligamento 
periodontal com  maior potencial para diferenciação O/C, assim como determinar quais genes 
são mais expressos durante o processo de diferenciação O/C. A identificação deste perfil 
transcricional tem como objetivo o melhor entendimento da regulação gênica nestas populações 
a fim de servir como base para a proposição de novos marcadores, assim como moléculas-alvo 
para aplicação em procedimentos regenerativos mais previsíveis e com ampliação na indicação 
em Periodontia.  
Identificamos que os clones C-O apresentaram maior expressão dos genes WNT2, 
WNT16 e WIF1, relacionados às vias de sinalização Wnt/Caderina e ao processo biológico 
“desenvolvidmento de estrutura anatômica”. Genes relacionados a estas vias já foram 
reportados na literatura por estarem envolvidos no maior comprometimento de células 
mesenquimais da medula óssea para a diferenciação osteoblástica (Granchi et al., 2010).  
Quando os clones C-O são estimulados à diferenciação O/C, observou-se maior 
quantidade de genes expressos do que quando cultivados em condições padrões (sem estímulo 
à diferenciação O/C). Processos biológicos incluindo “diferenciação celular mesenquimal”, 
“regulação de diferenciação osteoblástica”, “regulação de ossificação”, “desenvolvimento 
mesenquimal” e “desenvolvimento vascular” foram significativamente mais aumentados. As 
vias consideradas significativamente elevadas foram as vias da angiogênese e CCKR. É sabido 
pela literaturatura que o aumento da formação de vasos sanguíneos é importante para a 
formação óssea e diferenciação das células mesenquimais em células osteoprogenitoras 
(Kaigler et al., 2010), o que está de acordo com os dados encontrados neste estudo. Apesar de 
vários genes relacionados à via Wnt também terem sido significativamente mais expressos nos 
clones C-O durante o processo de diferenciação O/C, esta via não foi considerada 
signficativamente elevada durante o processo em virtude da proporção dos genes relacionados 
a esta via em relação ao número total de genes diferencialmente expressos ter sido menor do 
que a proporção de genes desta via na condição sem estímulo.  
Além disso, a análise comparativa dos genes diferencialmente significativamente 
expressos entre as condições sem e com estímulo à diferenciação O/C foi realizada nos clones 
C-O e também não foi observado o aumento o enriquecimento da via Wnt após a diferenciação 
O/C (dados não mostrados). Nós observamos  que, pelo fato de genes relacionados à via Wnt 
já estarem mais expressos mesmo em condições sem estímulo para a diferenciação nos clones 
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C-O, o envolvimento desta via não foi significativamente aumentado após a indução à 
diferenciação. Contudo, a maior expressão dos genes relacionados à via Wnt nos clones C-O 
comparados aos clones C-F, tanto quando cultivados sem estímulo, como quando cultivados 
com estímulo à diferenciação, demonstram que os genes relacionados à esta via parecem ser 
importantes para o maior compromentimento das células do ligamento periodontal para o perfil 
O/C. Adicionalmente, para a diferenciação dos clones C-O em células produtoras de matriz 
mineralizada in vitro, é necessário o estímulo com o meio indutor de diferenciação celular 
(OM), que é suplementado com β-glicerol fosfato, dexametasona e ácido ascórbico, o qual 
estimula o aumento da  expresssão de outros genes, principalmente relacionados à via CCKR e 
angiogênese para promover o comprometimento com o fenótipo O/C dos clones C-O.   
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4 CONCLUSÃO 
Pela análise do perfil transcricional entre os clones celulares derivados do ligamento 
periodontal humano com potencial para diferenciação osteo/cementoblástica e clones sem este 
potencial (perfil fibroblástico), nós concluímos que genes relacionados às vias de sinalização 
Wnt/Caderina e processo biológico “desenvolvidmento de estrutura anatômica” são 
constitutivamente mais expressos em clones com maior potencial para diferenciação 
osteo/cementoblástica mesmo na ausência de estímulo para diferenciação. Após a estimulação 
para diferenciação, genes relacionados à via de sinalização da angiogênese e CCKR, assim 
como processos biológicos relacionados à mineralização e diferenciação mesenquimal são 
significativamente mais expressos em clones com maior potencial para diferenciação, 
favorecendo a aquisição do fenótipo osteo/cementoblástico.   
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ANEXO 1 - CERTIFICADO DE APROVAÇÃO DO COMITÊ DE ÉTICA EM 
PESQUISA
 
